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Abstract
Background: Coronary artery bypass graft surgery is a commonly performed
procedure. The internal thoracic or mammary artery is gaining widespread preference as
the bypassing conduit. Synthetic grafts used for large diameter substitutes are successful
but have dismal patency as small diameter (< 6mm) grafts due to compliance mismatch
and thrombogeniecity. To overcome this, cell adhesion to synthetic scaffolds is used to
construct tissue engineered grafts. For this to be successful a precise understanding of
the behaviour of cells at the synthetic graft surface is required under static and
haemodynamic conditions.
The aim of this research was to investigate gene expression of seeded human umbilical
vein endothelial cells (HUVEC) on the novel compliance conduit under physiological
flow condition; furthermore various physiological shear stress preconditioning was used
to investigate adhesion of HUVEC on the conduit.
Methods: HUVEC seeding of a novel polymer nanocomposite was undertaken. An
optimal method for extracting mRNA from HUVEC seeded onto conduits was then
validated. The optimal seeding conditions for the conduits were delineated.
Haemodynamic conditions were applied to the seeded conduits and gene expression
was investigated using polymerase chain reaction (PCR). Shear stress was used to assess
the ideal preconditioning environment.
Results: Studies of nanocomposite graft material and cultured HUVEC proved that the
novel nanocomposite polymer was non-toxic to cells and supported good rates of
growth. To provide useful flow studies an extrusion-phase inversion method was used
to reproducibly fabricate conduits of this nanocomposite with compliance similar to the
native artery. The optimal seeding density of the conduits was found to be 1.2 x 10
4
cells/cm
2. It was demonstrated that RNA can be extracted from seeded conduits and I
succeeded in showing the optimal technique.
This study culminates in the combination of all these techniques when the gene
expression of HUVEC under flow was studied after physiological shear stress was
applied on the conduits. Genes significantly upregulated included TGF-β1, COL-1 and
PECAM-1. Low shear stress demonstrated the optimal preconditioning environment
with increasing expression of VEGFR-1 and VEGFR-2 genes.
Conclusion: This thesis demonstrated that novel nanocomposite small diameter bypass
graft can be seeded with human endothelial cells.3
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unclog it
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response in a specific application
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Cardiac Cycle: One complete heartbeat, consisting of one complete contraction and
relaxation of the heart muscle
Collagen: An extracellular protein found in blood vessel walls, exhibited as fibres of
high stiffness
Compliance: Measure of radial dissention with respect to pressure change
Coronary artery bypass graft: is a surgical procedure performed to relieve angina and
reduce the risk of death from coronary artery disease
Cytotoxicity: is the quality of being toxic to cells. Examples of toxic agents are a
chemical substance or an immune cell
Dacron (PET): Polymer used to create woven or knitted vascular grafts
Dynamic Test: When a material is stretched and effects caused by movement, such as
viscoelasticity, occur
Elastic: An object’s ability to return to its original shape after the removal of a
deforming load
Endothelial cells: Cells lining the luminal surface of blood vessels, making up the
endothelium
Extracellular matrix: is the defining feature of connective tissue27
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Haemodynamics: The study of blood flow
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Hydrolysis: is a chemical reaction or process in which a chemical compound reacts
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Millimeter of mercury (mmHg): is a non-SI unit of pressure. It is the atmospheric
pressure that supports a column of mercury 1 millimeter high
Morphology: The study of the form and structure of an object
Myointimal: Concerning the intima and media of a blood vessel
Neo-adventitia: The adventitial layer forming on a vascular graft after implantation
Neo-intima: The intimal layer forming on the luminal surface of a vascular graft after
implantation
Occlusion: Closing/blocking of blood vessel or graft
Patency: State of open
Pathologic: Involving disease
Peripheral: Further from the heart
Plaque: Fatty build up on the luminal surface of a vascular wall28
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Polymer: Molecules with large molecular mass composed of repeating structural units,
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Proximal: Close to heart
Pulse Pressure: The difference between systolic and diastolic pressure
Radial Artery: Artery found in the arm
Right coronary artery: originates above the right cusp of the aortic valve
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Stenosis: A constriction of a duct or passage
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Stroke Volume: The amount of blood that gets released from the heart into the arterial
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Systole: The normal rhythmical contraction of the heart, during which the blood in the
chambers is forced onward
Teflon (PTFE): Polymer used to create vascular grafts
Thrombus: A fibrous clot that forms in and obstructs a blood vessel
Tissue Engineering: is the use of a combination of cells, engineering and materials
methods, and suitable biochemical and physio-chemical factors to improve or replace
biological functions
Tunica Adventitia: External layer of a blood vessel
Tunica Intima: Internal (luminal) layer of a blood vessel29
Tunica Media: Middle layer of a blood vessel that resides between the intima and the
media
Vascular Bypass Graft: Conduit used to bypass a diseased blood vessel
Vasoconstriction: Narrowing of blood vessel
Vasodilation: Dilation of blood vessel
Venules: Small veins joining capillaries and larger veins
Viscoelastic: Pertaining to a substance having both viscous and elastic properties
Viscosity: The property of a fluid that resists the force tending to cause the fluid to
flow
Young’s Modulus: A coefficient of elasticity of a substance, expressing the ratio
between a stress that acts to change the length of a body and the fractional change in
length caused by this force30
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Cardiovascular tissue engineering
1.1 Introduction
Occlusive cardiovascular disease of the blood vessel is the main cause of death in
the aged western population (1). The symptoms and treatment depend on which set (or
sets) of arteries are affected. However, the symptomatic prevalence is mainly in vessels
that are smaller than 6 mm internal diameter. In coronary disease, atherosclerotic plaques
(inflamed fatty deposits in the blood vessel wall) obstruct the coronary arteries (2). If
interventional procedures (angioplasty and stenting) are not successful the only
therapeutic option left is to carry out reconstructive or bypass surgery (3). Veins or
arteries from elsewhere in the patient's body are grafted from the aorta to the coronary
arteries, bypassing coronary artery narrowing’s thereby improving myocardial blood
supply. Coronary artery bypass graft (CABG) surgery was originally performed using
saphenous vein (SV) (4) from the leg to carry blood around the obstruction. In the 1970's
and 1980's, cardiothoracic surgeons discovered that an artery from the inside of the chest
wall, the internal thoracic artery (also called the internal mammary artery), could be used
instead of vein for the bypass grafts. It was shown that these grafts stayed open longer
than SV grafts (5). Today most CABG operations are performed using a combination of
bypass grafts including this artery and some SV. The main problem is that many patients
do not have veins or arteries suitable for grafting due to preexisting vascular disease orChapter 1: Cardiovascular tissue engineering
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previous surgery. Hence the development of small diameter vascular grafts has been a
rapidly growing area of research (6).
Prosthetic materials that are currently used clinically are expanded
polytetrafluoroethylene (ePTFE) or knitted/woven poly(ethylene)terephthalate (Dacron)
and have been successful as large vessel substitutes in peripheral artery disease, but have
not proven useful for long-term application as small diameter arterial conduits (7;8). This
is accentuated in less than 6 mm grafts or in areas of low-flow. Failure has occurred in
both infrainguinal and coronary circulations where very high-flow rates are essential.
Graft failure is associated with a number of critical factors. Both material mismatch
between the graft and the host artery and junction haemodynamics are cited as being
major factors in disease formation at the junction (9). Baird and Abbott's hypothesis that
a difference in circumferential compliance of a vascular graft and the host artery is
detrimental to graft performance (10;11). The nature of compliance mismatch is complex,
as it is determined by the compliance differences of the host artery, the anastomosis, and
the graft itself. Such failures are often seen primarily at the downstream end of the graft.
This asymmetry suggests that a flow mechanism of some sort is responsible. The
haemodynamic consequences of mismatch include increased impedance and decreased
distal perfusion as well as disturbed flow, turbulence and low shear stress rates (12).
These changes lead to the development of myointimal hyperplasia and thrombosis
around the anastomosis, finally resulting in graft failure, particularly in small diameter
vessels (13). Previous experimental and numerical studies have shown that lower than
normal wall shear stresses (WSSs) and trapping of particles (such as cells and other blood
elements) are observed at junctions between a stiff graft and compliant artery (14). Some
efforts have been made over the years to engineer prosthetic grafts with compliance
similar to that found in human artery, so that the pulsating blood can flow from the
viscoelastic graft into the compliant artery (15). To date these attempts have still failed
due to a variety of reasons; highly noncompliant and inferior graft materials.
The absence of EC at the luminal surface of prosthetic vascular grafts potentates’
thrombosis and neointimal hyperplasia, which are common causes of graft failure in
humans. Because adding functional endothelium to artificial grafts potentially could
overcome these problems, endothelialisation of prosthetic vascular grafts has been a goal
in clinical medicine for well over two decades. Up to now, this goal has not beenChapter 1: Cardiovascular tissue engineering
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achieved. Autologous cells grown in culture tend to lose their differentiated phenotype
and therefore lack the adhesive strength to resist the force of flowing blood when the
graft is implanted in vivo. Hence, loss of the cells from the implanted graft is one of the
most vexing problems in this field.
This chapter gives an overview of the conduits clinically used for CABG surgery,
history of patency and graft failure. A crucial factor for the development of a successful
vascular graft is the ability of the artificial device to undergo endothelialisation. Therefore,
in this Chapter the biology of ECs has been described in detail, with particular attention
to their importance in more than just a lining of blood vessels.
1.1.1 Coronary artery structure
Oxygenated blood is distributed to the heart via the coronary arteries that are on
the surface of the heart. The two primary coronary arteries are the left main coronary
artery and the right coronary artery. These originate near the cusps of the aortic valve.
The left coronary artery (LCA), which divides into the left anterior descending (LAD)
artery and the circumflex branch, supplies blood to the left ventricle and left atrium. The
right coronary artery (RCA), which divides into the right posterior descending (RPD) and
acute marginal arteries, supplies blood to the right ventricle, right atrium, and sinoatrial
node (cluster of cells in the right atrial wall that regulates the heart's rhythmic rate).
Additional arteries branch off the two main coronary arteries to supply the heart muscle
with blood. Since coronary arteries deliver blood to the heart muscle, any coronary artery
disorder or disease can have serious implications by reducing the flow of oxygen and
nutrients to the heart, which may lead to myocardial infarction and possibly death.
1.1.2 Conduits used for bypass
With the rise in the number of bypass surgeries, more patients are undergoing
repeat coronary revascularisation. Veins that are used either have their valves removed or
are reversed so that the valves in them do not occlude blood flow in the graft. Vein grafts
are not the preferred choice as arterial substitutes. They are fragile and sometimes
damaged when transplanted into the arterial system. Over time they undergo structuralChapter 1: Cardiovascular tissue engineering
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and functional changes that can lead to thrombosis, calcification and premature occlusion
of the graft.
Typically, the left internal thoracic artery (LITA) (previously referred to as left
internal mammary artery or LIMA) and right internal thoracic artery (RITA) are used for
coronary bypass surgery (16). In the most common situation the LITA was used as a graft
to the LAD coronary artery (Figure 1-1 A) and SV grafts were used from the aorta to the
other coronary vessels (Figure 1-1 B). LITA grafts are longer lasting than vein grafts, both
because the artery is more robust than a vein and because, being already connected to the
arterial tree, the LITA need only be grafted at one end (17). Alternatively, an artery such
as the radial artery from the arm or gastroepiploic artery (GEA) from the stomach may be
used in place of a vein. The latter choice is a difficult operation to perform and it has not
become the bypass graft of choice (18). The radial artery graft has an advantage as they
are easy to prepare but has the occurrence of graft occlusions (19).Chapter 1: Cardiovascular tissue engineering
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A
B
Figure 1-1. This illustration shows a heart with A) the left internal thoracic artery (LITA) grafted
to the anterior descending coronary artery (bottom right) and B) a saphenous vein graft
connected to the aorta (upper left) and to the coronary artery at the (lower right) (20)Chapter 1: Cardiovascular tissue engineering
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1.1.3 Graft patency
Grafts can become diseased and may occlude in the months to years after bypass
surgery is performed. Patency is a term used to describe the chance that a graft remains
open. Graft patency is dependant on a number of factors, including the type of graft used
(internal thoracic artery, radial artery, or great SV) and the size or the artery that the graft
is anastomosing with. Occlusions can develop in SV to coronary bypass grafts and that
the likelihood of obstructions developing is related to time. Within 5 years of surgery
approximately 20 % of SV grafts developed partial or total obstructions, and between 5
and 10 years after operation these processes continued to progress such that by 10 years
after operation almost half of SV grafts were either totally obstructed or showed some
angiographic evidence of pathologic changes (21).
The best patency rates are achieved with the LITA, when the distal end being
anastomosed with the coronary artery (typically the LAD artery or a diagonal branch
artery). Studies of angiograms performed after bypass surgery have shown that not only
did the LITA to LAD graft have a more than 90% chance of functioning well early after
operation, but that these grafts continued to function well for many years and that even
20 years after operation the development of obstructions in these grafts is extremely
uncommon (21). Over time, patients with a LITA-LAD graft are less likely to die or to
need a re-operation when compared with patients who received only vein grafts (22).
Since these studies have been completed the LITA-LAD graft has become a standard
part of operations for coronary bypass grafting.
It is very clear that the internal thoracic arteries are the best bypass grafts to use
for coronary bypass surgery. However not all patients can be completely treated with just
the internal thoracic arteries, the search continues to go on for other arterial bypass
conduits and/or total arterial revascularization.
1.1.4 Prosthetic vascular grafts
In the early phases of the use of prostheses as vascular grafts, the establishment of
flow without leakage or thrombosis and the survival of flow-dependent tissues were the
main objectives. As long-term survival of grafted patients became the norm, otherChapter 1: Cardiovascular tissue engineering
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problems presented themselves and it became clear that the mechanical and
haemodynamic properties of the prosthesis were very significant. The importance of
differing mechanical properties of different parts of the arterial tree is referred to later
(see review Chapter 2).
By the early 1950s, a number of polymeric materials such as polyethylene and
methacrylate had been tried as arterial substitutes in animal experiments (23). It was
hoped that their smooth and impermeable surfaces might help to minimize the formation
of thrombus. In 1952, Vorhees et al. reported that a silk suture exposed for several
months to flowing blood became covered by a glistening film of tissue free of
microscopic thrombi (24) and this observation inspired the idea that a woven rather than
a smooth material, by stimulating the formation of this layer, would provide a non-
thrombogenic surface suitable for an arterial prosthesis. The first clinical use of hand-
woven fabric made from Vinyon N as an arterial prosthesis showed all detectable leakage
of blood through the weave had ceased within 1 minute after the prosthesis was filled
with blood at arterial pressure (25). Once the idea of porous woven fabrics was
introduced, a variety of materials including nylon, Teflon, Orlon, Dacron, and
polyurethane were tested (26). Nylon was unsuccessful as it was found to degenerate
rapidly following implantation. However, early clinical comparisons of graft success
suggested that Dacron was the most promising material (27).
Although Dacron is still widely used as a graft material it remains the most widely used
for aortic and iliac grafts. Dacron used especially in cardiovascular applications seems to
cause an adverse reaction towards blood and the surrounding tissue resulting in
inflammation and MIH (28;29). A number of other compounds have been developed, the
most important being ePTFE (30) and polyurethane (31). PTFE is widely used due to its
high bio-stability and reasonable tolerance by the body but as with Dacron there is a high
adherence of platelets and blood proteins to the surface (32).
Polyurethane grafts have characteristics that would be ideal for use in bypass
procedures namely similar compliance to native arteries and a surface that is conducive
for seeding (33-36). Several variations of polyurethane graft have been investigated (37)
(38), (39), (40) and are available commercially (41). But these have been associated with a
significant rate of thrombosis and infection, with patency rates sometimes worse than
PTFE grafts (42;43); also, they suffer from aneurysm formation (44). This has led to theChapter 1: Cardiovascular tissue engineering
40
development of a compliant polyurethane graft based on poly(carbonate-urea)urethane
(PCU). For longstanding implantation without biodegradation, PCU is currently
considered to be much more stable than either polyester or polyether. The PCU graft
eliminates ester and ether links (45) and thus improving biostability. It is an elastic graft
making it potentially suitable for vascular access and small vessel bypass (46). Compared
with other polyurethanes it has favourable haemocompatability (40), although its
thrombogenecity can be lowered further by surface modification (47-49) or EC seeding
(50). Unfortunately, even polycarbonate-based polyurethanes show biodegradation and
aneurismal changes after just 10 weeks implantation in sheep model (47). As might be
expected from their chemical structure, the polycarbonate soft segments are susceptible
to hydrolysis. However, it is the enhanced hard segment interaction with polycarbonate
that can render the overall structure resistant to degradation (51). The challenge in our
department has been to optimise this interaction to yield a non-biodegradable graft (52).
The physical and mechanical properties of commercially available grafts vary
widely, but a number of characteristics common to all successful vascular prostheses may
be identified (26;53;54). Table 1-1 shows the current and the possible future plethora of
bypass grafts that are or will be in used in cardiac and peripheral vascular bypass
procedures.Chapter 1: Cardiovascular tissue engineering
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Table 1-1. Current and possible future choices for cardiac and peripheral vascular bypass grafting
Graft Type Applied experimentally Under clinical trial Used routinely
Autogenous vein b √ √ √
Radial artery (55) √ √ √
Internal mammary artery (56) √ √ √
Gastro-epiploic artery (28) √ √ √
ePTFE* √ √ √
Dacron* √ √ √
PCU* √ √ a
Tissue engineering
Seeded/hybrid √ √ c
Living graft √ c c
ePTFE: expanded polytetrafluoroethylene (29); Dacron: polyethylene terephtalate (32;33); PCU:
compliant polyurethane graft (57).
a Clinical trial imminent.
b Saphenous or arm vein.
c Not to date.
*Prosthetic grafts not of choice in CABG surgery.
1.1.5 The requirement for coronary bypass grafts
Even now, there is no synthetic small calibre vascular prosthesis that has been
clinically proven to improve on ePTFE. Prosthetic conduits for CABG surgery are rarely
in use because they have far lower patency rates compared to autologous vein or artery
grafts. This is supported by a study that compared ePTFE and SV grafts. At 1 year follow
up, 86% of the vein grafts were patent while only 59% of ePTFE grafts were patent (29).
Chard and colleagues found that ePTFE coronary bypass grafts were 86% patent at 1
week, 64% at 12 months, 32% at 24 months, 21% at 36 months, and 14% at 45 months
(34). Other evidence for artificial CABG is Dacron, for instance, has been utilized as a
polymeric graft (3-4 mm) in a few case reports with patent vessels at 17 months (32;33).
Compliance mismatch aside, thrombogenicity is the major cause of prosthetic
coronary graft failure. The low medium-term patency rates of prosthetic grafts haveChapter 1: Cardiovascular tissue engineering
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restricted primarily to patients with inadequate autologous conduits or to selected
emergencies. This can be reduced by either coating these grafts with EC (as discussed in
depth later in this chapter) and RGD-peptide sequences (36) or ensuring high blood flow
rates within the graft. A small vessel prosthesis that better emulates normal arterial walls
would greatly improve the treatment of both peripheral vascular disease and coronary
artery disease. Over 20,000 peripheral bypass and over 25,000 coronary artery bypass
grafts are implanted annually in the United Kingdom: the potential annual market value is
for synthetic CABG (58).
An ideal vascular graft (Table 1-2) would be biocompatible in that the graft should
be resistant to both thrombosis and infection and possess sufficient mechanical strength
that when the graft is placed in the arterial circulation it must be capable of withstanding
long-term haemodynamic stress without material failure (14;59). The prosthesis should
allow the leakage of a small amount of blood. This leads to a tightly adherent thrombus,
permitting its subsequent replacement by fibrin and fibrous tissue. The end result of this
process is the formation of a non-thrombogenic surface resembling that of the native
vessel (13). Availability, suturability and durability are also desirable for minimising
operating time, risk and expense.Chapter 1: Cardiovascular tissue engineering
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Table 1-2. Characterisation and desirable features of the ideal cardiovascular graft.
1) Biocompatibility
No healing disturbances
Non-toxic
Non-allergenic
No induction of malignancies
Minimally traumatic to blood compounds
Non-thrombogenic
Resistance to infection
2) Compliant
Flexible, elastic, without kinking
Ability to stretch
Tensile and shear strength sufficient to resist fraying
Circumferential strength sufficient to withstand arterial pressures
Mechanical properties approximate to those of the native vessels to which they are
attached
Resistant to MIH
3) Easy Processing
Adequate physical and chemical properties, mechanical durability
Readily available in a variety of sizes and lengths
No need for special storage
Easy to suture
Sterilisation (Radiation)
4) Optional
Capable of local drug delivery
Low costs
1.1.6 Possible role of nanocomposite for CABG
Nanotechnology is concerned with manipulation at the molecular or atomic level
to provide useful applications (60;61). The main unifying theme is the control of matter
on a scale smaller than 1 micrometer, normally between 0.1-100 nanometers, as well as
the fabrication of devices on this same length scale. One nanometer (nm) is one billionth,
or 10
-9 of a meter. Materials reduced to the nanoscale can suddenly show very different
properties compared to what they exhibit on a macroscale, enabling unique applications
(60). For instance, inert materials become catalysts (platinum); solids turn into liquids at
room temperature (gold); insulators become conductors (silicon). A material such as gold,
which is chemically inert at normal scales, can serve as a potent chemical catalyst atChapter 1: Cardiovascular tissue engineering
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nanoscales. Much of the fascination with nanotechnology stems from these unique
quantum and surface phenomena that matter exhibits at the nanoscale.
The difficulties involved in fulfilling the numerous ideal characteristics using
traditional synthetic materials have lead biomaterials research towards the fields of
nanotechnology and tissue engineering. Nanotechnology is concerned with the
incorporation of man-made molecules into traditional materials to express novel
advantageous properties such as anti-thrombogenecity and biostability (62).
Hybrid inorganic–organic composites are an emerging class of new materials that hold
significant promise. Materials are being designed with the good physical properties and
the excellent choice of functional group chemical reactivity associated with organic
chemistry. Nano-engineered materials integrated with its constituents at the nanoscale
level result in a ‘supermaterial’ with numerous enhanced properties: greater strength,
higher resistance to permeability and higher heat stability.
1.1.7 Poly(carbonate-urea)urethane (PCU) incorporating polyhedral oligomeric
silsesquioxane (POSS) nanocomposite
Our group has concentrated on the use of PCU. As discussed earlier the polymer
is relatively biostable. However, specific hydrolytic enzymes such as cholesterol esterase
as well as exposure to oxidative solutions have shown in vitro degradation. Monocyte-
derived macrophages could hydrolyse PCU as predicted by in vitro cholesterol esterase
action (63). Although in vivo, macrophage-derived oxidative compounds are also released
this may be protective against hydrolytic degradation. To some extent PCU is protected
from degradation by the shielding effect of the hard segment. Research in our department
has undergone to modify polycarbonate-based polyurethane to improve biostability with
a view to using it as a long-term implant material, in particular cases the much need for a
CABG.
Using conventional silicon-containing polydimethylsiloxane) (PDMS) as a coating,
a surface modifying end group (64;65) and by partial incorporation into the soft segment
of the polyurethane backbone (66;67) could reduce biodegradation and the extent of the
inflammatory response to the polymer (68). The rationale behind this approach has been
that silicon has an unstable surface free energy that would repel protein and plateletChapter 1: Cardiovascular tissue engineering
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adhesion as well as increase degradative resistance to hydrolysis and oxidation. As PDMS
itself is a rigid polymer, efforts have been made to link silicon with more compliant
materials such as rubber so as to better mimic the elastic properties of arteries (13).
Rubber possesses high elastic extensibility. Crystalline polymers are harder than rubber
but not brittle like glass. They comprise rigid polymer chains (crystallites) embedded in an
amorphous gel. However, the latter soft phase is vulnerable to biodegradation in vivo.
Figure 1-2. Monomer of polydimethylsiloxane (PDMS).
In our laboratory, silsesquioxane technology was targeted due to previous
incorporation of siloxane (Si-O chains) in the form of PDMS (Figure 1-2) into
polyurethanes. Siloxane groups are biologically inert and have similar bond properties as
ether groups within polyurethanes. Silsesquioxane means one silicon atom for 1.5 oxygen
atoms. It represents a class of silicon-oxygen compounds that include the polyhedral
oligomeric silsesquioxane (POSS). This latter comprises cyclical rings of alternating Si-O
atoms in layers. POSS is being used increasingly to synthesise hybrid nanocomposites
(69).
PCU-POSS is a nonaocomposite material covalently bonding polyurethane with a
silsesquioxane ‘nanomolecule’. PCU-POSS contains one of the most widely used POSS
structures, namely the Octahedral-Dimeric Silsesquioxane (see Figure 1-3). The initial aim
upon development of this nanocomposite was to improve biostability further for long-
term biological implant functionality. However, it has also been found to have a very
favourable blood compatability as well (52).
The nanocomposite polymer investigated in this thesis is being characterised in our
laboratory and has also demonstrated in vitro biostability (70).
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Figure 1-3. Molecular structure of trans-cyclohexanediolisobutylsilsequioxane, the POSS moiety
used in PCU-POSS.
1.1.8 Tissue engineering
Tissue engineering is a broad field defined as the use of a combination of cells,
engineering materials, and suitable biochemical factors to improve or replace biological
functions in an effort to affect the advancement of medicine. The first definition of tissue
engineering was by Langer and Vacanti who stated it to be "an interdisciplinary field that
applies the principles of engineering and life sciences toward the development of
biological substitutes that restore, maintain, or improve tissue function or a whole organ"
(71). There are more general definitions such as MacArthur and Oreffo defined tissue
engineering as "understanding the principles of tissue growth, and applying this to
produce functional replacement tissue for clinical use" (72). These more general
definitions are by recent scientific progress with completely autologous approaches. That
is, demonstrating functional tissue engineered devices/organs without using synthetic
biomaterials/scaffolds. These recent approaches are based more on an understanding of
cell biology than materials science.
The important factor implicated in graft failure is the lack of EC lining the lumen
of the graft (73). This endothelial monolayer that lines the normal blood vessel serves as aChapter 1: Cardiovascular tissue engineering
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bioregulator of cardiovascular physiology. The endothelium provides structural integrity
to the blood vessel by forming a continuous selectively permeable, thromboresistant
barrier between circulating blood and the arterial wall. It also controls blood flow and
vessel tone (74), platelet activation, adhesion and aggregation (75), leukocyte adhesion
(76) and SMC migration and proliferation (77). This is the key rationale behind utilising
autologous EC to make a haemocompatible artificial polymeric surface that will perform
the major functions of an intact healthy endothelium that would normally be found in the
blood vessel itself.
1.2 Adding endothelium to artificial vascular grafts
1.2.1 Normal vascular anatomy and function
Differentiation of arteries and veins results in the gradual formation of three
anatomic layers: the adventitia the media and the intima, (Figure 1-4).
1.2.1.1 Tunica adventitia
The strong outermost layer of arteries and veins is the tunica adventitia or the
adventitia. It is composed of connective tissue and is composed primarily of fibroblasts as
well as collagen and elastic fibers. These fibres allow the arteries and veins to stretch
whilst preventing overexpansion due to the pressure that is exerted on the walls by blood
flow.
1.2.1.2 Tunica media
The tunica media or media is the middle layer of the wall. It is composed of smooth
muscle cells (SMC) and extracellular matrix (ECM), such as collagen types I and III,
elastin fibronectin and proteoglycans such as versican. This layer is thicker in arteries than
in veins and gives the vessel properties to contract and relax in response to different
stimulus. The media of elastic arteries is composed of layers of SMC and elastic laminas.
In contrast, muscular arteries have less elastic tissue that organises into laminae only atChapter 1: Cardiovascular tissue engineering
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the boundaries of intima with the media and the adventitia. Veins develop thinner walls
than arteries and have the media composed primarily of SMC with relatively low amounts
of elastic tissue.
1.2.1.3 Tunica intima
The innermost layer, which is in direct contact with the flow of blood, is the tunica
intima, commonly called the intima. This layer is made up of mainly EC. This layer is
supported by a basement membrane that contains type IV collagen, laminin and heparin
sulphate proteoglycans such as perlecan and syndecans. The basement membrane
separates endothelium from the underlying layers. EC act as protective barrier and
control the exchange of nutrients and fluid between blood and tissue, which is the basis
for the maintenance of the stability of the physiological environment essential to cell
survival.Chapter 1: Cardiovascular tissue engineering
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Figure 1-4. Structure of an artery and vein and anatomy of the arterial wall.Chapter 1: Cardiovascular tissue engineering
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1.2.2 Endothelial cell biology
The endothelium is more than a layer lining the blood vessels. The structural and
functional integrity of EC is important in the maintenance of the vessel wall function. As
a barrier, the endothelium is semi-permeable and controls the transfer of small and large
molecules from the bloodstream to the vascular bed (i.e. tunica media, adventitia and
perivascular layers). ECs are also capable of conducting a variety of metabolic and
synthetic functions. The synthesis and release of paracrine factors (see Figure 1-5) by ECs
influences underlying SMCs or circulating blood elements, such as platelets and white
blood cells (78;79).
Figure 1-5. Synthesis and release of important mediators in endothelial cells(80).
1.2.3 EC phenotype & structure
Normal EC has a typical ‘cobble-stone’ morphology at confluence. By contrast,
when cells are sparse or intercellular junctions’ disrupted, fibroblastoid/mesenchymal
morphology predominates (Figure1-6). ECs are about 1-2 µm thick and some 10-20 µm
in diameter. They form flat, pavement-like patterns on the inside of the vessels and at the
junctions between cells there are overlapping regions which help to seal the vessel(81).Chapter 1: Cardiovascular tissue engineering
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These intercellular junctions are critical for the integrity of the vessel. Toxic substances
open up these junctions and allow large molecules to pass through the wall. Thus such
toxins can potentiate degenerative changes in blood vessels and lead to serious vascular
diseases.
The cytoplasm is relatively simple with few organelles, mostly concentrated in the
perinuclear zone (80;82). The most obvious feature is the concentration of small vesicles
(pinocytotic vesicles) adjacent to the EC membranes. This is a mechanism for passing
materials, especially fluid, across the cells from the blood stream to the underlying tissues.
Gases simply diffuse through very rapidly, and this is exemplified in the lung capillaries
where there is very efficient movement of gases (carbon dioxide, oxygen and anaesthetics
etc).
Figure 1-6. Phenotypes of confluent and sparse cells (82).
A typical characteristic of EC is the presence of Weibel-Palade-bodies (WP-
bodies). These are large rod-shaped organelles that are specific for EC. WP-bodies store
large amounts of von Willebrand Factor (vWF) that can quickly be released upon
activation of the cells (83). Secretion of vWF can be constitutive or regulated and also
occurs in the absence of WP-bodies. vWF is a large adhesive glycoprotein synthesised in
EC and megakaryocytes. Its primary function is binding to other proteins, particularly
Factor VIII and it is important in platelet adhesion to wound sites (83).
vWF binds to a number of molecules. The most important ones are:
ECs behave differently in confluent or sparse conditions (see figure;
from left to right, respectively).
Confluent cells
•Epithelloid phenotype
•Contact inhibition of growth and motility
•Rearrangement of actin microfillaments
•Protection form apoptosis
Sparse cells
•Fibroblastoid morphology
•Active growth
•MotilityChapter 1: Cardiovascular tissue engineering
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 Factor VIII is bound to vWF while inactive in circulation and degrades rapidly
when not bound to vWF. Factor VIII is released from vWF by the action of
thrombin.
 vWF binds to collagen, e.g., when it is exposed in EC due to damage occurring to
the blood vessel.
 vWF binds to platelet gpIb when it forms a complex with gpIX and gpV; this
binding establishes a transient bond that slows down platelets and thus facilitates
their activation (84).
On the surface of EC is a glycocalyx layer. The glycocalyx ("sugar coat") is a
complex and highly dynamic polymeric meshwork that coats the surfaces of most cells
and consists of proteoglycans, glycosaminoglycans (GAGs), and glycoproteins, as well as
adherentplasma proteins (85). The glycocalyxlayer on the EC surface plays a critical role
in regulating vessel permeability, modulating the dynamics ofnear-wall movement of red
blood cells, and coordinating interactionsbetween leukocytes and the vascular wall during
inflammation.
Perturbation of the glycocalyxon the endothelium appears to be associated with vascular
damage, as well as increased vulnerability to the development of atherosclerosis (86).
. A
number of studies have demonstrated that the presence of anintact glycocalyx is essential
for EC sensitivity and responsiveness to fluid mechanical stimulation, thereby supporting
the idea of a central role for the glycocalyx in endothelial cell flow-mediated
mechanotransduction (87;88).
1.2.4 Endothelium modulates vascular tone
As ECs are directly exposed to the cellular and molecular components of blood,
as well as being exposed to the physical forces inherent in the circulation, they play a
major role in modulating vascular wall function (78;80). The EC surface expresses
receptors for circulating hormones including catecholamines, angiotensin and
vasopressin, and local autacoids, including bradykinin, serotonin and acetylcholine.
Furthermore, the cell membrane responds directly to physical stimuli, allowing calcium
release from subsarcolemmal storage sites through non-specific cation channels when
subjected to stretch, and allowing potassium efflux when shear stress is increased (89).Chapter 1: Cardiovascular tissue engineering
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The result of these various stimuli is to controls vasodilatory mediator synthesis and
release.
ECs locally control vascular tone by releasing potent vasodilatory mediators, such as
endothelium-derived relaxing factor (EDRF), and vasoconstrictor mediators such as
endothelin-1. Furchgott & Zawadzki (74) demonstrated the phenomenon of
endothelium-dependent relaxation. It has been described that the vasodilatory actions of
acetylcholine are mediated indirectly through release of a mediator from the endothelium.
This mediator was initially described as EDRF, however the mediator of endothelium-
dependent relaxation is now known to be a nitric oxide (NO) (90).
NO is synthesised by the enzyme NO synthase (NOS) from the amino acid L-
arginine. Once synthesised, NO diffuses from endothelium to the underlying smooth
muscle where it activates guanylate cyclase to cause a rise in intracellular cyclic GMP and
relaxation of the vessel (refer to Figure 1-7). There are two endothelial forms of NOS:
constitutive NOS (cNOS; type III) and inducible NOS (iNOS; type II) (91).
Under normal basal conditions in healthy blood vessels, NO is continually produced by
cNOS. The activity of cNOS is calcium and calmodulin dependent. There are two
pathways for the stimulation of cNOS, both of which involve release of calcium from
subsarcolemmal storage sites. 1. Shearing forces acting on the vascular endothelium
generated by blood flow causes a release of calcium and subsequent cNOS activation.
Therefore, increases in blood flow stimulate NO formation. 2. Endothelial receptors for a
variety of ligands (acetylcholine, bradykinin, substance-P and adenosine) stimulate
intracellular calcium release and subsequent NO production (78). The NO generated can
only act locally, since it has a chemical half-life of a few seconds in biological solutions
and is rapidly inactivated upon contact with haemoglobin.
The other isoform of endothelial NOS is iNOS. It differs, in part, from cNOS in that its
activation is calcium independent. Under normal, basal conditions, the activity of iNOS is
very low. The activity of iNOS is stimulated during inflammation by bacterial endotoxins
(e.g., lipopolysaccharide) and cytokines such as tumor necrosis factor (TNF) and
interleukins (92).
Certain agents usually thought of as vasoconstrictors, including noradrenaline and
serotonin, also stimulate NO synthesis, with the NO released blunting the direct
constrictor action on vascular smooth muscle. In the case of serotonin, this indirect effect
can override the constriction such that, in vessels with healthy endothelium, serotoninChapter 1: Cardiovascular tissue engineering
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may cause vasodilatation, whereas when endothelial integrity is breached, it is a potent
vasoconstrictor (93).
Figure 1-7. Nitric oxide synthesis in endothelial cells to promote vasodilatory effects on the
vessel wall.
The endothelium has a major basal dilator influence on the blood vessels by
continuously adjusting dilator tone through the release of NO from the luminal side of
the vessel, with the sympathetic nervous system as the major basal constrictor influence.
The latter achieved by continuously adjusting constrictor tone through the release of
noradrenaline, ATP and neuropeptide Y onto the adventitial side of the vessel.
NO is not the only vasoactive mediator produced by ECs. Vasodilator and
vasoconstrictor prostanoids are synthesized and released (80). A vasorelaxant,
endothelium-derived hyperpolarizing factor (EDHF) has been described (94). ECs also
express renin, angiotensin I and angiotensin converting enzyme (95), constrictor
superoxide anions (96) and endothelin (97). Endothelin is the most potent
vasoconstrictor yet discovered.
How do other endothelium-derived mediators fit into vascular control? Endothelin has a
long duration of action and therefore could enhance the action of low background levels
of circulating vasoconstrictor hormones (98). Renin-angiotensin has been demonstrated
to make contribution to vessel tone and provides a link between the endothelium and
nerves, by locally generated angiotensin II diffusing from the endothelium through the
vessel wall to increase noradrenaline release from neurones (99). Synthesis and release ofChapter 1: Cardiovascular tissue engineering
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the unstable prostaglandin endoperoxide (PGH2) may account for the activity of the
elusive short acting EDCF (100) but its role in the control of human vasculature is
entirely unknown.
1.2.5 Endothelium maintains thromboresistant barrier
One of vascular ECs major role is the prevention of thrombin generation and
platelet adhesion to luminal surface of blood vessels. Molecules physiologically important
in suppressing platelet activation and platelet-vessel wall interaction include prostacyclin
(PGI2), nitric oxide (NO) and ecto-adenosine diphosphatase (ADPase) (101). Molecules
involved in controlling coagulation also include the surface-expressed thrombomodulin,
heparin-like molecules, protein S and tissue factor pathway inhibitor (102). Finally, ECs
synthesise and secrete tissue-plasminogen activator (tPA) and urokinase-type plasminogen
activator (uPA) to promote fibrinolysis (81).
1.2.5.1 Antiplatelet activity
When vessel wall damage occurs, proteins from the subendothelial matrix (vWF,
collagen and fibronectin) are exposed and proteins from the circulation (particularly
fibrinogen) are absorbed to the subendothelial matrix. Platelets adhere to the exposed
proteins present in this matrix and become activated (103).
Under normal circumstances, ECs have an antithrombogenic function. Platelets do not
adhere to the unperturbed EC luminal membrane. This is due to the large negatively
charges sulphate proteoglycans (glycocalyx) bound to EC membrane (85). As well as NO
and PGI2 production inhibit platelet adhesion and aggregation and cause blood vessel
dilation (104).
Most studies have focused on PGI2. It is produced in ECs from PGH2 by the
action of the enzyme prostacyclin synthase. Although prostacyclin is considered an
independent mediator, it is called PGI2 (prostaglandin I2) in eicosanoid nomenclature,
and is a member of the prostanoid fasmily (together with the prostaglandins and
thromboxane) (105). Its platelet-inhibitory activities are mediated via a guanosine
nucleotide binding receptor thus activating adenylate cyclase and the elevation of platelet
cyclic adenosine monophosphate (cAMP) levels with resultant inhibition of plateletChapter 1: Cardiovascular tissue engineering
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activation (106). It also induces vascular SMC relaxation, blocks monocyte-endothelial
interaction, and reduces SMC lipid accumulation. The actions of PGI2 on other cells are
thought to be mediated by a similar receptor-mediated signal transduction pathway.
1.2.5.2 Anticoagulant surface
The endothelium serves as an anticoagulant surface in order to maintain a
thromboresistant luminal surface. In vivo, the initiation of coagulation in response to
trauma occurs almost instantly after an injury to the blood vessel damages the
endothelium. Platelets immediately form a hemostatic plug at the site of injury (primary
hemostasis). Simultaneously, proteins in the blood plasma, called coagulation factors,
respond in a cascade to form fibrin strands that strengthen the platelet plug (Secondary
haemostasis). The coagulation cascade of secondary hemostasis has two pathways that
lead to fibrin formation the contact activation pathway (known as the intrinsic pathway)
and the tissue factor pathway (known as the extrinsic pathway). The extrinsic pathway is
initiated at the site of injury in response to the release of tissue factor; also called
thromboplastin, factor III or CD142 (107).
Although they are initiated by distinct mechanisms, the two converge on a common
pathway that leads to clot formation. The pathways are a series of reactions, in which a
zymogen (inactive enzyme precursor of a serine protease) and its glycoprotein co-factor
are activated to become active components that then catalyse the next reaction in the
cascade, ultimately resulting in cross-linked fibrin. Each of these pathway constituents
leads to the conversion of factor X (inactive) to factor Xa (active) (108). Factor Xa
activates prothrombin (factor II) to thrombin (factor IIa). Clot formation occurs when
thrombin, in turn, converts fibrinogen to fibrin. The activation of thrombin occurs on the
surface of activated platelets and requires formation of a prothrombinase complex (109).
One important way in which ECs control the clotting system is by regulating the
expression of binding sites for anticoagulant and procoagulant factors on the cell surface.
In the quiescent state, ECs maintain blood fluidity by promoting the activity of numerous
anticoagulant pathways, including the protein C/protein S pathway (110;111). After
activation, as can be brought about by cytokines, the balance of endothelial properties can
be tipped to favor clot formation through coordinated induction of procoagulant and
suppression of anticoagulant mechanisms. Tumor necrosis factor suppresses theChapter 1: Cardiovascular tissue engineering
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endothelial anticoagulant cofactor thrombomodulin and induces expression of the
procoagulant cofactor tissue factor (112). Working in concert, these changes can allow
fibrin formation to proceed in an inflamed focus but maintain blood fluidity in the
surrounding area of normal vasculature.
1.2.5.3 Fibrinolysis
Fibrinolysis is a process where a fibrin clot, the product of coagulation, is broken
down. The enzyme plasmin cuts the fibrin mesh at various places, leading to the
production of circulating fragments that are cleared by other proteases. Plasmin is
produced in an inactive form, plasminogen. Although plasminogen cannot cleave fibrin, it
has a high affinity for it and is incorporated into the clot when it is formed. Tissue
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) convert
plasminogen to the active plasmin, thus allowing fibrinolysis to occur (113;114). t-PA is a
serine protease normally found on the surface of ECs and is released into the blood very
slowly by the damaged endothelium. This enzyme plays a role in cell migration and tissue
remodeling. u-PA is present in the ECM. t-PA and u-PA are inhibited by plasminogen
activator inhibitor-1 and plaminogen activator inhibitor 2 (PAI-1 and PAI-2). In contrast,
plasmin further stimulates plasmin generation by producing more active t-PA and u-PA
(114;115).
1.2.6 Regulation of cell growth, survival and apoptosis
Apoptosis is programmed cell death or a physiological cell “suicide” mechanism.
It serves to remove supernumerary cells during development and tissue remodelling
(116); maintain homeostasis in adult tissues; remove self-reactive or non-reactive immune
cells (117) and delete damaged, infected or transformed cells. Throughout the process the
cell membrane integrity is maintained to avoid the initiation of an inflammatory response.
This contrasts with necrosis in which cells die relatively passively following overwhelming
damage, leading to loss of membrane integrity and to inflammation (118).
Within blood vessels, vascular ECs play an especially important role in regulating
overall vessel structure. Most ECs in adult blood vessels are relatively quiescent and
resistant to apoptosis. However, they are thought to retain the latent capacity forChapter 1: Cardiovascular tissue engineering
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proliferation and apoptosis to mediate angiogenesis and regression, respectively. In
support of this concept, EC apoptosis has been detected within remodelling vessels in
vivo, and inactivation of EC apoptosis regulators has caused dramatic vascular phenotypes
(119).
EC apoptosis may also contribute to angiogenesis. Several EC types spontaneously form
vessel-like structures in vitro (vascular morphogenesis) when cultured on an extracellular
matrix or with matrix-producing cells. Incubation of EC with anti-apoptotic caspase
inhibitors or overexpression of the anti-apoptotic protein Bcl-2 appears to inhibit
vascular morphogenesis in vitro (120).
As well as supporting vessel regression and possibly promoting angiogenesis, EC
apoptosis may in addition play a role in lumen formation. In support of this hypothesis,
ECs undergoing apoptosis are seen in the centre of developing vascular structures (121),
To prevent the activation of this conserved “suicide” cascade, most cells must be
continuously exposed to survival factors. Basic FGF (bFGF) growth factor modulates cell
proliferation and differentiation (122). The responses of vascular EC to bFGF in vitro
include transient stimulation of the expression of multiple genes including c-fos and c-
myc (123), increased production of plasminogen activator and collagenase, cytoskeletal
reorganisation (124), and, ultimately, stimulation of cell proliferation as well as migration
(125).
1.2.7 EC migration
The migration of ECs plays an important role in vascular remodeling and
regeneration. EC migration can be regulated by different mechanisms such as chemotaxis
and mechanotaxis. EC migration and mechanotransduction can be modulated by
cytoskeleton, cell surface molecules such as integrins and proteoglycans, chemical and
physical properties of ECM and cell-cell adhesions. The shear stress applied on the
luminal surface of the endothelium can be sensed by cell membrane and associated
molecules and transmitted throughout the cell to cell-ECM adhesions and cell-cell
adhesions. As a result, shear stress induces directional migration of ECs by promoting
lamellipodial protrusion and the formation of focal adhesions (FAs) in the flow direction
and the disassembly of FAs at the rear. Persistent EC migration in the flow direction can
be driven by polarized activation of signaling molecules and Rho GTPases. Rho GTPasesChapter 1: Cardiovascular tissue engineering
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regulate cytoskeletal organization and cell adhesion,thereby contributing to cell migration
(126) and endothelial permeability (127). Given the haemodynamic environment of the
vascular system, mechanotransduction during EC migration has a significant impact on
vascular development, angiogenesis, and vascular wound healing.
1.2.8 EC role in angiogenesis and vasculogenesis
The vascular endothelium not only forms the innermost multifunctional cell lining
and permselective barrier of the entire cardiovascular system, but centrally contributes
under disturbed or activated conditions to neovascularization, wound repair and vascular
remodelling). Angiogenesis, the growth of new blood vessels from the existing
vasculature is associated with physiological (wound healing, endometrial cycle and
embryonic development) and pathological processes (tumour growth, rheumatoid
arthritis, diabetic retinopathy, and brain and cardiac infarctions) (128;129). During new
growth, quiescent EC are stimulated to degrade their basement membrane and to invade
the surrounding stroma, initially as solid EC cords. Later, these cords develop a lumen
and deposit a new basement membrane, thus resulting in functional new capillaries.
Alterations in at least three EC functions occur during this series of events: 1) modulation
of interactions with the ECM, which requires alterations in cell-matrix contacts and the
production of matrix-degrading proteolytic enzymes; 2) an initial increase and subsequent
decrease in migration, which allows cells to translocate towards the angiogenic stimulus
and to stop once they reach their destination; and 3) an increase in proliferation, which
provides new cells for the growing and elongating vessel, and a subsequent return to the
quiescent state once the vessel is formed. Together, these cellular functions contribute to
the process of capillary morphogenesis i.e. the formation of three-dimensional tube like
structures (see Figure 1-8) (129).
Angiogenesis is mediated by pro-angiogenic factors including vascular endothelial
cell growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiopoietin, and
epidermal growth factor (EGF) (130;131). Several platelet-derived anti-angiogenic factors
including thrombospondin, platelet factor 4 or transforming growth factor-ß1 (TGF- ß1)
have been shown to inhibit endothelial cell proliferation, migration or capillary tube
formation (132).Chapter 1: Cardiovascular tissue engineering
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VEGF comprises a family of multifunctional cytokines that include the variants VEGF-
A, -B, -C, -D and-E and placental growth factor (PlGF) (133). VEGF-A is mitogenic in
vitro and angiogenic in vivo (134) and its role in angiogenesis and vasculogenesis has been
elucidated (135). VEGF is also associated with pathological angiogenesis (136) and exerts
its biological action upon binding with two high affinity receptor tyrosine kinases;
VEGFR-1 (flt-1) and VEGFR-2 (kinase domain receptor; flk-1) (134;136). VEGFR-1 has
a 50 times higher binding affinity for VEGF than VEGFR-2 (137). However, VEGFR-2
has a stronger receptor tyrosine kinase activity than VEGFR-1 and acts as a major
mitogenic receptor on ECs (138).Chapter 1: Cardiovascular tissue engineering
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Figure 1-8. The formation of new vessels during vasculogenesis and angiogenesis.
Vasculogenesis, the de novo organization of EC into vessels in the absence of pre-existing
vascular structures, takes place during embryogenesis in the blood islands of the yolk sac
(pictured) and in the embryo through expression of growth factors,in particular fibroblast growth
factor (FGF) and vascular endothelial growth factor (VEGF). The tyrosine receptor kinases,
VEGFR-1 (flk-1) and VEGFR-2 (flt-1), are expressed on mesenchymal cells and newly formed
EC, respectively, and are essential for the generation and proliferation of new EC and the
formation of tube EC structures. Angiogenesis, the continued expansion of the vascular tree, is
mediated through the expression of additional tyrosine kinase receptors, tie-2, which binds to
Ang1 and Ang2 (angiopoietins), resulting in the maintenance of mature vessels, the development
of new vessels, and the regression of formed vessels (81).
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Transforming growth factor-beta (TGF-β) has profound effects on all cell types
making up the vasculature, including ECs, SMCs, and adventitial connective tissue. As
such, it plays a prominent role not only in the physiologic vasculogenesis and
angiogenesis but also in vascular disorders such as the arterial thickening associated with
pulmonary hypertension. The actions of TGF-β on these vascular cells in vitro and in vivo
are extremely complex. TGF-β exerts stimulatory effects on cell proliferation,stimulating
proliferation and migration at low concentrations, whereas at higher concentrations, it
inhibits these processes. It regulates the activation state of ECs via receptors ALK-5 and
ALK-1 (139). The TGF-β/ALK-1 pathway stimulates endothelial cell proliferation and
migration, whereas the TGF-β/ALK-5 pathway inhibits these processes. TGF-ß1 also
affects vascular permeability by upregulating the expressionof Claudin-5, an EC–specific
component of tight junctions (140), and inhibits the expression of adhesion molecules.
TGF-β also inhibits gene that promote inflammation, interleukin-6 (IL-6), monocyte
chemoattractant protein-1, andgranulocyte–colony-stimulating factor (141).
1.2.9 EC role in inflammation
In inflammation, white blood cells interact with the vascular endothelium by
specific cell surface receptors and adhesion molecules. Leukocytes are normally repelled
by endothelium, in order to allow the free flow of blood cells over the surface. However,
in inflammatory states, the leukocytes are attracted to the endothelium by adhesion
molecules. At the site of inflammation, the endothelium recruits circulating white blood
cells by inflammatory cytokines and direct cell-cell contact(142). Following arrest at the
site of inflammation, leukocytes pass through the endothelial cells by a process called
diapedesis, which literally means "walking through". Many leukocytes pass through ECs,
especially in capillaries as part of their normal life cycle, so that they can monitor foreign
agents (antigens) in the tissues.
Leukocytes cross the endothelial barrier in a multistep process involving the
capture and rolling of leukocytes on the blood vessel wall, firm adhesion of leukocytes to
ECs, and subsequent leukocyte crawling and transmigration. Proinflammatory mediators,
such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), and the lipopolysaccharide
(LPS) of bacterial walls, or hemodynamic forces imposed by blood flow increase the
surface levels of a variety of molecules on ECs implicated in EC–leukocyte interaction.Chapter 1: Cardiovascular tissue engineering
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Moreover, both these stimuli and EC–leukocyte interaction induce changes in endothelial
cell shape, permeability, and gene expression (143).
1.2.10 EC adhesion
Another important property of ECs is to separate blood from underlying tissues.
These cells function as gatekeepers, controlling the infiltration of blood proteins and cells
into the vessel wall. This is achieved through specialised transcellular systems of transport
vesicles and by coordinated opening and closure of cell-cell junctions. These systems
must be tightly regulated to maintain endothelial integrity and to protect the vessels from
any uncontrolled increase in permeability, which would lead to inflammation or
thrombotic reactions.
Cell-cell junctions are not only sites of attachment between ECs; they can also function as
signalling structures that communicate cell position, limit growth and apoptosis, and
regulate vascular homeostasis. Through their cytoplasmic tail, junctional adhesion
proteins bind to cytoskeletal and signalling proteins, which allows the transduction of
extracellular signals to the cytoplasm (144;145). The association with actin is required not
only for stabilisation of the junctions, but also for the dynamic regulation of junction
opening and closure. In addition, the interaction of junctional adhesion proteins with the
actin cytoskeleton might be relevant in the maintenance of cell shape and polarity (146).
The development in our understanding of ECs concerns the knowledge of the cell
surface molecules. These proteins are transmembrane receptors and are composed of
three domains: an intracellular domain that interacts with the cytoskeleton, a
transmembrane domain and an extracellular domain that interacts with either other cell
adhesion molecules or the ECM. Most of the cell adhesion molecules belong to four
protein families; Ig (immunoglobulin) superfamily, the integrins, the cadherins and the
selectins (147).
1.2.10.1 Calcium dependent adhesion molecules (Cadherins)
ECs have specialised junctional regions called adherent juctions and tight
junctions. Tight junctions in ECs are combined with adherent junctions all the way along
the cleft (Figure 1-9). Adherent junctions are cell-cell adhesion complexes that containChapter 1: Cardiovascular tissue engineering
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cadherins and catenins. Catenins (α-catenin and β-catenin) are proteins found in
complexes with cadherin cell adhesion molecules. α-catenin can bind to β-catenin and can
also bind actin. Tight junctions contain claudin-5 (148). Junctional proteins can aso
function as scaffolds by binding several effector proteins and facilitating their reciprocal
interaction. Example of this includes the tight junction component zona occludens-1
(ZO1), which can associate with many transmembrane proteins, such as claudins,
occludin or junctional adhesion molecules (JAMs); with cytoskeletal binding proteins
such as α-catenin, vinculin and α-actinin; or with signalling mediators such as ZONAB
(ZO1-associated nucleic-acid binding)(149;150).
Figure 1-9. The organization of endothelial cell–cell junctions.
Transmembrane adhesive proteins at endothelial junctions. At tight junctions, adhesion is
mediated by claudins, occludin, members of the junctional adhesion molecule (JAM) family and
EC selective adhesion molecule (ESAM).
At adherens junctions, adhesion is mostly promoted by vascular endothelial cadherin (VE-
cadherin), which, through its extracellular domain, is associated with vascular endothelial protein
tyrosine phosphatase (VE-PTP). Nectin participates in the organisation of both tight junctions
and adherens junctions. Outside these junctional structures, platelet-endothelial cell adhesion
molecule (PECAM) contributes to endothelial cell–cell adhesion (151).
Cadherins are a family of adhesion molecules (152) that bind homophilically and
heterophilically in a cation-dependent and protease-sensitive manner. ECs express at least
three cadherins: N-, P-, and VE-cadherin (Vascular Endothelial Cadherin or CD144). N-
cadherin is diffusely spread across the cell (153), P-cadherin is present in trace amounts
(154). VE-cadherin is a strictly endothelial specific adhesion molecule located at junctionsChapter 1: Cardiovascular tissue engineering
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between ECs. It is a calcium-dependent EC-EC adhesion glycoprotein functioning by
granting the cells with the ability to adhere in a homotypic manner; this protein plays an
important role in EC biology through control of the cohesion and organisation of the
intercellular junctions. VE-cadherin is linked to the actin cytoskeleton via β-catenin (82).
In addition as of vital importance for the maintenance and control of EC contacts, VE-
cadherin regulates various cellular processes such as cell proliferation and apoptosis and
modulates vascular endothelial growth factor receptor (VEGFR) functions (137). VE-
cadherin has been described to mediate contact inhibition of cell growth, thereby
negatively interfering with VEGFR-2-stimulated cell proliferation.
1.2.10.2 Cell to cell surface carbohydrate binding proteins (Selectins)
Selectins are a family of transmembrane molecules, expressed on the surface of
leukocytes and activated ECs and platelets. The initial attachment of leukocytes, during
inflammation, from the blood stream is afforded by the selectin family, and causes a slow
downstream movement of leukocytes along the endothelium via transient, reversible,
adhesive interactions called leukocyte rolling. L selectin, P-selectin and E-selectin can
mediate leukocyte rolling. L-selectin is the smallest of the vascular selectins, and can be
found on leukocytes. P-selectin, the largest selectin, is expressed on activated platelets and
ECs. E-selectin is expressed on activated endothelium upon chemical stimulation or
cytokine-induced inflammation.
P-selectin (CD62P) attaches to the actin cytoskeleton through anchor proteins and
extends approximately 40nm from the endothelial surface. It is a component of the
membrane of the alpha and dense granules of platelets, and also of the membrane of the
WP- bodies of ECs. In common with the other selectins, P-selectin has an epidermal
growth factor motif (155). P-selectin plays an essential role in the initial recruitment of
leukocytes to the site of tissue injury during inflammation. When ECs are activated by
inflammatory mediators such as histamine or thrombin, WP- bodies are mobilised and
degranulate their vWF. P-selectin is also expressed at the cell surface as rapidly as two
minutes after stimulation (156;157), as a consequence of the exocytosis of WP-bodies.
Thrombin is one trigger that can stimulate EC surface translocation of P-selectin. Recent
studies suggest an additional Ca2+-independent pathway involved in P-selectin surface
expression regulation (156).Chapter 1: Cardiovascular tissue engineering
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Additional synthesis of P-selectin is brought about by cytokines, such as interleukin-1,
tumour necrosis factor-, and by thrombin,lipopolysaccharide or oxygen radicals. NO has
been shown to be a regulator of P-selectin expression as inhibitors of NO synthase
increased P-selectin expression (158). This may be clinically important as Minamino et al
(159) suggest thatconcurrent low NO metabolites and high platelet P-selectin expression
are linked. Although P-selectin will bind to heparan sulphate, its primary ligand is P-
selectin glycoprotein ligand-1 (PSGL-1). PSGL-1 is found on a number of cells such as
platelets, neutrophils, lymphocytes, eosinophils, monocytesand other myeloid progenitor
cells (155;160).
1.2.10.3 Cell to cell and cell to matrix binding through Integrins
Integrins are cell surface receptors that interact with the ECM and define cellular
shape, mobility, and regulate the cell cycle. These integral membrane proteins are attached
to the cellular plasma membrane through a single transmembrane helix (161). Integrins
play a role in the attachment of cells to other cells, and also a role in the attachment of
ECs to the ECM. Besides the attachment role, integrin also plays a role in signal
transduction (162).
The integrins are unusual membrane proteins because they transduce signals in
two directions; 1) inside-out by transforming cytoplasmic information into surface
conformational changes. 2) outside-in; by transducing from the ECM to the cytoplasm.
This allows cells to make rapid and flexible responses (163). There are many types of
integrins, and many cells have multiple types on their surface. They appear on the cell
surface as heterodimers that comprise two distinct chains, α and β subunits (162). In
addition, variants of some of the subunits are formed by differential splicing, for example
4 variants of the β-1 subunit exist. Through different combinations of these alpha and
beta subunits, some 24 unique integrins are generated, although the number varies
according to different studies. The β subunits are directly involved in coordinating at least
some of the ligands that integrin bind (164).
Integrins bind to ECM components such as collagen (e.g. integrins α1 β1, and α2
β1) and fibrinogen (e.g. integrin αIIb β3) or act as cell-cell adhesion molecules (integrins
of the β2 family) (165). Laminin, a major glycoprotein component of vessel basementChapter 1: Cardiovascular tissue engineering
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membranes, is recognized by β1- and β3-integrins expressed on ECs. The integrins VLA-
2 (α2/β1-CD49b/CD29), receptor for laminin and collagen (166), VLA-5 (α5/β1-
CD49e/CD29), receptor for fibronectin (167), VLA-6 (α6/β1-CD49f/CD29), receptor
for laminin (168), and αVβ3-CD51/CD61, receptor for vitronectin (169) have been
identified on ECs.
1.2.10.3.1 Attachment of cell to the ECM
The ECM is a complex structural entity surrounding and supporting cells that is
found within mammalian tissues. As mentioned earlier the ECM is composed of 3 major
classes of biomolecules: 1. Structural proteins; e.g. collagen and elastin, 2. Specialised
proteins; e.g. fibrillin, fibronectin, and laminin and 3. Proteoglycans; composed of a
protein core to which attached long chains of repeating disaccharide units termed of
glycosaminoglycans (GAGs). ECM proteins can induce diverse intracellular signals by
providing both mechanical and chemical stimuli to cells (170).
Integrins couple the ECM outside a cell to the cytoskeleton inside the cell. The
interactions between the cell and the ECM may help the cell to endure pulling forces
without being ripped out of the ECM (171). Integrins are not simply hooks, but give the
cell critical signals about the nature of its surroundings. Together with signals arising from
receptors for soluble growth factors like VEGF and EGF, they enforce a cellular decision
on what biological action to take, be it attachment, movement, death, or differentiation.
The attachment of the cells takes place through formation of focal adhesion complexes,
which contain integrins and many cytoplasmic proteins that include talin, vinculin,
paxillin and alpha-actinin. Focal adhesions act by regulating kinases like FAK (focal
adhesion kinase) (172;173) and Src kinase family members to phosphorylate substrates
such as p130CAS, thereby recruiting signaling adaptors such as Crk. These adhesion
complexes attach to the actin cytoskeleton (Figure 1-10). Activation of FAK leads to
subsequent alterations in the cytoskeleton and cell morphology, changes in adhesion
strength, and changes in cellular responsiveness to mechanical stimuli (172). Fibronectin
and type I collagen binding requires transcription factors (c-Fos and c-Jun) which are
important in cell proliferation.Chapter 1: Cardiovascular tissue engineering
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Figure 1-10. Integrins are receptors at sites of cell-substrate and cell-cell contact. Interaction
between the extracellular domain of integrin and an extracellular ligand generate a variety of
signals. The interaction leads to clustering of integrins and the rapid tyrosine phosphorylation of
proteins at the cytoplasmic face of focal adhesions by the tyrosne kinase, Src. Focal adhesion
kinase (FAK) is an effector in integrin-mediated responses (173).
One of the most important functions of surface integrins is their role in cell
migration (174). Cells adhere to a substrate through their integrins. During movement,
the cell makes new attachments to the substrate at its front and concurrently releases
those at its rear. When released from the substrate, integrin molecules are taken back into
the cell by endocytosis; they are transported through the cell to its front by the endocyticChapter 1: Cardiovascular tissue engineering
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cycle where they are added back to the cell surface. In this way integrins enable the cell to
make fresh attachments at its leading front (175).
1.2.10.4 Non-calcium dependent cell to cell binding (Immunoglobulin)
Adhesion molecules of the immunoglobulin superfamily are involved in cell-cell
adhesion, especially important during embryogenesis, wound healing, and the
inflammatory response (176). They are transmembrane proteins that bind to the
cytoskeletal system inside the cells. Outside the cell, the binding may be homophilic (to
each other) or heterophilic (to different molecules)
As discussed above, leukocytes first establish transient interactions with the
endothelium that allow them to roll along the endothelial surface. This is achieved
primarily through the interaction of members of the selectin family and their ligands.
Leukocytes then encounter chemokines on the endothelial surface. This activates
leukocyte integrins such as Lß2 (also known as lymphocyte function-associated antigen-1;
LFA-1) and 4ß1 (also known as very late antigen-4; VLA-4), allowing them to establish
firm adhesions with the EC by interacting with endothelial ICAM-1 and VCAM-1 (177).
ICAM-1 and VCAM-1 are enriched in F-actin-rich structures that extend from the
luminal surface of ECs towards leukocytes (178;179). During diapedesis, leukocytes cross
the endothelium either through intercellular junctions (paracellular pathway) or through
the EC body (transcellular pathway). The paracellular pathway involves platelet-
endothelial cell adhesion molecule-1 (PECAM-1) and members of the junctional adhesion
molecule (JAM) family (180). Less is known about the mechanism underlying the
transcellular route, which is often observed in vivo (181). Leukocyte-EC interaction is
believed to drive cytoskeleton and membrane rearrangements to "open" a transient
channel across the EC for leukocyte transcellular migration (182). ICAM-1 engagement
rapidly induces changes in EC morphology and redistribution of cell membrane proteins
(178;179). This is followed by changes in gene expression, including modulation of
endothelial adhesion molecule expression and production of proinflammatory mediators,
which may mark these sites on the endothelium to recruit further leukocytes and prolong
the inflammatory response (183).Chapter 1: Cardiovascular tissue engineering
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ECs express other cell-specific homophilic adhesion proteins at intercellular
contacts. Platelet endothelial cell molecule (PECAM; also known as CD31) is an Ig
superfamily adhesion molecule highly expressed on EC. It was originally described as a
protein capable of mediating cell-cell adhesion through homophilic interactions (184;185).
In addition to being an adhesive protein, PECAM-1 has important intracellular signalling
capacities that function to control cell activation and survival (186;187).
1.3 Clinical relevance: Role of EC in development of tissue
engineered bypass graft
1.3.1 Development of hybrid/seeded graft
Prosthetic grafts do not spontaneously endothelialise in humans except for a short
peri-anastomotic region, where the anastomosis is made (188;189). It is thought that this
lack of EC contributes to the failure of the prosthetic graft by thrombosis in this region
devoid of cells (73). Matsuda and co-workers have been investigating the development of
hybrid vascular prostheses composed mainly of SMC, collagen with reinforcement onto
polyester fibres. These grafts once developed could then be seeded and have shown
promising results (190). This group has also been evaluating polyurethane and Dacron
scaffolds (191), (192). Polyurethane scaffolds have been used because of their unique
properties in tissue engineering. This scaffold has been either seeded with both SMC and
EC (193) or lined with an artificial membrane composed of collagen and dermatan
sulphate before seeding. SMCs make the scaffold more viscoelastic rather than elastic,
thus mimicking the mechanical properties of native vessels. Such grafts were then used in
canine models and showed promising results after implantation, with patency rates of up
to 75% after 26 weeks (194).
Developing a bio-hybrid vascular graft would require the EC to undergo four
phases (see Figure 1-11). These cells have to first remain viable within the culture
medium exposed to fragments of the polymer as well as on direct contact with the
polymer (Phase I). Next, the EC would have to adhere to the polymer surface, preferably
within a short time, to minimise the complications associated with long-term cell culturesChapter 1: Cardiovascular tissue engineering
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(Phase II). These adherent ECs would then need to proliferate at a steady rate (phase III)
in order to achieve a confluent EC monolayer (Phase IV).
Figure 1.11. Schematic representations of the stages of cell seeding on biomaterials.
A cellular engineering approach called ‘seeding’ has been used to overcome graft failure.
In simple terms, it involves lining the lumen of the graft in vitro with EC (195;196). To be
successful in a clinical situation, seeding of grafts has required the culturing of EC over a
period of weeks to date. As a result of this problem, there have been numerous attempts
at creating fully tissue-engineered vessels composed of prosthetic (ePTFE, Dacron or
polyurethane), bioresorable (e.g. polyglycolic acid (PGA), poly-L-lactic acid (PLLA)) or
fully biological materials together with autologous cells, which can be readily available on
the shelf of any operating theatre (197).
1.3.2 Seeding techniques with mature EC
There are currently two strategies in seeding of grafts: a two-stage or a single-stage
procedure (195;198;199). Two-stage seeding is the conventional and successful technique
used and is discussed below. Single-stage seeding is the technique most aspired for and
this is discussed subsequently. The principal sources for EC extraction are vein, artery,Chapter 1: Cardiovascular tissue engineering
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omental or subcutaneous fat, laparotomy washes and blood as progenitor cells. These
tissues are relatively easily accessible in clinical practice (200).
1.3.2.1 Two-stage seeding
In two-stage seeding, the EC are extracted and made to undergo a prolonged
period of cell culture in the laboratory in order to increase the cell numbers before
seeding. The cells are normally cultured for a period of between 2 and 4 weeks (201). The
main source of EC in two-stage seeding has been a vein harvested from the patient
though arteries are used occasionally. This technique has given rise to excellent patency
rates in animal studies: patency rates of 62.5% without antiplatelet drugs and 100% with
them (202-204). The high initial density of seeded EC means that even with cell loss on
exposure to pulsatile blood flow on implantation, the EC is still functionally effective as a
whole since a relatively high number of cells are still left attached. However a
confounding factor is that in animals, such constructs tend to show improved results
compared to studies in humans. This is due to the inherent ability of many animals to
self-endothelialise their vascular lumens (205), a problem which was only realised when
initial clinical trials in humans with these seeded grafts showed poor results. This problem
may be overcome if older animals are used as a model (206;207). It is for this reason that
the authors tend to assess the efficacy of their seeding experiments in vitro with the use of
physiological blood flow pumps (199;208).
An apparent disadvantage of the two-stage seeding procedure in clinical practise is
that it cannot be used in the emergency situation because of the prolonged cell culture
time (2 – 4 weeks), the ever-increasing probability of infection within the cell culture
medium and the inability of the cells to proliferate effectively with time (209;210). In
addition, it incurs the extra cost of a cell culture technician and the need for a culture
laboratory.
1.3.2.2 Single-stage seeding
This method also utilises freshly harvested EC of either venous or microvascular
origin (200). Microvascular sources include omental and subcutaneous fat (211;212). In
the single-stage procedure, the EC are harvested and then immediately seeded ontoChapter 1: Cardiovascular tissue engineering
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grafts. The obvious benefit of this is that it can be performed during a surgical operation,
thus avoiding a second procedure and the costs and risk of infection associated with
prolonged cell culture.
Herring et al introduced the concept of single-stage seeding in 1978 using EC
derived from canine veins. They showed that grafts seeded by this way in a canine animal
model established an extensive EC lining (195). However for reasons mentioned above,
animal models may not be the most suitable method of assessing the efficacy of seeding.
The results of the initial clinical trials of single-stage seeding using vein as a source of EC
were disappointing (196;198). The reason was thought to be the low seeding density of
EC due to the low number of EC that can be extracted from veins using current
methods. Therefore when undertaken, these low numbers exert a minimal effect on the
endothelialisation of the PTFE graft (209). This is because a proportion of seeded cells
are lost when exposed to pulsatile blood flow (213). This could be overcome by
improving the cell density.
1.3.3 Improving cell adherence and retention to the graft lumen
For both tissue engineers and biomaterial researchers, precise control of cell
interactions with the prosthetic or biomaterial surface is critical. To this end, the tissue
engineer requires the interaction of specific cell types with the material surface used in the
vascular construct in order to promote tissue ingrowth as well as regeneration of the
construct. In bio-hybrid tissue constructs, the tissue engineer seeks to obtain very specific
cells such as ECs to place into biomaterial based scaffolds. Optimal cell–polymer
interaction would allow the host tissue to integrate with the graft and allow for the
development of actual tissue formation. The development of bio-hybrid or fully tissue-
engineered biological vascular grafts requires the very selective adhesion of actual
donor/patient cells onto the implanted vascular graft in such a way that these cells
optimally integrate and most importantly adhere onto the surface with limited
inflammatory cell-mediated encapsulation (214).
Numerous research groups have examined whether modifications to the luminal
surface of the prosthetic graft can stimulate self-endothelialisation or allow improved
adherence of pre-seeded cells when exposed to arterial flow (215). This lack of adherenceChapter 1: Cardiovascular tissue engineering
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as discussed earlier is an important cause of the problems associated with low density
seeding; the major cause of graft failure so far in clinical trials. The majority of the work
on promoting EC adherence and growth to permanent non-biodegradable polymers has
involved the modification of the surface with a single coating of endothelial cell-specific
adhesion proteins. These substances include albumin (216), albumin–heparin conjugates
(217), collagen (218-220), collagen–elastin matrices (221), fibronectin, gelatin (222), fibrin-
gelatin (223), laminin (224), extracellular matrix (225), dipyridamole (47), granulocyte-
stimulating factor (G-CSF) (226), peptide fragments (227), preclotting with blood,
plasma, fibrin glue (228) and serum (229). Fibrin glue is the commonest substrate used in
trials of two-stage seeding in humans (230). Non-ligand based techniques have included
carbon deposition, photo discharge, chemical vapour deposition (231) and plasma
discharge technology (232) in order to deposit reactive groups onto polymer surfaces or
to directly influence the proteins adsorbed to the surface. These methods to encourage
cell attachment have met with limited success owing to the lack of specificity and poor
control over protein orientation. Physical methods to improve the development of a
pseudointima on the surface have involved altering the porosity and nano-texture (233) of
luminal surfaces to promote tissue ingrowths into the graft and allowing it to act as a
three-dimensional scaffold for cell seeding and tissue engineering (219).
Haemodynamics flow is a way of increasing cell retention to the graft surface. This
method is the main consideration in this thesis and is further discussed in Chapter 2.
1.4 Conclusion
The success of current clinical grafts such as Dacron in large calibre high flow
vessel replacement has not been replicated when considering small diameter vessels with
low flow. The non-clinical studies in cardiovascular tissue engineering have led to
important advances in the progression to a blood vessel substitute that can serve as a
living graft. These should be responsive to the surrounding biological environment, be
self-replicating and have an inherent healing potential. It is now been shown to be
possible to develop cellular engineered grafts composed purely of human cells. The
mechanical strength of biomaterials derived from the ECM, the production of the matrix
and the integrity of the cellular sheets themselves could be significantly enhanced by
simple alterations in cell culture conditions. The optimal biological coronary or vascularChapter 1: Cardiovascular tissue engineering
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graft can only be used in vitro if they are incubated within bioenvironmental conditions
that they would confront in vivo or during their natural formation. For example, studies
have shown that culturing SMC within a pulsatile flow model similar to in vivo arterial
systems helped mimic nature’s vessels. Seliktar et al. (234) have discovered that gene
expression is enhanced when such constructs are subjected to in vivo cyclic strain. Chello
et al, (235) have found that in vitro pressure distension markedly increases expression of
adhesion molecules like inter-cellular adhesion molecule (ICAM-1) while earlier studies
showed that haemodynamic forces were able to stimulate the expression of platelet-
derived growth factor (PDGF), an SMC mitogen (236) and (237).
The problems associated with graft thrombosis and neointimal hyperplasia are most
prevalent in small calibre (<6 mm) prosthesis, leading to their poor medium and long
term results, so the development of these conduits from the nanocomposite would have
the highest impact. The multiple demands placed on a small calibre CABG grafts have
meant that a synthetic prosthesis with good long-term patency has not been developed. A
tissue-engineered graft could fulfil the ideal characteristics present in an artery. ECs are of
great interest because of their potential in cell therapy for vascular diseases and ischemic
tissue, tissue engineering for vascular grafts and vascularized tissue beds, and modeling
for pharmaceutical transport across endothelial barriers.
Studying the biology of endothelial cells is a new understanding of the response of
endothelial cells to biomaterials and will aid in the design of the next generation of
scaffolds for cardiovascular tissue engineering76
Aim of thesis:
The aim of this thesis was to understand the behaviour of endothelial cells
seeded on the novel nanocomposite for development of small diameter coronary artery
bypass grafts.
Ultimately to determine the influence of haemodynamic shear stress responsive genes
on endothelial cells seeded on nanocomposite conduits.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Molecular aspects of haemodynamics and vascular tissue engineering
2.1 Mechanical forces in the vessel
The haemodynamic forces within blood vessels regulate vascular development,
adaptation and pathogenesis of vascular disease. The major stresses affecting the blood
vessel wall are shear stress - the longitudinal frictional element that flowing blood
directly exerts on EC lining - and circumferential tensile stress, generated by the
repetitive pulsatile pressure and translating to a cyclical stretch in the circumferential
direction (Figure 2-1).
Figure 2-1. Schematic diagram of vessel wall and the mechanical forces.
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Stress exerted on the EC can detach them from the graft surface.
Circumferential stress stretches individual cells that are anchored. However, due to
blood’s direct interaction with the inner vessel WSS is the most relevant to thrombosis
(238). Shear stress is described as the force per unit area generated by flow of a viscous
liquid (238). On the basis of a Newtonian fluid (239), in a tubular chamber having radius
r, flow direction z, fluid viscosity μ, and fluid velocity v the following mathematical
formula can be used to calculate shear stress  (see equation 1):
) 1 ( ) ( dr
dvz   
Poiseuille considered Newtonian fluid behaviour in a vessel. However, the
mechanics of blood flow are more complex than Poiseuille fluid dynamics that apply
principality to steady flow in a rigid tube of circular cross section. In the arterial
circulation, blood flow is pulsatile; it is non-Newtonian and the vessel is a compliant
tube of changing cross-sectional shape and area with many side branches and
bifurcations. Each of these variables have been considered in flow models in order to
achieve accurate assessment of WSS in vivo (240-242).
Shear stress and shear rate values are usually given as dynes/cm
2 (or Pa) and 1/s,
respectively. Alternatively, wall shear stress can be expressed as N/m
2. According to the
international system (SI) of units as the viscosity of whole blood is about 0.035 Pa (243),
the normal shear stresses and shear rates in the human aorta are 1.6-12 dynes/cm
2 and
45-305 1/s, respectively. The average shear stress in a venous circulation is 0.2
dynes/cm
2 that is substantially less than the shear stress in a bypass graft inserted into
the arterial circulation (3-6 dynes/cm
2) (244). Table 2-1 illustrates the range of normal
shear stress gradients experienced at various locations. Of note is that the average shear
stress in a venous circulation is substantially less than the shear stress in a bypass graft
inserted into the arterial circulation (244).Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Table 2-1. As blood flow is pulsatile, the velocity profile varies within the cardiac cycle to
produce a range of shear stress gradients and is influenced by curvatures in the vessel wall
notably, bifurcations and branches. This table shows the range of calculated mean shear stress in
regions of uniform geometry and away from branched vessels. Zamir et al calculated wall shear
stress at every point in the arterial tree to be at the same constant value of 15 dynes/cm2 (245).
Blood vessel Mean shear stress range (dynes/cm
2)
Human aorta 1.6-12
Large artery 20-40
Vein 0.2
Bypass graft inserted into arterial circulation 3-6
Pathology based studies indicate that atherosclerotic lesions are at branches and
bends of the arterial tree (246) where there are variations in shear stress. Initially, it was
suggested that high shear stress resulted in mechanical damage of the endothelium
thereby initiating vessel wall pathology (247). Extremely high shear values, 105-350
dynes/cm
2 have been detected at top of plaques in stenotic atherosclerotic coronary
arteries (248). Further work has led to the conclusion that low shear stress also has an
important factor in the development of early atherosclerotic lesions (246;249;250), yet it
is still not fully understood as to why and no single theory has been suggested that
adequately answers this paradox. Atherogenesis due to decreased shear stress is
associated with a reduction in several vascular wall functions including endothelial nitric
oxide synthase (eNOS) production, vasodilation and EC repair. These are coupled with
an increase in leukocyte adhesion, apoptosis, SMC proliferation and collagen deposition
(251).
The effects of shear stress have been extensively studied in blood vessels that
respond with an active process ‘remodelling’ that involves the endothelium, vascular
SMC, fibroblasts and ECM. Much of the investigation of the effect of haemodynamics
has been conducted in vitro with precise control of the mechanical environment. The
range of shear stresses examined in vitro has typically been 0-100 dyn/cm
2 mainly in
steady unidirectional laminar flow, but with some attention to the effects of pulsatile
flow (252).Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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2.1.1 The endothelial response to shear stress
Although the entire vessel wall, including ECs, SMCs and the ECM is subjected
to stretch as a consequence of pulsatile pressure, shear stress is received principally at
the endothelial surface therefore in this thesis we are primarily interested in the EC
response to shear stress. To determine the effects of flow on ECs, studies in which flow
can be systematically varied are needed. It is difficult to achieve this in vivo and it is also
difficult to define the characteristics of the haemodynamic environment. Limited studies
have been performed using pressure transducers, Doppler ultrasound and ex vivo models
of the vasculature. As a result, a vast amount of work has been focused on evaluating
EC function when they have been exposed to flow in vitro. Shear stress has been
achieved by flowing fluid across EC monolayer under controlled conditions. Tensile
stress is generated by applying a cyclic strain which stretches the EC monolayer.
The tools that have been used to apply flow have been the parallel-plate and the
cone-plate apparatus. A parallel plate is a flow chamber with one side consisting of a
gelatine-coated glass plate on which the cultured EC rest, the other side is usually a
polycarbonate plate and these two flat surfaces are held apart by a Teflon gasket (253).
Cone-plate apparatus consists of a stainless steel cone driven by an electric motor and a
stage that holds a culture dish with a glass plate inserted at the bottom of the dish.
Rotation of the cone forces the fluid concentrically between the cone and glass plate,
exposing cells attached to the gelatine-coated glass plate to fluid shear stress (254). Many
researchers have used flow circuits as an in vitro system to investigate the responses of
cultured EC to haemodynamic forces at the cellular and molecular level (255;256).
In response to shear stress EC undergo changes in cell shape, alignment and
microfilament network remodelling in the direction of flow (Figure 2-3). Bovine aortic
endothelial cells (BAEC) exposed to nonreversing sinusoidal shear stress of 40 ± 20
dynes/cm
2 for 24 hours showed marked elongation compared to static (no flow)
conditions (252;257). This response mimics the phenotype of EC observed in its in vivo
state (258). Reorganisation of the F-actin filaments, a major component of the
cytoskeletal structure of EC, was observed prior to the morphological response of the
EC; suggesting that it may be related to the sensing mechanism of shear stress (257).
Adaptation to flow is believed to contribute to reducing shear gradients along the EC
surface (259). When exposed to reversing sinusoidal shear stresses of 20 ± 40 and 10 ±Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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15 dynes/cm
2, BAEC changed less rapidly in shape and were less elongated than their
steady controls. With oscillatory shear stresses of 0 ± 20 and 0 ± 40 dynes/cm
2, BAEC
cell shape remained polygonal as in static culture and did not exhibit actin stress fibers,
such as those that occurred in all the other flows (252). These results demonstrate that
EC can discriminate between different types of pulsatile flow environments.
Figure 2-2. Morphology of endothelial cells before (a) and after (b) applying shear stress (252).
2.1.2 Shear stress regulates gene expression
Shear stress regulates EC function by altering the gene expression profile,
including growth factors, adhesion molecules, vasoactive substances and cell signalling
molecules. Various genes have been shown to be upregulated or downregulated in
response to different magnitudes of shear stress (see Table 2-2). Previous in vitro and in
vivo findings have shown that a sudden onset of shear stress activates EC signalling
pathways and modulates EC gene expression (260-262).
Laminar shear stress induces gene expression in a time dependant manner. The
sudden application of shear stress to EC in static culture showed a transient increase in
the expression of a large number of genes, but most of these genes were downregulated
during sustained application of shear stress (24 hours) (260). DNA microarray studies
have been performed and reveal comprehensive analysis of gene expression profiles in
EC under shear stress (263;264). Human aortic endothelial cell (HAEC) monolayer were
seeded onto glass slides and placed into a flow system composed of a silicone gasket
mounted between the glass slide and an acrylic plate and exposed to laminar shear stress
of 12 dynes/cm
2 for 24 hours (263). This level of shear stress is encountered under
physiological conditions in the straight part of the aorta and is frequently used to study
the effects of shear stress on EC (265). A significance difference (P < 0.05) wasChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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observed in 125 genes between the sheared and static samples. Several proinflammatory
and prothrombotic genes were significantly downregulated, including an adapter protein
myeloid differentiation primary response gene 88 (MYD88, 0.37 ± 0.15) that is essential
for signalling.
The EC growth factor, transforming growth factor-β2 (TGF-β2, 0.42 ± 0.05)
was also significantly downregulated by 24 hours of shear stress (263). Furthermore,
ECM-related genes such as cytokeratin 4 (0.34 ± 0.04) and laminin-α4 (0.54 ± 0.08)
were also observed to be significantly downregulated. This was further confirmed by the
significant upregulation of matrix metalloproteinase-1 (MMP-1, 2.77 ± 0.35) in response
to 24 hours of shear stress. Many signal transduction related-genes in particular those
related to endothelium-specific receptor tyrosine kinases such as angiopoeitin-Tie 2 and
FlK-1 (266;267) were found to be upregulated. The screening of mRNA from human
umbilical vein endothelial cells (HUVEC) identified 52 genes to have significantly
altered expression when exposed to shear stress of 25 dynes/cm
2, compared with static
conditions (264). The most dramatically up-regulated gene expression was observed in
the cytochromes P450 (CYP) gene’s (264;268). In particular, the CYP1A1 and 1B1 were
only affected by shear stress in HUVEC. The strong induction of these CYP genes by
shear stress is consistent with the suggestion that physiological levels of shear stress are
protective forthe endothelium.
Turbulent flow patterns including flow separation, flow reversal, and low and
fluctuating wall shear stress (< few dyne/cm
2) occurs at branched points and
bifurcations in the arterial vasculature where they are prone to atherosclerotic lesions
(250;269). Several studies have examined the response of EC to turbulent shear stress.
EC produce urokinase-type plasminogen activator (uPA) that has been shown to
stimulate the migration and proliferation of SMC and indirectly activate MMP that
degrades the ECM (270). Its increased expression has also been observed in SMC
during neointimal formation in injured rat arteries (271).
The effects of laminar and turbulent shear stress on the expression of uPA at both
protein and mRNA level was investigated in human coronary artery endothelial cells
(HCAEC) (272). A parallel plate-type apparatus (253) was used to apply laminar shear
stress of 15 dynes/cm
2 and a cone-plate-type apparatus (254) was used to apply
turbulent shear stress of 1.5 dynes/cm
2. ELISA and real-time PCR analysis showed
laminar flow to downregulate uPA gene expression by HCAEC whilst turbulent shearChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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stress markedly increased its expression. A nuclear run-on assay demonstrated a
decrease in the transcription of uPA gene expression in HCAEC after 3 hours exposure
to laminar flow, whereas turbulent shear stress had no effect. This study provides some
evidence that turbulent shear stress may contribute to the pathogenesis of
atherosclerosis by increasing endothelial uPA production. Laminar shear stress increases
the atheroprotective gene NO in HUVEC whereas turbulent shear stress has no effect
(273). Recent studies have revealed striking differences in the number of endothelial
genes that respond to laminar or turbulent shear stress (274).
Table 2-2. mRNA response to mechanical forces when exposed to cultured cells.
Keys: BAEC – bovine aortic endothelial cells; HAEC – human aortic endothelial
cells ; HUVEC – human umbilical endothelial cells; HCAEC – human coronary
artery endothelial cells; PCAEC – porcine coronary artery endothelial cells; HUSMC
– human umbilical smooth muscle cells; HSVEC - human sapheneous vein
endothelial cells; HASMC – human aortic smooth muscle cells; TGF – transforming
growth factor; PDGF – platelet derived growth factor; bFGF – basic fibroblast
growth factor; MMP – matrix metalloproteinase; TIMP - Tissue inhibitors of
metalloproteinases, ICAM- intracellular adhesion molecule; VCAM – vascular
adhesion molecule; EGR1-early growth response-1; cfos – transcription factor; Tie2
- angiopoeitin-1; eNOS – endothelial nitric oxide synthase; CYP - cytochrome P450;
MCP-1 - monocyte chemoattractant protein-1; tPA – tissue plasminogen activator ;
uPA – urokinase-type plasminogen activator; PAR-1 - protease-activated receptor-1.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Gene Cell type Shear stress/Cyclic strain Period Response Author
Growth factors
TGF-β1 BAEC 15 dynes/cm2 24 hrs Increase (275)
TGF- β2 HAEC 12 dynes/cm2 24 hrs Decrease (263)
PDGF-A HUVEC 16 dynes/cm2 1.5-2 hrs Increase (268)
PDGF-B HUVEC
BAEC
31 dynes/cm2
60 cycles/min; 10 % strain
4 hrs
4hrs
Decrease
Increase
(268)
(276)
bFGF HUVEC
BAEC
15 dynes/cm2
36 dynes/cm2
20 cycles/min; 20 % strain
24 hrs
6 hrs
20 min
Increase
Increase
No change
(277)
(278)
(278)
ECM/ECM degradation enzymes
Collagen VII HCAEC 15 dynes/cm2 3, 6, 12, 24, and
48 hrs
Increase (279)
MMP-1 HAEC 12 dynes/cm2 24 hrs Increase (263)
MMP-2 BAEC 60 cycles/min; 2.5 % strain 8 hrs Increase (280)
TIMP1/2 HAEC 12 dynes/cm2 24 hrs No change (263)
Adhesion molecules
ICAM-1 HUVEC
HUVEC
2-25 dynes/cm2
15 dynes/cm2
12 hrs/48 hrs
4 hrs
Increase
Increase
(281;282)
(283)
VCAM-1 HUVEC
HUVEC
HUVEC-HUSMC
coculture
2-25 dynes/cm2
15 dynes/cm2
12 dynes/cm2
12 hrs
4 hrs
6 hrs
Decrease
No change
Decrease
(281)
(283)
(284)
E-selectin HUVEC-HUSMC
coculture
12 dynes/cm2 6 hrs Decrease (284)
Cell signalling
EGR-1 HUVEC 20 dynes/cm2
3 dynes/cm2
30 min
30 min
Increase
No change
(285)
c-fos HUVEC
HUVEC
16 dynes/cm2
16 dynes/cm2
30 min
1 hr
Increase
Decrease
(286)
(286)
Tie2 HAEC 12 dynes/cm2 24 hrs Increase (263)
Vasoactive compounds
eNOS BAEC
PCAEC
HUVEC
60 cycles/min; 10 % strain
60 cycles/min; 6 % strain
8 dynes/cm2
24 hrs
18-24 hrs
6 hrs
Increase
No change
Increase
(287)
(288)
(273)
Endothelin-1 HUVEC
HUVEC
25 dynes/cm2
8 dynes/cm2
6 hrs, 24 hrs
6 hrs
Decrease
Decrease
(264)
(273)
CYP 2C PCAEC 60 cycles/min; 6 % strain 18-24 hrs Increase (288)
Others
MCP-1 HUVEC
EC-SMC
coculture
16 dynes/cm2
12 dynes/cm2
1.5 hrs
1.5 and 6 hrs
Increase
Decrease
(289)
(290)
tPA HSVEC
HUVEC
60 cycles/min; >7 % strain
25 dynes/cm2
1, 3 and 5 days
24 hrs
Increase
Increase
(291)
(292)
uPA HCAEC 1.5 dynes/cm2 I hr
3hrs
Increase
Decrease
(272)
PAR-1 HASMC 60 cycles/min; 20 % strain 6 hrs Increase (293)
CYP 1A1,
CYP 1B1
HUVEC 25 dynes/cm2 24 hrs Increase (264)Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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2.2 Haemodynamics plays a key role in tissue engineering
2.2.1 Neointimal thickening in prosthetic grafts
Following prosthetic arterial grafting, neointimal thickening, prominently at the
distal anastomosis, has been implicated as the major cause of restenosis and long term
graft failure. Studies have established that non-uniform haemodynamics including
disturbed flows in particular at the anastomosis, abnormal WSS, compliance mismatch
and mitogen release from platelets, leukocytes and vessel wall cells are the aetiologies of
neointimal hyperplasia. The extent of neointimal thickening depends on the rate of
blood flow or shear stress. When grafts are allowed to heal under high blood flow or
high shear stress, a smaller neointima is formed as compared to those that heal under
normal flow or shear stress (294). Subsequently when the high shear stress (~50
dynes/cm
2) exposed grafts are returned to normal shear stress (~10 dynes/cm
2), the
neointima begins to expand due to SMC proliferation and ECM production (295).
During arterial development there is a balance between cell proliferation and matrix
protein synthesis and as well as cell death and matrix degradation (296-298).
Berceli and colleagues examined whether flow-induced neointimal regression in
prosthetic grafts occurs through a similar perturbation mechanism. PTFE grafts (5 cm
in length and 4 mm in diameter) were placed in male baboons and the haemodynamics
were monitored using Duplex ultrasonography (299). The prosthetic graft was able to
heal and the growth of neointima was observed in a normal flow environment largely
because of subendothelial SMC replication. They demonstrated that the rate at which
neointimal hyperplasia develops is dependent on the balance between subendothelial
cell replication and cell death in the region adjacent to the graft. By modulating the
haemodynamics environment and more specifically through changes in shearing forces,
the balance between these processes appears to be altered and results in a change in
neointimal thickness within the graft. Regression occurred by day 7 through
simultaneous reduction in cell number and loss of surrounding matrix. This agrees with
recent findings that reveal an increase in MMP such as MMP-2 and MMP-9 under
conditions of high flow (300). These findings are similar to other studies where cell
proliferation and death were closely regulated by shear stress (297). To examine ECM
changes during neointimal regression, blood flow through PTFE grafts, which had
healed for 2 months under normal blood flow (~10 dynes/cm
2), was switched to highChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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flow (~40-60 dynes/cm
2) for up to 56 days. Under all conditions studied the graft
neointima was rich in hyaluronan and verscan and lacked elastin, similar to the intimal
ECM produced after angioplasty (301).
2.2.1.1 Genes involved in neointimal thickening
Compliance mismatch between the graft and native artery at the anastomosis
leads to excessive stretching of the SMC, leading to enhanced proliferation. Turbulence
of blood flow around the anastomosis causes EC damage which in turn leads to
expression of growth factors that affect the SMC. This alteration of active genes can
change the levels of intracellular proteins and the production of ECM molecules,
resulting in the SMC migrating into the neointima then proliferating and so causing
deposition of an ECM causing a restenotic anastomotic lesion. While many researchers
have identified factors responsible for intimal hyperplasia, the mechanism of action of
these factors has yet to be elucidated.
Several genes have been identified with altered expression at the distal
anastomosis following prosthetic arterial grafting (302-304). Using microarray
technology, gene expression patterns in vivo were evaluated at the distal anastomosis of a
canine prosthetic arterial grafting model across several time intervals (305). After 7, 14,
30 and 60 day implantation, 1 cm of distal ePTFE grafts at the anastomosis and adjacent
native artery was removed for RNA extraction. The screening of selected genes, in
particular collagen type I, α-I and α-II and osteopontin, showed an increase in mRNA
expression at all time points. Collagen type 1 was also shown to be upregulated by
Geary et al. in the neointima as compared to normal primate aorta and is a major part of
the ECM (306). Subsequently Kalish and colleagues used a similar model and found
collagen type I (α-II), III, IV and XI and procollagen type I expression to be
upregulated in autologous vein bypass grafting in vivo (307). However certain genes
which have been associated with IH were shown to be absent, including fibroblast
growth factor, PDGF-α, TGF-β, osteopontin and elastin (307). It is suggested that the
genes that are associated with vein graft remodelling are not identical to the genes
expressed after injury models and prosthetic arterial bypass grafting. As well as collagen
expression, osteopontin a phosphoprotein that functions as a cell adhesion and
migration molecule has found to be involved in the development of medial thickening
and neointima formation (308). Reduced mRNA expression of genes such asChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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smoothelin-B, a marker of mature contractile VSMC (309) were also observed at the
anastomosis (neointima and adjacent) throughout each time point examined in both
prosthetic and autologous vein bypass grafting (305;307). Overall the genes that have
been found to be expressed at earlier time points were found to be transcription factors
(jun-B and c-fos) key for activating growth promoting genes. However, many of the
genes that were upregulated at the later time points (30 - 60 days) of implantation, such
as allograft inflammatory factor (AIF-I) in which its expression may be due to the
prosthetic material present at the anastomosis and matrix –associated genes such as
fibronectin and collagen type II (α-I) (301). Further studies are required to localise such
gene products to a specific cell type at the anastomosis.
EC that produce, among other substances PDGF-BB and bFGF, have an
important role in the development of anastomotic neointimal hyperplasia. PDGF has a
major role in promoting migration of SMC from the media to the intima and bFGF is
characterised by its affinity for heparin and its ability to stimulate EC and SMC
proliferation. ePTFE disks were seeded with HUVEC in serum-free media (310). The
release of PDGF-BB and bFGF from EC seeded ePTFE was significantly higher when
than that released by EC seeded into TCP. This release of mitogens confirms that EC
seeded ePTFE grafts might synthesise and release growth factors that regulate SMC
proliferation and the process of intimal thickening (311). Pitsch and colleagues seeded
EC on Dacron grafts and implanted them in a canine model (n = 11) for 20 weeks in
order to identify the cells in vascular grafts that produce PDGF (312). The EC and SMC
were cultured from grafts and adjacent aorta. Increased PDGF was observed in graft
SMC as compared with aortic SMC, suggesting that graft SMC may be a contributing
factor to the development of intimal hyperplasia. Elsewhere the effect of high blood
flow on the expression of eNOS was investigated in femoral arteriovenous shunt (AVS)
rats created by inserting U-shaped polyurethane tubes in the left femoral arteries and
veins. At the site of the distal anastomosis mRNA expression levels of eNOS were
increased whereas inducible nitric oxide synthase (iNOS) was not (313).
2.2.2 Gene expression in prosthetic grafts
Understanding the cellular response to a foreign substance is vital. The
investigation of gene expression patterns allows determining if the cells are expressing
any detrimental effects in the short and long term. In later chapters, gene expression ofChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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cells seeded on nanocomposite is the prime investigation of this thesis. In particular the
cells response to shear stress is examined.
Gene expression associated with cellular proliferation, adhesion and ECM
formation have been poorly studied on cylindrical prosthetic grafts. The lack of such
studies may have been due to the difficulties in harvesting cells from the graft surface in
order to extract mRNA. As reported above, studies to characterise gene expression in
response to flow have been determined through applying flow to cultured EC and
vascular SMC. Other reports have focused on seeding cells onto flat sheets of polymer
and monitoring gene expression (314;315). Zhang and colleagues (314) assessed cell
growth in vitro on a peptide based poly(urea-urethane) polymer. Rabbit bone marrow
stromal cells (RBMSC) were cultured for 7 days on flat sheets of degradable lysine-di-
isocyanate-glycerol-urethane (LDI-glycerol) and compared expression for collagen type
1, TGF-1 and osteocalcin. There was no significant difference between the mRNA
expression of these factors in RBMSC grown on LDI-glycerol polymer or on control
tissue culture polystyrene. The Menconi group (315) extracted RNA from BAEC after 5
days of culture of flat sheets of two poly(ether)urethanes: Biomer and Tecoflex SG60D
respectively. Expression of fibronectin, actin, vimentin, histone and collagen was
investigated and it was found that significantly lower levels of fibronectin, actin and
vimentin were being produced by day 5, whilst no collagen at all by day 5 and very
limited levels of histone in both polymers.
Although the expression of vital genes has been found to alter when present on
flat sheets of polymer in response to shear stress, there is still the question whether
these genes behave in a similar way when seeded on cylindrical grafts and exposed to
flow. In this thesis, one objective was to focus on developing a reliable method for
obtaining functional mRNA from cells seeded on vascular prosthetic grafts (see Chapter
4). This would then enable the next major challenge in this work of investigating gene
expression in response to shear stress.
Currently only two-dimensional models exist and three-dimensional studies are
required to understand the behaviour in particular gene function of vascular cells when
seeded onto three-dimensional grafts used for bypass surgery. Three-dimensional
models also more accurately represent an in vivo environment. Li and colleagues studied
the profile genomic remodelling of SMC in three-dimensional collagen matrix and on aChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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two-dimensional collagen matrix surface and to elucidate the signalling events leading to
the differential expression profile (316). HASCMC were cultured on two-dimensional
and three-dimensional collagen matrix for 24 hours and then extracted for RNA
isolation. DNA microarray revealed changes due to the differences in matrix geometry.
Compared to two-dimensional matrix, the expression of p21 (cell cycle regulator) was
found to increase compared to three-dimensional matrix. Hence this may suggest the
factor responsible for the decreased proliferation in three-dimensional culture.
Moreover, three-dimensional matrix yielded higher levels of gene expression for matrix
proteins collagen 1 and fibrinogen, indicating that SMC were more synthetic in this
matrix. The matrix remodelling gene, MMP-1 did not change with matrix geometry.
This study helped to define the molecular mechanisms involved in the phenotypic
modulation by matrix geometry, as the results suggest that SMC in three-dimensional
matrix are more synthetic, less proliferative and less contractile.
In vitro models of vasculogenesis and angiogenesis have shown EC to sprout,
proliferate, migrate or differentiate in a three-dimensional manner (317). Ueda et al
constructed an in vitro three-dimensional model composed of networks of capillary-like
structure in order to assess the effects of shear stress on microvessel formation (318).
Bovine pulmonary microvascular EC (BPMEC) were seeded onto collagen gels and
supplemented with bFGF to promote network formation (319). The collagen gel with
three-dimension networks were then placed into a parallel-plate flow chamber and
subjected to laminar shear stress. Growth of the network was observed by electron
microscopy and measured in terms of length. After 9 hours, applied shear stress did not
significantly affect the network formation (length, 1.38 ± 0.14); however after 24 hours
the enhancement was significant (length, 3.13 ± 0.46). Previous studies reported that
laminar shear stress induced bFGF mRNA expression (320;321), this study shows that
in the presence of bFGF, the migration velocity of EC without shear stress only slightly
increased, whereas that of EC under shear stress conditions significantly increased.
Few studies have been attempted to understand the molecular response vascular cells
have when present on vascular grafts. Ideally further work is still required to understand
the interaction of cells present on biomaterials and their ability to adapt and create a
functional tissue.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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2.2.3 Application of shear stress for development of small diameter grafts
Recent efforts in developing small diameter grafts for CABG have been limited.
These efforts range from developing hybrid grafts such as a bypass graft constructed
from a synthetic material and lining the lumen with EC, to growing a living tissue (in
vitro) using EC, SMC and ECM components (as discussed in Chapter 1).
In cell culture, EC rapidly lose their differentiated nature and when seeded onto
vascular graft material, they do not sufficiently adhere or differentiate. Furthermore, as
with most eukaryotic cell culture preparations, a proportion of the seeded cells will
spontaneously lose their initial attachment, become spherical, and float away, caused by
either cell death or damage during the culture process (322). Once the graft is exposed
to in vitro and in vivo pulsatile flow, a high proportion of the remaining cells are washed
off from the lumen (323). Maximum cell loss from the graft occurs rapidly in the first 30
minutes with up to a mean cell loss of 70.2% of the original number. After that, a
slower exponential cell loss occurs from 30 minutes to 24 hours after implantation. In
arterial vessels the high shear stress on EC is successfully resisted by a well-developed
intracellular cytoskeleton, which guarantees better surface attachment as well as the
flattened, longitudinal alignment of spread EC. The differentiation of the cytoskeleton
begins only after a confluent monolayer is achieved (324) and therefore cell attachment
and then spreading remains a primary principle during the period of preconfluence.
In an effort to improve EC attachment and EC retention rate (retention of EC
when the grafts are exposed to flow) techniques have been used which include
precoating the graft lumen with EC specific adhesive moieties (325), and shear stress
preconditioning (326).
Many researchers have used a variety of precoating substrates that are mostly
found in the extracellular basement membrane of blood vessels these range from
chemical coating such as collagen type I/III, laminin and poly-1-lysin to preclotting with
plasma, blood and fibroblast matrix/fibrin glue (327). In a recent report, Fernandez et al.
assessed the quality control of precoating 4 mm internal diameter ePTFE grafts for in
vitro EC seeding (328). The grafts were coated with fibronilitically inhibited fibrin glue
which is currently being used in clinical trials (329;330). Histologic cross sections of the
graft lumen revealed the inner surface completely covered by a monolayer of flattenedChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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EC, positive for CD31 and CD34. Furthermore the EC monolayer integrity was still
maintained after 2 hours of physiological shear stress. In an in vitro experiment, EC were
seeded to vascular biomaterials which were coated with fibrin. In comparison those that
were not coated with fibrin revealed approximately 40 % of cell adhesion whereas the
coated grafts presented a confluent monolayer of cells after 48 hours. After 1hour of
shear stress of 2.5 dynes/cm
2, coated ePTFE and Dacron grafts showed an undisturbed
confluent monolayer whereas few cells were retained on the bare ePTFE and Dacron
(331). These studies have shown that surface coating dramatically improves cell
adhesion, proliferation and cell retention to resist forces of shear stress on vascular
material surfaces. ECM (collagens, proteoglycans elastin etc) secreted from cells
contribute to the adherence of cells to the prosthetic graft.
2.2.3.1 Stabilizing the ECM
A further study investigated whether increasing and stabilising the ECM secreted
from cells could enhance cell adhesion and therefore improve cell retention on the
prosthetic graft (332). As SMC secrete greater amounts of ECM than EC, they
hypothesised that seeding SMC could be used to improve cellular adhesion onto
prosthetic materials. Seeding of SMC on grafts has been studied by a few groups
(333;334) but limited reports have focused on SMC seeding in the context of enhancing
EC adhesion and retention. The SMC cellular layer between the seeded EC and the graft
surface was used to enhance EC retention on prosthetic grafts (335). Furthermore, a
zymogen tPA mutant gene was transduced into the EC. As discussed earlier, tPA is a
thrombolytic protease which converts inactive plasminogen into active plasmin, which
then degrades fibrin complexes, a major component of a thrombus. Transfecting cells
with the wild-type tPA leads to overexpression of tPA which induces non-specific
proteolysis of the supporting ECM and so decreasing the retention of seeded EC on
prosthetic grafts (336;337). Zymogen tPA has low protease activity once secreted from
the cells and should exhibit limited digestion of the ECM while being able to enhance
the antithrombogenic activity of seeded cells. After ePTFE grafts were exposed to in
vitro flow of 6.1 dynes/cm
2 for 60 minutes, approximately 60 % of EC (retention rate of
39 %) were lost when the cells had been seeded an a graft alone. The retention rate of
EC seeded on top of SMC (73 %) was significantly higher than that of EC seeded alone.
Grafts seeded with cells carrying the gene for the zymogen tPA showed significant
improvement in cell retention (54 %) compared to those with wild-type tPA (39 %). InChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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conclusion to this study, dual seeding with SMC and EC could result in a better
adhesion of SMC on the graft surface, or the interaction between EC and SMC increase
the cell adhesion respectively.
The dual-cell seeding on the surface of prosthetic grafts will best mimic the
natural vessel structure of vessels. In addition, the presence of zymogen tPA was not
shown to increase protease activity significantly but played a part in decreasing fibrin on
the lesion site thus enhancing antithrombosis and therefore increasing cell retention.
Dual seeding of ePTFE grafts was assessed in vivo and further confirmed an increased in
cell retention after 1 day implantation (335). Further studies are still required to
determine whether the overlying EC modulate proliferation of underlying SMC.
2.2.4 Shear stress preconditioning
Shear stress preconditioning of EC seeded grafts has made a major impact in
vascular tissue engineering and has been shown to promote EC retention and
differentiation on the inner graft surface (326;338-340). The idea has been to subject
cells to low shear stress and then to apply the insult that is physiological levels of shear
stress. Table 2-3 outlines the preconditioning studies that have been carried out on
vascular cell seeded grafts.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Table 2-3. Overview of preconditioning in tissue engineering.
Keys: ePTFE – expanded polytetrafluoroethlene; PU – polyurethane; PCU –
poly(carbonate)urethane; RAEC – rat aortic endothelial cells; PASMC – porcine aortic smooth
muscle cells; PAEC – porcine aortic endothelial cells; FB – fibroblasts; SMC – smooth muscle
cells; EC – endothelial cells; SV – sapheneous vein.
Year pub. Vascular graft Application cells Test/preconditioning Outcome
1988
(341)
ePTFE, Dacron Evaluate conditions to
produce EC
monolayer
HUVEC Perfused in vitro to
confluence then subjected to
varying flow to achieve
durable EC monolayer on
graft
Confluence complete post
2hrs of in vitro perfusion (15
ml/min)
Confluency maintained
after exposure to flow (100
ml/min)
1991
(342)
Fibronectin-
coated ePTFE
Flow applied to study
effects of cell density
and post-seeding
incubation time on
cell retention
HSVEC Grafts with different cell
densities and incubated at
various times were exposed
to 90 minutes of pulsatile
flow in vitro
 cell retention when grafts
exposed to flow for 90
minutes after seeding
compared to later time
points
1991
(343)
Porous PTFE Assessment of cell
proliferation
SMC In vivo luminal shear stress Elevated shear stress
inhibited SMC proliferation
1995
(339)
PU Assessment of cell
retention
BAEC In vitro culture for 6 days
with/without laminar shear
stress (1-2 dyne/cm2 for 3
days and 25 dyne/cm2 for 3
days)
 cell loss in static grafts
compared to grafts
preconditioned by shear
stress
1998
(208)
ePTFE, PCU Effect of shear stress
on polymer
HUVEC In vitro pulsatile shear stress Higher % of cells retained
on PCU than ePTFE grafts
1999
(338)
PU Assessment of cell
retention
RAEC In vitro shear stress initiated at
1 dyne/cm2 for 3 days,
following 25 dyne/cm2 for
further 3 days. Grafts
underwent in vivo
implantation for 24 hrs and 3
months
Confluent EC monolayer
observed lining the graft
lumen after shear stress
pre-treatment prior to
implantation in vivo. Grafts
pre-treated contained
undisrupted EC post
implantation
2002
(214)
PCU Development of
tissue engineered
bypass graft
HUVEC In vitro pulsatile flow  cell metabolic activity
observed on RGD/Hep-
bonded graft than native
PCU
2003
(344)
Micropatterned
PU films
Flow studies to assess
cell retention on μ-
patterned/non-
patterned PU
BAEC In vitro shear stress of ~60
dynes/cm2 for 1 hr
μ-patterned PU polymer
generated reduced stress,
leading to notably  in
retention of EC under high
shear stress
2003
(344)
PU To reduce
thrombogenecity by
lining luminal surface
with vascular cells
SMC,
FB and
EC from
SV
Grafts perfused under
pulsatile flow
Seeding of mix culture of
cells resulted in improved
EC adherence and
resistance to shear stress
2004
(326)
Tissue engineered
graft using
Dacron scaffold
Assessment of cell
retention
PASMC,
PAEC
In vitro 1-2 dyne/cm2 Confluent EC lining with 
numbers of flattened cells
on preconditioned SMC
collagen matrixChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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The application of shear stress to vascular prosthesis was investigated recently.
This study aimed to assess whether cells seeded onto vascular grafts or heart valve
prosthesis could withstand shear stress immediately or whether they required a period of
low flow to adapt (345). In contrast to artificial precoating of the graft surface, the
synthesis of ECM proteins by interstitial or other vascular cells could improve the link
between EC and the surface. Excellent adhesion of EC was shown on the ECM built
with Fb (346;347). The matrix was composed of culturing foetal human Fb on
polyurethane sheet. Fb and SMC represent the physiologic substrate on which EC
attach. Together with these cells, EC can synthesise their own ECM and form a
basement membrane that is proved by the increased synthesis of collagen IV and
laminin on grafts preseeded with Fb and SMC compared with EC seeded alone. PCU
vascular grafts were seeded with a mixed culture of Fb and SMC followed by EC from
SV. The grafts were exposed to recovery phase (0.9 ± 0.3 l/min at 80 pulses per minute
resulting in maximum pressure of 50/30 mmHg) and high flow (3.2 ± 0.61 l/min
resulting in maximum pressure of 160/0 mmHg). The first group of grafts were
exposed to high flow immediately, the second group were exposed to an recovery phase
of 15 minutes and the third group were subjected to 30 minutes of recovery phase. A
cell loss of approximately 40 % was found after 4 hours perfusion with normal flow
(grafts exposed to high flow immediately) from all cell types Fb SMC and EC. After 15
minutes of recovery phase, the remaining confluence coverage of this prosthesis was 82
± 8 % and the defects were much smaller compared to those seen on the grafts
perfused without an recovery phase.
Immunohistochemical staining against CD90 and -actin revealed a still
confluent layer on the luminal surface of the grafts. Staining against collagen IV and
laminin proved the basement membrane to be uninterrupted. After 30 minutes of
adaptation phase, there was no cell loss observed and EC layer remained confluent. The
cells demonstrated a change in shape indicating adaptation to shear stress. An
adaptation phase of 30 minutes proved to be sufficient to allow seeded cells to adapt to
shear stress and increase their adhesion and resistance. In this study, the cells faced
shear stress after static culturing. The intention was to examine whether the cells could
adapt to flow within a reasonable time interval. Miyata et al also reported improved EC
adhesion on PTFE prosthesis after delayed exposure to shear stress (348). There was
great cell loss from the grafts when normal flow was applied immediately. The
introduction of an adaptation phase with lower flow and resulting pressures, however,Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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showed that the cells had not lost their ability to react to shear stress after being cultured
under static conditions.
In our department the effect of flow on EC and SMC seeded grafts have also
been studied (208;326). The objective has been to assess a compliant graft for effective
cell attachment and cell retention at physiological levels of pulsatile shear stress over a 6-
hour period of physiological pulsatile flow. HUVEC seeded on PCU and ePTFE
vascular grafts were exposed to varying shear stress (13.8  0.6 dyne/cm
2) using a
pulsatile flow model. Dynamic scintigraphy images showed a higher percentage of cells
were shown to be retained on the PCU graft after exposure compared to ePTFE (208).
The flow model used in this study provided an effective model for assessing cell
retention on graft materials under flow. Other groups have also analysed the effects of
shear stress in vitro on vascular cell seeded bypass grafts (344;348). Our group employed
both tissue engineering and shear-stress preconditioning to generate conduits suitable
for the application as vascular grafts (326). Tissue engineered grafts were composed of
compliant outer wraps of Dacron used to give physical structure to the constructs,
fibronectin together with collagen to form the ECM substratum, porcine aortic EC and
a layer of underlying SMC in order to increase EC adherence and differentiation. This
study tested the hypothesis that incorporation of such elements into the development of
arterial substitutes would result in significantly improved EC retention. A physiological
flow circuit was used to precondition the tissue engineered grafts at 10–20 dynes/cm
2.
On being subjected to 1 hour of shear stress, the tissue engineered grafts that had been
pre-coated with fibronectin prior to EC seeding demonstrated significant enhanced
resistance to shear stress compared to static grafts (p < 0.05) and the continued viability
of the endothelium was indicated by steadily increasing tPA production. Furthermore,
environmental scanning electron microscopy revealed an almost confluent EC lining in
tissue engineered grafts to compared non-preconditioned groups. We have enhanced
EC attachment and resistance to shear stress by incorporating a period of
preconditioning at 10–20 dynes/cm
2, as well as by surface modification with fibronectin
and collagen to mimic endogenous ECM. Whilst the benefit of seeding EC on to these
tissue engineered grafts is not apparent in acute studies, it is hypothesized that the
interaction of SMC within the matrix and EC will lead to ultimate basement-membrane
formation and subsequently a stable endothelium will be sustainable in the long term.
Evidence in the literature supporting this hypothesis is based on co-culture models
(349). Seliktar and colleagues (350) investigated the ECM-remodelling capacity of tissueChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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engineered grafts undergoing mechanical conditioning and concluded that matrix
remodelling occurs via the MMP system, and that such remodelling would be highly
beneficial in an engineered construct. Stegemann and co-workers (351) have
demonstrated that rat SMC in collagen gels, when subjected to mechanical strain, adopt
a contractile phenotype and produce dense ECM. Similarly, Gulbins et al also seeded
human EC, Fb and SMC onto nondegradable polyurethane vascular grafts and
preconditioned them with 30 to 40 mL/min at 80 pulses per minute, resulting in a
pressure of 50/30 mmHg (344). Flow was then increased to 120 mL/min after 30 mins,
resulting in a pressure of 140/80 mmHg. Total shear stress lasted for 2 hours. Seeding
of a mixed culture improved EC adhesion and resistance to shear stress. This outcome
was caused by an increased synthesis of ECM proteins, collagen IV and laminin. This
supports the hypothesis that Fb and SMC are of great importance for the synthesis of
the ECM and that intercellular interactions contribute to improved adhesion.
The action of shear stress on the attachment, morphology and adherence of
human EC to ePTFE, Dacron and polyurethane has been assessed. These were coated
with ECM proteins (collagen type I/III) (352). Fluid shear stresses of 10 and 20
dynes/cm
2 (1 and 2 Pa), equivalent to the mean shear stress that develops at the
proximal end of a femoro-popliteal bypass (339;353), was applied by using a cone-and-
plate rheometer (354-357) for 1 hour. The number and area of cell coverage and degree
of cell spreading was determined by using image analysis techniques. The researchers
found that an increase in shear stress from 10 to 20 dynes/cm
2 showed a significant
reduction in the number of cells remaining adherent in ePTFE (66 ± 19 % at 10
dynes/cm
2 and 49 ± 20 % at 20 dynes/cm
2) and Dacron (48 ± 24% and 30 ± 2 %) but
not on poly(ether)urethane (44 ± 17 % and 40 ± 14 %) respectively. It was evident from
this study that after 6 days in culture and 1 exposure to flow enabled the remaining
HUVEC to resist shear stress, having spread to a greater extent than on static control
samples. These results are consistent with recent reports in that the action of shear
stress exposed to growing EC significantly enhances cell adhesion in vitro (338;358).
They also found that collagen coating improved primary cellular adhesion and coverage
significantly, the degree of spreading depended on the application of shear stress.
Previous studies have identified that both fibronectin and collagen type I/III results in a
higher attachment of HUVEC to prosthetic vascular biomaterials (325;359).Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Ott and colleagues seeded poly(ether)urethane vascular grafts (1.5 internal
diameters) with BAEC and cultured for 6 days with/without laminar shear stress, first at
1-2 dynes/cm
2 for 3 days and then 25 dynes/cm
2 for 3 days (360). The preconditioned
grafts and static grafts were further exposed to shear stress at 25 dynes/cm
2 for 25
seconds. Preconditioned grafts showed less cells being dislodged (1.05 x 10
4 ± 0.16 x
10
4) compared to static grafts (1.35 x 10
6± 0.44 x 10
6). These findings suggest that EC
adhesion and retention on vascular grafts in vitro is markedly enhanced by
preconditioning the seeded EC monolayer with long-term shear stress. This study
demonstrated EC to exhibit increased adhesive strength in response to arterial levels of
shear stress (360) and therefore it has been suggested that this concept of shear stress
pre-treatment could also enhance EC retention on vascular grafts implanted in vivo.
As viscosity is an important factor influencing shear stress, blood does not
behave like an ideal fluid, thus causing additional forces on the EC layer compared with
those caused by a cell-free medium. Therefore grafts will have to prove their resistance
to physiological shear stress in animal experiments. Despite a lack of in depth molecular
studies in this field of preconditioning using shear stress, research to date indicates that
preconditioning promotes cell retention. In addition increase in ECM proteins and cell
spreading has been observed.
2.2.5 Genes of potential relevance to shear stress studies on seeded vascular
conduits
This chapter has provided an insight of gene expression and signal transduction
pathways involved in determining the responses of vascular cells to shear stress and the
role of haemodynamic forces in thrombus formation and intimal hyperplasia following
bypass surgery. Despite the intensive studies on the effects of shear stress on EC, the
interplay between shear stress and vascular grafts in modulating EC gene expression and
function has been very limited. In vascular tissue engineering, shear stress has been
mimicked in vitro to enhance EC retention and adhesion to biomaterials. A lack of
understanding has been the gene response of vascular cells to biomaterials with and
without flow. From this literature review a selection of genes are of potential interest in
understanding EC behaviour on vascular grafts, in particular in response to shear stress
in the development of a small-diameter vascular graft. The genes described below are of
potential interest in this thesis.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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2.2.5.1 PECAM-1 is more than an endothelial marker
PECAM-1 has been implicated in a number of important biological processes,
including vascular development (361;362), leukocyte emigration at sites of inflammation
(363;364), T cell activation (365;366), platelet aggregation and homeostasis (367;368)
and the maintenance of vascular endothelial barrier function (369). PECAM-1 also plays
a role in angiogenesis. In terms of EC, angiogenesis can be viewed as a process in which
these cells sever their initial cell-cell contacts, proliferate and migrate into the
perivascular matrix where they re-establish their cell-cell associations to form new patent
vascular channels (370). Although studies do not support a role for PECAM-1 in EC
proliferation (371), a number of reports have implicated PECAM-1 in EC motility (372-
374) and in the EC cell-cell associations required for the organisation of EC into tubular
networks (371;374-377). The mechanism of PECAM-1’s participation in angiogenesis is
still unsettled.
The expression of PECAM-1 has been investigated in EC seeded on vascular
graft materials (378). Dacron coated with fibronectin was used as circular pieces of 15
mm in diameter and seeded with EC from HUVEC and adipose microvessels
(HAMVEC). Cells were cultured for 1-2 days and the expression of PECAM-1 was
determined by flow cytometry and immunofluorescence microscopy. The cells were not
stimulated. The expression of PECAM-1 was found to be constitutively expressed with
similar mean fluorescent intensities suggesting that its expression is dependent neither
on the EC origin nor on the underlying polymer surface. This report has been
consistent with studies based on the in vivo situation, where PECAM-1 is found to be
constitutively expressed on the endothelium of all vessel types (379). In contrast Cenni
et al, reported the downregulation of PECAM-1 expression by HUVEC cultured on
knitted Dacron (380). It can be hypothesised that a decrease in the expression of
PECAM-1 underlies poor adhesion capability of these cells on knitted Dacron or that
the lack of fibronectin coated on this polymer in the latter study, thus resulting in
deficient cell spreading and many nonherent cells. Although many researchers have used
fibronectin to coat vascular materials in order to improve endothelialisation, in the areas
not covered by endothelium an increase in platelet deposition occurs (381).Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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2.2.5.2 Vascular endothelial growth factor receptor in activation of ECs
VEGF, the prototype member of an expanding family of angiogenic polypeptides (382-
384) is an EC specific mitogen that acts through two tyrosine kinase receptors,
VEGFR-1 (385) and VEGFR-2 (386), whose expression is restricted almost exclusively
to EC (387;388). Expression of VEGF and VEGFRs correlates well with phases of
vasculogenesis and angiogenesis, and disruption of either the VEGFR-1 or the VEGFR-
2 gene results in lethal hematopoietic and vascular abnormality (389). In addition to its
involvement in angiogenesis, VEGF may serve other functions such as the endogenous
regulation of vessel permeability, raising the possibility that factors other than VEGF
may determine the angiogenic or nonangiogenic status of EC. For example, it has been
observed that cytokines such as TGF-β1 are capable of modulating VEGF-induced in
vitro angiogenesis (390;391). Regulation of VEGFR expression is likely to play a
fundamental role in the determination of EC activation status. It has been demonstrated
that VEGFRs -1 and -2 is strongly upregulated during phases of capillary growth
(387;388). To date, very little is known about the molecular mechanisms that regulate
VEGFR expression.
2.2.5.3 Vascular growth factors
The transforming growth factor – beta (TGF-β family of cytokines exert
pleiotropic effects upon a wide variety of cell types. Three mammalian isoforms exist;
TGF-β1 -β2 and -β3 encoded by separate genes. TGF-β1 isoform has been
demonstrated to be of fundamental importance during vascular development,
atherogenesis, neointimal proliferation and vessel remodelling (392). It has been found
to be a potent regulator of ECM synthesis, cell cycle progression, apoptosis,
differentiation and migration.
The predominant effects of TGF-β1 on EC are the inhibition of migration,
restriction of cell cycle progression and induction of apoptosis, all of which are dose-
dependant (393). TGF-β1 induces increased expression of integrins, fibronectin,
collagens types I, IV and V and plasminogen activator inhibitor (394). TGF-β1 also
influences SMC proliferation in a dose-dependant manner (395;396). It has been shown
to be stimulatory at low concentrations and inhibitory at high concentrations.Chapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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In angiogenesis, TGF-β1 has shown to facilitate VEGF and bFGF dependent capillary
sprout formation (397) and promotes the stabilisation of the developing vessel by
mediating the recruitment of perivascular cells, promoting ECM synthesis and reducing
ECM proteolysis (398).
Shear stress is the potent stimulator of TGF-β1 expression. EC have shown to
express TGF-β1 in a shear stress-dependent manner (399). Increases of TGF-β1 mRNA
were observed from 6 hour to 24 hour points of applied shear stress (15 dynes/cm
2).
Different forms of fluid shear stress have shown to influence vascular endothelial TGF-
β1 mRNA expression. TGF-β1 mRNA was shown to be up-regulated during steady
pulsatile flow (19 dynes/cm
2) than for oscillatory flow (0+/-19 dynes/cm
2) (400). Given
the preferential localisation of early atherosclerotic lesions in arterial regions exposed to
low and/or oscillatory shear stress and the implication of TGF-β1 as an athero-
protective gene, these results are consistent with the notion that regions transiently
exposed to oscillatory flow may be particular prone to atherosclerosis. TGF-β1
expression is a key interest in this thesis. Understanding the expressional response in a
three-dimensional grafts would more likely represent an in vivo environment. It has
shown to increase the expression of the major ECM proteins, fibronectin and collagen.
This effect is general response to TGF-β1 seen in primary cultures and established lines
of cells from various types, normal and transformed.
2.2.5.4 Extracellualr matrix genes
Collagens are the major protein comprising the ECM. There are at least 12 types
of collagen. Types I, II and III are the most abundant and form fibrils of similar
structure. Type IV collagen forms a two-dimensional reticulum and is a major
component of the basal lamina. This review has shown the expression of collagen’s
involved in particular in neointimal thickening (Section 2.3). Increases in collagen type 1
(COL-1) have been observed at the anastomosis following prosthetic arterial grafting
(306). Increased expression of COL-1 suggests its involvement in the development of
medial thickening and neointima formation (308). COL-1 importance in this thesis has
been demonstrated later.
Another gene of interest is MMPs due to their particular role in cell behaviour
such as endothelial cell migration and matrix remodeling. As discussed earlier (seeChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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Section 2.2.3.6.1) its importance its investigation in this thesis would gain an
understanding of cell-graft behaviour.
2.2.5.5 Housekeeping gene
Control genes, which are often referred to as housekeeping genes, are frequently
used to normalise mRNA levels between different samples. Housekeeping genes are
constitutively expressed; however the expression level of these genes may vary among
tissues or cells and may change under certain circumstances. Thus, the selection of
housekeeping genes is critical for gene expression studies.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) an enzyme of glycolysis
is one of the most commonly used housekeeping genes used in comparisons of gene
expression data. The expression of GAPDH mRNA has been measured in a panel of 72
different pathologically normal human tissue types (401). Comparative levels of
expression were observed demonstrating that GAPDH can be used as the internal
control to add value to gene expression data. Many researchers have used GAPDH as a
control in expressional studies (402-405). The expression of GAPDH has not been
effected by shear stress (406-408).
2.3 Conclusion
The study of haemodynamics is a prosperous field that involves characterising
the biological responses to mechanical forces. Specific arteries exhibit flow
characteristics that are three-dimensional and developing. Diseased arteries can create a
high level of turbulence that can cause the tubes to collapse. The normally functioning
endothelium maintains patency and haemostasis in the vascular system.
Due to the poor patency rates of prosthetic grafts currently used clinically
primarily due to poor compliance and thrombogenicity, seeding and tissue engineering
are being used to improve patency in artificial conduits. Upon implantation of EC
seeded vascular graft into the arterial circulation, cells are immediately exposed to
arterial pressure, shear stress and pulsatile flow. One obstacle of a tissue engineered
graft has been the poor retention of cells after exposure to in vivo flow (208). Various
groups have investigated the effects of shear stress on cell retention (345;409). ShearChapter 2: Molecular aspects of haemodynamics and vascular tissue engineering
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stress preconditioning has been employed as a means of increasing the retention of cells
to the graft surface prior to implantation (338). However, the great disadvantage of such
a conduit is the time necessary for maturation leading to unacceptable delays. This
maturation process is essential to produce a graft that can withstand haemodynamics
stress. Once implanted, the tissue-engineered graft can contract in response to
immediate haemodynamics conditions and remodel in the long term.
The studies in this review demonstrate that the exposure of EC to
haemodynamic flow alter the gene expression of these cells. This represents an
alteration to the physiology of the cells and heralds the case for preconditioning of
grafts before exposure to arterial flow. Results obtained from studies of adhesion
molecule expression have been conflicting with VCAM-1 expression has been reported
to be decreased (281), unaffected (282) or increased (410). Both shear stress and cyclic
strain promote the expression of NOS (273) and subsequently we assume NO. Likewise
in experimental set-ups, the application of shear stress to cultured EC induces increases
in prostacyclin and tPA release (292;411). Key to the studies of cellular adhesion is the
ECM modulation by EC; increases in MMP2/9 (280) and decrease in laminin (263).
The multiple methods and genes used in the studies reviewed here demonstrate many
interesting areas of further research but, at present, this field lacks direction. A key point
is that, to date, no gene expression studies have been conducted on endothelial cell
seeded cylindrical grafts in vitro. In the absence of such studies the interactions between
cells, biomaterials and flow can not be adequately elucidated to aid development of
future strategies. The future of this research must focus upon such studies if meaningful
advances are to be made in this field.Chapter 3: Materials and methods
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Materials and Methods
3.1 Introduction
This chapter discusses the methods and rationale behind the techniques used
throughout this thesis.
Early investigators used animal tissue such as bovine, porcine or canine
endothelium as their source of EC (412). In order to make the transition from
laboratory research to clinical practice it is necessary to obtain a source of cells from the
patient themselves. In humans there is increasing evidence to show that cells of the
same type from different tissues are morphologically, biochemically and functionally
diverse. These findings of endothelial heterogenecity have resulted in debate regarding
which type and source of EC are suitable for in vitro and in vivo studies and it has become
accepted that this is a major consideration in tissue engineering. As a result of this
numerous sources of cells have been investigated, including non-essential vessels such
as the SV or umbilical vein and omentum or subcutaneous adipose tissue (212;413;414).
EC from a suitable piece of SV allows approximately 1 x 10
4 cells to be extracted
(195;415). This amount of cells would only provide a sparse coating of cells in a single
stage procedure, requiring an extensive cell proliferation post-seeding to achieve aChapter 3: Materials and methods
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monolayer. In addition blood-flow induced shear stress could also result in the loss of a
large number of seeded cells (323).
Two techniques that have been developed in order to harvest EC from
autologous vein are mechanical scraping (416) and enzymatic digestion using collagenase
or trypsin (417). Mechanical scraping uses an abrasive action to remove EC from the
vascular wall which leads to significant EC damage, the possibility of contamination
with SMC and provides a poor harvest of EC (417). Enzymatic digestion using
collagenase or trypsin to remove the endothelium avoids the problem of mechanical
damage to the cells and provides much improved EC recovery. This technique can be
used to extract EC from tissue samples however contamination with other cell types has
been a significant problem (418). From solid tissues, extraction is more difficult. Usually
the tissue is minced, and then digested with the enzymes trypsin or collagenase to
remove the extracellular matrix that holds the cells. After that, the cells are free floating,
and extracted using centrifugation or aspheresis. Digestion with trypsin is very
dependent on temperature. Higher temperatures digest the matrix faster, but create
more damage. Collagenase is less temperature dependent, and damages fewer cells. Cells
are often categorized by their source.
Some groups have claimed that no EC could be extracted from subcutaneous fat
using conventional collagenase digestion whereas others have claimed that up to 80 %
of cells extracted are EC using the same technique (419-421). Many authors have
suggested that the only way to obtain a pure culture of EC from subcutaneous fat would
be to use purification techniques such as a Percoll gradient, filtration or magnetic beads
(200). This is because it is thought that collagenase digestion of fat leads to the
extraction of EC, FB and SMC. The problem with the Percoll and filtration techniques
is that they reduce the number of EC that can be extracted whereas Percoll is also
thought to be detrimental to the subsequent proliferation of the extracted EC (200).
Magnetic beads, including platelet endothelial cell-adhesion molecule (‘PECAM’; CD31)
and Ulex Europaeus I-coated Dynabeads, have been used for extraction of EC for
culture and cell characterization but have never been used for seeding.
A further potential source of cells for seeding are those extracted from
omentum. These have been characterized as mesothelial cells (MC) (422). Both EC andChapter 3: Materials and methods
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MC have a similar function producing substances such as tPA and urokinase
plasminogen activator (423;424). In animal experiments, most trials involving the
seeding of grafts using cells derived from omentum have shown good results (417;425-
428), except those reported by Verhagen and co-workers (429). Based on this work
another potential source of MC may be from peritoneal lavage, which has not been
previously evaluated for vascular seeding. Ivarsson and co-workers proposed that it was
possible to extract between 3 x 10
6 and 8 ×10
6 cells from about 500 ml of lavage fluid
(430). A convenient source of EC has been the human umbilical vein. The extracted
cells can be cultured and propagated for at least 16 population doublings. In all cell
experiments throughout the work in this thesis, human umbilical vein endothelial cells
(HUVEC) were extracted from human umbilical vein cords using the collagenase
enzymatic digestion technique.
Various approaches to the assessment of EC proliferation and viability have
been undertaken. Foremost are methodologies looking for known morphological
factors, including ultrastructural studies that require substantial effort, skilled personnel,
and often expensive equipment but during the extensive processing required do not
yield quantifiable results and destroy the sample (431). The assessments of EC
membrane integrity with dye uptake and vital stains have been used as an indirect
measure of viability, but they are terminal assays that destroy the cell or interfere with its
function (432-434).
Continuous monitoring of EC viability is achievable by the measurement of
glucose uptake and lactic acid release into an incubation medium, but such
methodologies are labour intensive and relatively insensitive (435). The reduction of
colourless tetrazolium salts by mitochondrial succinate dehydrogenase activity into an
intensively coloured formazan product uses hazardous reagents and requires washing,
fixing and extraction steps that destroy the cell (436-438). Furthermore, the insoluble
intracellular crystals that disrupt the cellular membrane result in an extracellular
precipitates attached to the polymeric substrate that on polyurethanes remains bound to
the substrate even after extraction by detergent, thus affecting the outcome of this
particular assay (439). Other methods of assessing cell viability are measurement of
Trypan Blue exclusion or propidium iodide exclusion and measurement of crystal violetChapter 3: Materials and methods
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inclusion or Neutral Red inclusion.
3H-thymidine incorporation has been used as a
measure of viability and cell proliferation in EC (440) but radioisotopes have many
disadvantages, including the terminal nature of the measurement, labour-intensive
handling and disposal (along with expense), and excessive processing time with
3H-
thymidine incorporation. Quantification of DNA synthesis by measuring
bromodeoxyuridine (BrdU) uptake is a method of assessing cell proliferation. The use
of BrdU requires extensive processing of samples at predetermined time points;
therefore, no continuous monitoring of a single sample can be performed with this
method (441).
The evaluation of seeded cell viability is hindered by the current lack of a
reproducible method that is non-toxic to EC, allows continuous or repeated
measurements, has a range of sensitivity that allows the measurement of degrees of
viability, is not dependent on cell division, and is convenient and safe to use. Direct cell
counting, cell dislodging, dye uptake,
3H-thymidine uptake, or DNA or protein staining
either requires a transparent scaffold or leads to termination of culturing before
measurement (442;443). Furthermore, the dyes and solubilisers used in spectroscopic
assays such as the end-product formazan of the calorimetric MTT (3-(4,5-dimethyl
thiazoloyl-2-yl)-2,5-5diphenyl tetrazolium bromide) assay (MTT assay) chemically
interact with the polymer itself and/or any surface coatings present, particularly for
polyurethane formulations (436;437). In this study, it is essential that the EC remain
viable after being seeded onto the prosthetic graft and those samples can be monitored
at several time points. Thus the requirement was to use a suitable technique to monitor
viability of EC seeded on prosthetic grafts. The Alamar blue
TM redox assay has been
applied as a technique to monitor the viability of EC seeded on prosthetic grafts (444).
The validity of the test was assessed with sodium azide and mitomycin C, known
physiological perturbators. The Alamar blue
TM redox assay demonstrated that EC were
viable and functional postseeding on the prosthetic grafts. The technique allows the
continuous assessment of the metabolism and viability of seeded cells, is simple to
perform, and does not destroy the cells or graft materials. As well as viability,
proliferation may also be measured by this assay. As with tetrazolium salts, Alamar blue
monitors the reducing environment of the proliferating cell. Alamar blue
TM is soluble,
stable in culture medium and is non-toxic. The continuous monitoring of cells in cultureChapter 3: Materials and methods
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is therefore possible. Specifically, Alamar blue
TM does not alter the viability of cells
cultured for various times as monitored by Trypan Blue exclusion (445).
The techniques used in this thesis have been validated (as described below) and
demonstrate a reproducible technique that can be used to measure viability, proliferation
and cytotoxicity of cells.
In order to assess shear stress on cell function, a flow circuit mimicking
physiological shear stress was developed (214) and used for all flow studies. Chapter 2
provides a review of the techniques used for applying in vitro shear stress to cultured
cells using cone and plate apparatus or flow circuits.
The flow circuit used in the study is capable of stimulating in vitro the pulsatile flow
waveform, pressures and degrees of oxygenation of physiological arterial circulation in
vivo. This system has been validated extensively for physiological parameters (214) and
has been used in previous studies (36). This model was used to investigate the shear
stress response to EC seeded on nanocomposite conduits. The model stimulates
specifically a given artery situation such as coronary flow waveforms (see caption of
Figure 3.3 for further details).
3.2 Cell Culture
3.2.1 Extraction of endothelial cells from human umbilical cord
HUVEC were harvested from human umbilical cord vein as described by Jaffe
(444). All procedures were carried out using aseptic techniques in a tissue culture flow
hood. Human umbilical cords were obtained from the labour ward of the Royal Free
Hospital, Hampstead and stored in 40 ml of collecting medium consisting of 29.8 ml
basic medium, 10 ml foetal bovine serum (Invitrogen, Paisley, U.K.) and 0.2 ml of 50
mg/ml gentomycin (Sigma Chemical Company, Dorset, U.K.). The basic medium was
obtained from a stock solution made from 500 ml M199 medium (Invitrogen, Paisley,
U.K.), 15 ml of 7.5 % sodium bicarbonate solution and 5 ml of penicillin/streptomycin
solution consisting of penicillin 10,000 U/ml and streptomycin 10 mg/ml (Invitrogen,
Paisley, U.K.).Chapter 3: Materials and methods
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Cords approximately 15 cm in length were collected within 24 hours of delivery
and used if free of clamp marks or needle holes. Each end of the umbilical vein was
cannulated with 4 cm lengths of nasogastric tubing and then secured with sterile silk
ties. The cord was flushed several times with warm sterile phosphate buffered saline
(PBS) to remove all clotted blood prior to instillation of 25 ml of warm, filtered
collagenase solution consisting of 12.5 mg collagenase A suspended in 25 ml of basic
medium. Both ends of the vein were clamped and the cord incubated at 37 °C for 10
minutes. The cord was massaged gently in order to loosen the EC and the
collagenase/cell suspension was then collected into a 50 ml centrifuge tube. The vein
was further washed with PBS to collect any loose cells. The collagenase/cell suspension
was then neutralised by adding an equal volume of warm complete medium obtained
from stock made up of 157 ml basic medium, 40 ml Foetal bovine serum and 3.6 ml of
200 mM L-glutamine solution (Invitrogen, Paisley, U.K.). The cell suspension was
centrifuged at 300 g for 7 minutes, the supernatant medium was removed and the cell
pellet was resuspended in 5 ml of complete medium. The cell suspension was then
transferred to a 25 cm
2 tissue culture flask and incubated at 37 °C/5 %CO2. After 24
hours, the flasks were gently washed with 8 ml of warm PBS to remove red blood cells
and fed with 5 ml of complete medium. The flasks were viewed daily under high power
transilluminated microscopy and the presence of EC verified by confirmation of their
characteristic cobblestone morphology and staining for vWF (von willebrand factor).
Once a confluent monolayer was achieved cultures were passaged by removing
the cell culture medium, washing with 8 ml of PBS and then adding 3 ml of 10 %
trypsin-EDTA solution (Invitrogen, Paisley, U.K.). The flasks were then incubated for 3
minutes prior to gentle tapping in order to loosen all the cells. The trypsin was then
neutralised by the addition of 10 mls of complete medium. The cell suspension was
spun at 300 g for 7 minutes, supernatant discarded and cell pellet resuspended in 10 ml
of complete medium. The cell suspension was then placed in gelatine coated 75 cm
2
tissue culture flask. Cultures were passaged every 2-3 days at a ratio of 1:2 and fed every
48 hours.Chapter 3: Materials and methods
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3.3 Polymer synthesis
The Department has developed and patented (446); a new nanocomposite
polymer based on POSS-PCU. Details of the synthesis of the nanocomposite have been
previously described (70). In brief to synthesise the nanocomposite, dry poly-
hexamethylene carbonate diol was mixed with trans-
cyclohexanediolisobutylsilsesquioxane (Sigma-Aldrich) – the POSS, in a 500ml reaction
flask equipped with a nitrogen inlet and mechanical stirrer. The mixture was heated to
dissolve the POSS in the polyol and then gradually by removal of the heat source.
Methylene diisocyanate (MDI) was added to the polyol blend and then reacted, under
nitrogen, at 75 °C to form a pre-polymer. This consists of POSS moieties with MDI
attached at each of its hydroxyl groups, and polycarbonate with MDI reacted to the diol
groups on either end. Dimethylacetamide (DMAC) was slowly added to the pre-polymer
to form a solution, which is then cooled to 40 °C. Chain elongation was carried out by
drop-wise addition of a mixture of ethylenediamine and diethyamine in DMAC. Finally
a mixture of 1-butanol and DMAC was added slowly to the polymer solution. All the
chemicals, reagents, glassware and associated relevant equipment were purchased from
Aldrich Co. Ltd. (New Road, Gillingham, U.K.).
3.4 Assessment of cell metabolism and survival
3.4.1 Cell viability
Alamar blue
TM (AB; Serotec, Ltd., Kidlington, U.K) is an assay designed to
measure quantitatively cell metabolism and viability by incorporating resazurin and
resarufin as colorimetric oxidation reduction indicators that change in colour in
response to chemical reduction resulting from cell metabolism. The data may be
collected with either fluorescence based or absorbance-based instruments. In this study
absorbance was measured at 570 nm and background at 630 nm subtracted. Resazurin
has a much higher electrochemical potential than the carriers on the cell membrane, and
on contact with the membrane, it is reduced to resarufin. Resazurin acts as an
intermediate electron acceptor in the electron-transport chain between the final
reduction of O2 and cytochrome oxidase by substituting for molecular oxygen as an
electron acceptor. The rate of bio-reduction is related to the level of redox potential onChapter 3: Materials and methods
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the cell membrane that in turn characterises the constitutive part of the metabolic
activity of a given cell type. AB has certain properties that make this assay attractive. It is
soluble in media, stable in solution, and minimally toxic to cells and produces changes
that are easy to measure. AB has been used as a measure of cell viability in tumor
neurosis factor hyper-sensitive cell lines (447), studies of apoptotic neuronal death (448),
and studies of lymphocyte proliferation (445).
AB is not a new assay because it was first developed to determine how
susceptible microorganisms are to various growth-inhibition products and has been
used to examine bacterial antibiotic susceptibility (449) and yeast antifungal receptivity
(450) and to analyse the in vitro cytotoxicity of drugs and chemotherapeutic agents in
mouse fibroblasts, macrophages and human tumour cells (451). AB allows a continuous
assessment of the metabolism and viability of seeded cells, is simple to perform, and
does not destroy the cells (444). Limitations of AB are few. If prolonged incubation
times are used (> 24 hours), reversal of the reduction process occurs via a secondary
index step, resulting in a colourless solution, particularly when very high cell
concentrations are used. Microbial contamination would also reduce AB, thus yielding
erroneous results, but this would affect any other assay of EC as well and can be
estimated by use of a suitable blank.
All procedures with AB were performed under aseptic conditions because
microbial contaminants are also able to reduce AB. AB were added to cell culture
medium at a concentration of 10 %. At each AB assay time point, well/grafts were
washed with 1 ml PBS and 1 ml of the 10 % AB/medium mixture added to each
sample. Blanks were also included with 1 ml of the 10 % AB/medium added to samples
with no cells. After 4 hours a 100 l sample of AB/medium mixture was removed and
the absorbance at 570 nm and 630 nm measured in a 96-well plate (Helena Biosciences,
Sunderland, U.K.) using a Multiscan MS UV visible spectrophotometer (Labsystems,
Somewhere, U.K). The absorbance at 630 nm (background) was subtracted from that at
570 nm and results expressed as a percentage of the control (blank value). Duplicate
wells per treatment at each time point were measured and each experiment repeated
four times.Chapter 3: Materials and methods
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3.4.2 Cell proliferation
The Quant-iT™ PicoGreen® assay (Molecular Probes Europe BV, Leiden, The
Netherlands) quantifies double-stranded DNA in solution using an ultrasensitive
fluorescent nucleic acid stain. Detecting and quantifying small amounts of DNA is
important in a wide range of biological applications. The most commonly used
technique for measuring nucleic acid concentration is the determination of absorbance
at 260 nm. The Hoechst (bisbenzimide) dyes are sensitive fluorescent acid stains that are
selective for double stranded DNA (dsDNA), does not show significant fluorescent
enhancement in the presence of proteins, and allows the detection and quantification of
DNA concentrations as low as 10 ng/ml DNA. The PicoGreen dsDNA reagent enables
researchers to quantitate as little as 25 pg/ml of dsDNA with a standard
spectrofluorometer and fluorescein excitation and emission wavelengths. The sensitivity
exceeds that achieved with the Hoechst 33258-based assay by 400-fold. The PicoGreen
method is also simpler than that of previous methods (452) because a single
concentration of the PicoGreen reagent allows detection over the full dynamic range of
the assay. This assay has been extensively used in biocompatibility tests to evaluate the
viability and proliferation of cells cultured on polymers (453).
Stock standard DNA solution (100 μg/ml) was diluted in Tris-EDTA (TE) assay
buffer to provide a standard curve of 0 – 1000 ng/ml DNA (see Figure 3-1) for full
layout of preparation of the standard curve). Figure 3-1 demonstrates an example of a
typical standard curve prepared from these dilutions.
Cell samples were trypsinised as above and the cells frozen and thawed then further
disrupted by being passed through a small-bore needle three times. 100 µl of
standard/sample was added to a 96-well plate and 100 μl of diluted PicoGreen
(PicoGreen dimethylsulfoxide (DMSO) stock solution diluted ×200 in TE assay buffer)
was added to each standard/sample well. Plates were then incubated for 5 min in the
dark. Standards/samples were then excited at 480 nm and the fluorescence emission
intensity measured at 520 nm using a Fluroskan Ascent FL spectrofluorometer (Thermo
Life Sciences, Basingstoke, U.K.).Chapter 3: Materials and methods
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Figure 3-1. Validation of a typical standard curve between 0 – 1000 ng/ml calf thymus DNA in
TE. The calf thymus DNA standard, provided at 100 µg/ml in the PicoGreen Kit, was diluted
50-fold in TE to make the 2 µg/ml working solution. To serve as an effective control, the
dsDNA solution used to prepare the standard curve was treated the same way as the
experimental samples and should contain similar levels of such compounds. If the absorbance
measurement in the samples were high, the samples were then diluted and the assay repeated.
3.4.3 Cell toxicity
Lactate dehydrogenase (LDH) is a stable cytosolic enzyme. The normal plasma
membrane is impermeable to LDH, but damage to the cell membrane results in a
change in the membrane permeability and subsequent leakage of LDH into the
extracellular fluid (454). In vitro release of LDH from cells provides an accurate measure
of cell integrity and cell viability. As a result, measuring the release of LDH has proved
to be a method used in various tests for cytotoxicity in both immunological studies and
in biocompatibility studies, where it has now become an important in vitro screening test
(455).
To determine the amount of LDH released, LDH in cell culture medium is
measured by a spectrophotomeric enzyme assay. The amount of LDH released is
quantified using a 30 minute coupled enzymatic assay based on the conversion of a
tetrazolium salt INT (2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride)Chapter 3: Materials and methods
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into a red formazin product, with the amount of colour formed being proportional to
the number of lysed cells.
LDH was measured using a CytoTox 96
® non-radioactive cytotoxicty assay kit
(Promega, Southampton, U.K.). 50 μl CCM from each sample was transferred to a 96-
well plate (Helena Biosciences, Sunderland, U.K.). 50 μl of substrate mix (1 vial
substrate plus 12 mls assay buffer) was added to each well and the plate covered in foil
to prevent light access. Samples were then incubated at room temperature for 30 min
after which the reaction was stopped by the addition of 50 μl stop solution (1 M acetic
acid). Absorbance was then read at 492 nm using a Multiscan MS UV visible
spectrophotometer (Labsystems, Ashford, U.K.).
3.5 Application of physiological shear stress
Flow circuits consist of a pump, tubing and medium flowing through it. They
have a heater and pH-buffering system and have the capacity to exchange gases and,
depending on the culture period, nutrients for wastes. Furthermore they usually have
monitoring system to measure parameters like pressure and flow. They can be used for
developing tissues, assessing tissues both in biological and mechanical terms.
Traditional pumps – as for example used clinically for heart bypass and dialysis
machines - can be either centrifugal or roller. Centrifugal pumps consist of a fanned
impeller or a nest of smooth plastic cones that sit inside a plastic housing. The impellers
or cones are magnetically coupled with an electric motor and, when rotated rapidly,
generate a pressure differential that causes the movement of fluid. On the other hand a
roller pump includes a length of tubing, located inside a curved raceway. The raceway
lies at the outer perimeter of rollers mounted on the ends of rotating arms (usually two,
180 degrees apart). The system is arranged so that one roller is compressing the tubing
at all times. Flow of blood is induced by compressing the tubing, thereby pushing the
blood ahead of the moving roller. Flow rate depends upon the size of the tubing, length
of the track, and rotation rate of the rollers (revolutions per minute). For a given pump
and type and size of tubing, flow is proportional to pump speed (in revolutions per
minute) (456). An alternative pumping system has been described using a mechanical
ventilator to drive air into a fluid-filled circuit creating pulsatile laminar flow withChapter 3: Materials and methods
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physiological variables of flow, blood and pulse pressure (456-459). It has been used to
successfully tissue engineer myofibroblasts and EC on bio absorbable scaffolds into
vascular grafts in a ‘biomimetic’ environment (460). This innovative design has however
been confined to a limited number of researchers and is relatively complex compared to
more traditional systems.
The advantage of centrifugal pumps is that when the fluid is blood, there is less
cell destruction. The model employed (Figure 3-2) in this thesis has been developed and
validated in the department. The flow system has been extensively used in previous cell-
graft studies (36) and is capable of stimulating in vitro the pulsatile flow waveform,
pressures and degree of oxygenation of physiological arterial circulation in vivo (214).
The model consisted of a variable-speed electro-magnetic centrifugal pump (Bio
Medicus Inc., Minnetonka, U.S.A.); flexible plastic tubing and reservoir; flow waveform
conditioner (FWC); Maxima hollow fibre oxygenator (Johnson & Johnson
Cardiovascular, McNeilab Inc., Anaheim, CA, U.S.A.) supplied with 95 % O2/ 5 %
CO2; an outflow resistance; a 6 mm calibre tubular flow probe and Transonic Medical
Flowmeter (TMF) system (HT207, Transonic Medical System Inc., U.S.A.) and a Miller
Mikro-tip catheter transducer (Miller Instruments, Inc., Houstan, Texas, U.S.A.). The
flow circuit was primed with cell-culture medium adjusted for viscosity: M199; 10 %
Foetal Bovine Serum; 7.5 % sodium bicarbonate; 200 mM L-glutamine penicillin 10,000
U/ml, streptomycin 10 mg/ml and 8 % low molecular weight Dextran (77,000 Dalton,
purchased from Sigma, Poole, Dorset, U.K.) buffered at pH 7.2. The whole circuit was
kept under sterile conditions.Chapter 3: Materials and methods
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Figure 3-2. The flow circuit comprising a variable-speed electromagnetic centrifugal pump,
flexible plastic tubing, fluid reservoir and circulating solution oxygenated through a Maxima
hollow fibre oxygenator with 95% air and 5% CO2. Automatic pH, pO2 and pCO2 controller. A
flow waveform conditioner (FWC) sited in series with the circuit is used to generate arterial flow
waveforms. This was constructed in-house and consisted of a solenoid connected to an
electronic control box from which the frequency and duration of solenoid occlusion could be
governed. Instantaneous flow rate is measured using Transonic Medical Flowmeter (TMF)
system. Serial intra luminal pressure measurements can be made at discrete sites along the graft
using a Millar Mikro-tip catheter transducer introduced via a Y-connection port. Graft radius,
flow rate and shear stress are determined using an ultrasound duplex (US) scanner with a wall
tracking system (WTS). All outputs are fed into a computer using an analogue-to-digital data
acquisition recording system (ADC). Flow circuit also consists of a Variable Speed
Electromagnetic pump (VSECP) and Variable Outflow Resistance (VOR).
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3.6 Total RNA extraction
An RNeasy kit was used to isolate total RNA (Qiagen Ltd, Crawley, U.K). The
RNeasy procedure represents a novel technology for RNA isolation. It combines the
selective binding properties of a silica-gel-based membrane with the speed of microspin
technology. A specialised high-salt buffer system allows up to 100 µg of RNA longer
than 200 bases to bind the silica-gel membrane. Biological samples are first lysed and
homogenised in the presence of a highly denaturing guanidine isothiocyanate (GITC)-
containing buffer that immediately inactivates RNases to ensure isolation of intact RNA.
Ethanol is added to provide appropriate binding conditions, and the sample is then
applied to an RNeasy mini column where the total RNA binds to the membrane and
contaminants are efficiently washed away. High-quality RNA is then eluted in 30 µl or
more, of water. This kit was used as it provides a fast and simple method for the
preparation of up to 100 g total RNA from eukaryotic cells and tissues. A wide range
of biological samples can be simultaneously processed in less than 30 minutes. Time-
consuming and tedious methods, such as CsCl step-gradient ultracentrifugation and
alcohol precipitation steps, or methods involving the use of toxic substances such as
phenol and/or chloroform, are replaced by this procedure. The purified RNA was ready
to use in standard downstream applications such as reverse transcriptase polymerase
chain reaction.
The cell pellet was loosened by gentle tapping and 350 µl of buffer RLT (lysis
buffer containing guanidine isothiocyanate and 10 µl of β-mercaptoethanol (β-ME) per
1ml of buffer RLT) was added to the cell pellet. The resulting lysate was homogenised
by vortexing (with cell numbers ≤ 1 x 10
5). 350 µl of 70 % ethanol was added to the
homogenised lysate and mixed by pipetting. 700 µl of the sample, including any
precipitates that were formed was added to an RNeasy mini column placed in a 2 ml
collection tube and centrifuged for 15 seconds at ≥ 8000 x g (≥ 10,000 rpm). The flow-
through was discarded.
To wash the column 700 µl of buffer RW1 (containing guanidine salt) was added
to the column and centrifuged for 15 seconds at ≥ 8000 x g (≥ 10,000 rpm). The flow-
through and collection tube was then discarded. The column was transferred to a new 2
ml collection tube and 500 µl of diluted RPE buffer (Buffer RPE is a concentrate andChapter 3: Materials and methods
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100 % of ethanol was added before use) was pipetted onto the column. The column was
centrifuged for 15 seconds at ≥ 8000 x g (≥ 10,000 rpm) and the flow-through
discarded. Another 500 µl of buffer RPE was added to the column and centrifuged for 2
minutes at ≥ 8000 x g (≥ 10,000 rpm) to dry the silica-gel membrane. To eliminate any
chances of possible buffer RPE carryover (this can interfere with downstream
reactions), the column was placed in a new 2 ml collection tube and centrifuged for 1
minute at full speed.
To elute, the column was placed in a new 1.5 ml collection tube. 50 µl of RNase-
free water was directly added onto the silica-gel membrane and centrifuged for 1 minute
at ≥ 8000 x g (≥ 10,000 rpm). The elution step was repeated with a second volume of
RNase-free water into the same collection tube. Total RNA concentration was
measured and used for PCR. To avoid contamination or degradation of RNA, PCR was
conducted immediately post RNA extraction in all experiments. The extraction of RNA
is shown in Figure 3-3.Chapter 3: Materials and methods
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Figure 3-3. Protocol demonstrating stages of RNA extraction. Adapted from RNeasy mini
handbook 04/2006.
(1) Sample disrupted and lysed with GITC-
containing buffer (Buffer RLT)
(2) Sample homogenised to shear genomic
DNA and reduce viscosity of lysate
(3) Ethanol added to adjust binding
conditions
(4) Sample applied to spin column for
adsorption of RNA to membrane
(5) Contaminants removed with wash spins
(Buffer RW1 and RPE)
(6) RNA eluted ready-to-use in waterChapter 3: Materials and methods
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3.7 Analysis of gene expression
3.7.1 Polymerase chain reaction (PCR)
The original purpose of a PCR (Polymerase Chain Reaction) was to make a huge
number of copies of a gene. Reverse Transcription (RT reaction) is a process in which
single-stranded RNA is reverse transcribed into complementary DNA (cDNA) by using
a reverse transcriptase enzyme, primer, dNTPs, RNase inhibitor. The resulting cDNA
can be used in RT-PCR (reverse transcription-polymerase chain reaction) reaction. RT-
PCR is a sensitive technique for mRNA detection and semi-quantification. Compared to
the two other commonly used techniques for quantifying mRNA levels, Northern blot
analysis and RNase protection assay, RT-PCR can be used to quantify mRNA levels
from much smaller samples. This technique is sensitive enough to enable semi-
quantification of RNA from a single cell.
There are three major steps in a PCR (see Figure 3-4) process, which are
repeated for between 25 to 40 cycles (see Figure 3-5). This process is carried out on an
automated cycler, which can heat and cool the tubes with the reaction mixture in a very
short time. The three steps can be summarised as follows:-
Step 1 Denaturation at 94°C: During the denaturation, the double strand DNA melts
open to single stranded DNA and all enzymatic reactions are stopped (for example: the
extension from a previous cycle).
Step 2 Annealing: The primers move within the mixture by Brownian motion. Ionic
bonds are constantly formed and broken between the single stranded primer and the
single stranded template. Some more stable bonds form and last a little bit longer (where
primers match exactly). On those small pieces of double stranded DNA (template and
primer), polymerase can attach and begin to copy the template DNA. Once there are a
few bases built in, the ionic bond is so strong between the template and the primer that
it does not break down anymore.
Step 3 Extension at 72°C: This is the ideal working temperature for the polymerase.
The primers, where there are a few bases built in, have a stronger ionic attraction to theChapter 3: Materials and methods
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template than the forces attempting to break these attractions. The bases
(complementary to the template) are coupled to the primer on the 3' side (the
polymerase adds dNTP's from 5' to 3', reading the template from 3' to 5' side; bases are
added complementary to the template). Primers that are on positions with no exact
match become loose again (due to the increased temperature) and do not result in an
extension of the fragment.
Figure 3-4. The different steps in PCR. Because both strands are copied during PCR, there is
an exponential increase of the number of copies of the gene. If there is only one copy of the
wanted gene before the cycling starts, after one cycle, there will be 2 copies; two cycles will
result in 4 copies and so on.
25 – 40 cycles of 3 steps:
Step 1 Denaturation
1 minute 94 °C
Step 2 Annealing
1 minute with varying
temperature
Forward and reverse primers
Step 3 Extension
1 minute 72 °C
Only dNTP’sChapter 3: Materials and methods
121
Figure 3-5. The exponential amplification of the gene in PCR.
3.7.1.1 One-step reverse transcriptase polymerase chain reaction (RT-PCR)
The Qiagen one-step RT-PCR kit (Qiagen Ltd, Crawley, U.K.) was used in all PCR
experiments. This provided a convenient method for highly efficient and specific RT-
PCR using any RNA. The components in this method are optimised to allow both
reverse transcription (RT) and PCR amplification to take place as a “one-step” reaction.
The general method of conducting RT-PCR for the PCR experiments in the subsequent
chapters is summarised below.
The Qiagen one-step RT-PCR kit contains:
 RT-PCR enzyme mix (contains Omniscript
TM reverse transcriptase, Sensiscript
TM
reverse transcriptase and HotStartTaq
® DNA polymerase).
The Sensiscript
TM reverse transcriptase was optimised for use with very small
amounts of RNA (< 50 ng) ideal in these experiments where a low yield of RNA
was obtained. The HotStartTaq
® DNA polymerase provided highly specific
amplification. During the reverse transcription process the polymerase is completely
inactive and does not interfere with the reverse-transcriptase reaction. After reverseChapter 3: Materials and methods
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transcription (by Omniscript
TMand Sensiscript
TM) the reactions were heated at 95°C
to activate the DNA polymerase which eliminates extension from non-specifically
annealed primers and primer-dimers in the first cycle ensuring highly specific
reproducible PCR.
 RT-PCR buffer 5x (contains 12.5 mM MgCl2)
The buffer was designed to enable both efficient reverse transcription and specific
amplification. It was particularly important for one-step RT-PCR performed with
limiting RNA amounts.
 Q-solution 5x
This facilitates amplification of difficult templates by modifying the melting
behaviour of nucleic acids.
 dNTP mix contains 10mM each of dATP, dCTP, dGTP and dTTP
 RNase-free water
Total RNA concentration and purity was calculated by measuring the absorbance at
260 and 280 nm using an Eppendorf Biophotometer (Eppendorf
AG, Hamburg,
Germany). These absorbance measurements cannot discriminate between DNA and
RNA, therefore to determine the RNA concentration the ratio between the absorbance
at 260 and 280 nm provides a workable estimate. Pure RNA has an A260/A280 ratio of 1.8
- 2.3 in RNA free water.
A master mixture containing 10 µl of 5× Qiagen One-Step RT–PCR buffer, 10 µl of
5× Q-Solution, 400 µM of each of the deoxynucleoside triphosphates, 2 µl of Qiagen
One-Step RT–PCR enzyme mixture and 0.5 µM of each of the primers was added. The
master mix contains all the components required for RT-PCR except the template
RNA. The template RNA was added at a concentration of 1 pg – 2 µg/ reaction. A
negative control (without template RNA) was included in all experiments. RNase free
water was added to give a total volume of 50 µl. Samples were centrifuged and placed in
a thermal cycler, a MasterCycler Gradient PCR machine (Eppendorf
AG, Hamburg,Chapter 3: Materials and methods
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Germany) with a heated lid. For maximum yield and specificity, temperatures and
cycling conditions were optimised for each gene studied (see Table 3-1).
Table 3-1. Determining thermal cycle conditions for PCR.
* The PCR conditions for the primers used in this study are: GAPDH: 40 cycles (94, 50, 72 °C);
PECAM-1: 35 cycles (94, 50, 72 °C); TGF-β1: 35 cycles (94, 55, 72 °C); COL-1: VEGFR-1 and
VEGFR-2 35 cycles (94o, 59o and 72o). Primers were supplied by Sigma-Genosys (Sigma-
Genosys, Haverhill, U.K.).
STEP TIME TEMPERATURE ADDITIONAL COMMENTS
Reverse transcription 30 min 50 °C
Initial PCR activation
step
15 min 95 °C
3-step cycling
Denaturation
Annealing
Extension
1 min
1 min
1 min
94 °C
50 - 68 °C*
72 °C
~5 °C below Tmof primers
Number of cycles 25 - 40 Dependant on the amount of
template RNA and the
abundance of the target
transcript
Final extension 10 min 72 °C
3.7.1.2 PCR product analysis
PCR products were analysed by 2% agarose gel electrophoresis prepared with
100 mls 10 x TAE (Tris Acetate EDTA-buffer) and 2 g of agarose (Sigma-Aldritch,
Gillingham, Dorset U.K.). The solution was boiled in a microwave for 2 minutes to
dissolve the agarose. Once heated, the solution was left to cool down to about 60 °C at
room temperature. 2 µl ethidium bromide was added to the gel solution. This was then
poured into the gel rack with a comb at one side of the gel. Once the gel had solidified,
10 x TAE was added to fill the gel tank and the combs of the gel were slowly removed.
PCR samples (20 µl of PCR product and 5 µl loading dye) were loaded onto the gel and
run with a 100 base pair marker at 80 V for 1 hour. The products were semi-quantified
using a GeneGenius darkroom with ‘GeneSnap’ version 6.02. (Syngene, Cambridge,
U.K.).Chapter 3: Materials and methods
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Figure 3-6 demonstrates examples of amplification of PCR products on a gel.
It is important to determine if the product is of the right size. If there is a product, for
example a band of 500 bases, but the expected gene should be 1800 bases long. In this
case, one of the primers probably fits on a part of the gene closer to the other primer. It
is also possible that both primers fit on a totally different gene or that the primers fit on
the desired locations, and also on other locations. In this case, different bands are
present in one lane on a gel (see Figure 3-6).
Figure 3-6. Verification of a PCR product on a 2 % agarose gel.
The ladder is a mixture of fragments with known size to compare with the PCR fragments. The
distance between the different fragments of the ladder is logarithmic. Lane 1: PCR fragment is
approximately 1850 bases long. Lane 2 and 4: the fragments are approximately 800 bases long.
Lane 3: no product is formed, so the PCR failed. Lane 5: multiple bands are formed because one
of the primers fits on different places.
3.8 Cell visualisation
Examination of cells on synthetic polymers can only be performed by few
staining methods. Immunoflourescent staining using antibodies was found to stain the
polymer as well as the cells making it difficult to visualise the presence of cells on the
polymer. To overcome this, two techniques were used toluidine blue staining and
scanning electron microscopy (ScEM). Toluidine blue is a metachromatic dye. It is a
blue nuclear counterstain and can be used to demonstrate Nissl substance. It has beenChapter 3: Materials and methods
125
used as a surface stain or on paraffin sections. The Toluidine blue method has been
used as a successful stain in determining viability of cells on biomaterials (461).
ScEM is a type of capable of producing high-resolution images of a sample
surface. Due to the manner in which the image is created, ScEM images have a
characteristic three-dimensional appearance and are useful for judging the surface
structure of the sample. ScEM allows visualising the topography, morphology,
composition and crystallographic information of a sample.
3.8.1 Toluidine blue staining
Cells were washed with PBS and then fixed in formaldehyde for 10 minutes at
room temperature. Five hundred microlitre of a 0.1% solution of Toluidine blue (Sigma
Chemical Company, Poole, Dorset, UK) was then added to each well and incubated for
30 minutes at room temperature. Cells were then destained in water and photographed.
3.8.2 Scanning electron microscopy (ScEM)
All ScEM images in this thesis were conducted at the Electron Microscopy Unit,
Royal Free hospital. Samples were fixed in 1.5% glutaraldehyde for a minimum of 2
hours. The tissue was then washed with several changes of phosphate buffered saline
(Oxoid, Merck Ltd, Hunter Boulevard, Magna Park, Lutterworth, U.K.) and postfixed
using 1% osmium tetroxide/1.5% potassium ferricyanide for 12 hours. The grafts were
washed with distilled water and dehydrated through graded acetone (30%, 50%, 70%,
90% and 100% HPLC grade 2 x 15 minutes each). After dehydration the grafts were
transferred to Tetramethylsilane for 10 minutes and then allowed to air dry. The grafts
were attached to aluminium stubs with double sided sticky tabs (TAAB Laboratories
Equipment Ltd, Unit 3 Minerva house, Calleva Ind. Park, Aldermaston, Reading,
Berks.) and then coated with gold using an SC500 (EMScope) sputter coater. The stubs
were examined and photographed using a Philips 501 scanning electron microscope.Chapter 3: Materials and methods
126
3.9 Data analysis and statistical methods
In this thesis results were analysed using the statistical software package
GraphPad Prism. Student’s t-test or one way ANOVA were used during the data
analysis. Data are presented as mean ± SD or mean ± SEM.Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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Development of an RNA isolation procedure for the characterisation
of human endothelial cell interactions with cardiovascular bypass
grafts
4.1 Introduction
Insofar as can be established from the literature review in Chapter 2, little work
has been performed on gene expression studies of the effects of shear stress in a
cylindrical graft. Gene expression has been well characterised in vitro on monolayer’s of
EC seeded on glass and subjected to shear stress (462). There have been reports that
growth factors such as TGF-β have been shown to up-regulate and cause a decrease in
certain adhesion molecules such as VCAM-1 under physiological shear stress. An
important question is would the genotype be the same if physiological shear stress was
applied in cylindrical conduits rather than flat sheets of polymer? Cells interacting with
novel biomaterials may exhibit distinct patterns of gene expression depending on the
molecular nature of the surface they are contacting. It is well-documented that many cell
types grown in three-dimensional culture exhibit drastically different phenotypes than
their plate-grown counterparts (463;464). Studies of individual genes have demonstrated
that transcript levels can change as a function of biomaterial contact (465-468).
Recently, Gerritson et al. demonstrated differential gene expression of cells growing in
various human endothelial tube models (469).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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Research to date on seeding vascular grafts has focused on evaluating EC
attachment, adhesion and proliferation in cylindrical conduits by various methodologies
such as radiolabeling, immunostaining and the Alamar blue™ assay (444). There are
limited reports on evaluating the effect of polymers on gene expression for cell
proliferation, cell adhesion, cytoskeleton and ECM (314;315). Investigating gene
expression in a cylindrical graft would enable the understanding of the molecular effects
of cell adhesion and proliferation on the vascular substitute as well as potentially
evaluating the mechanisms responsible for prosthetic graft failure.
The lack of studies may be due to the difficulties in extracting cells present on the graft
surface in order to obtain functional messenger RNA (mRNA). This is because the
extraction of RNA from cells seeded on polymer presents many obstacles. Firstly, RNA
stabilisation is an absolute prerequisite for reliable gene-expression analysis. In general,
the extraction of RNA from cells or tissue must be performed quickly. The greater the
time it takes to extract the RNA; the higher the risk of RNA degradation thus
compromising RNA quality and yield. Changes in gene expression pattern can occur
due to specific and non-specific RNA degradation as well as transcriptional induction.
Such changes in gene expression pattern need to be avoided for a reliable quantitative
gene-expression analysis. In addition to RNA stability issues, cells present on the graft
are supplemented with cell culture medium and incomplete removal can inhibit lysis as
well as interfere with PCR. Finally and most importantly, the surface of a prosthetic
graft has a more complex chemistry than tissue culture plates making isolating cells
much more difficult and may result in a reduced RNA yield. As a result of this the
production of high quality RNA in a sufficient amount for further analysis from EC
seeded onto cylindrical prosthetic graft is a challenge.
In tissue culture studies, cell removal is usually achieved by trypsinising. Cells
that are grown in a monolayer in cell culture flask, or on slides, are usually trypsinised
and collected as a cell pellet for RNA extraction, in accordance with RNeasy kit
instructions. However, removing cells using trypsin from the surface of a seeded or
tissue engineered vascular graft is much more challenging. Zhang and colleagues (314)
have used a scraping technique in order to extract RNA from rabbit bone marrow
stromal cells cultured for 7 days on flat sheets of degradable lysine-di-isocyanate-
glycerol-urethane and compared expression for collagen type I, TGF-β1 and
osteocalcin. The group of Menconi (315) again used a scraping technique in order toChapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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isolate RNA but from bovine EC after 5 days culture on flat sheets of two
poly(ether)urethanes Biomer and Tecoflex SG60D respectively. Expression of
fibronectin, actin, vimentin, histone and collagen was investigated.
The study carried out in this chapter aimed to develop a highly reliable and
quantitative technique for the isolation of RNA from human EC grown on a vascular
graft that will allow accurate representation of the entire cell population, a key factor for
studies in cell/material interaction. As well as RNA purity and cell viability the
expression of two genes, TGF-β1 and GAPDH was assessed. GAPDH is a housekeeper
gene that has been shown to be expressed in constant amounts across cell lines (401).
TGF-β1 is involved in diverse biological processes, such as cell proliferation, migration,
differentiation, survival, and cell–cell and cell–matrix interaction and has been
demonstrated to be key to the formation of extracellular matrix (ECM) by EC under
flow (392;399;470).
4.2 Materials and methods
4.2.1 Material chemistry
The conduit used in this study was a vascular graft based on polyurethane, PCU
with an internal diameter of 5 mm and length of 50 mm that exhibits arterial
viscoelasticity (422;471).
4.2.2 Cell culture and graft seeding
HUVEC were cultured as described in Chapter 3. Cell numbers were amplified
in tissue culture at 37 °C and 5% CO2/95% air. Confluent cultures at third passage were
used in all experiments. Following trypsinisation and resuspension in complete tissue
culture medium, a cell count was obtained. Fifty millimetre tubular lengths of PCU graft
were seeded with HUVEC at 3 × 10
5 cells/cm
2. Cells were added as a suspension to
each graft segment, the ends of the graft plugged, and the graft segments rotated 90°
every 15 minutes for 2 hours to achieve an even covering of HUVEC on each graft.
Grafts were then left overnight for efficient cell adhesion and used the next day. As aChapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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comparison and to ensure each technique was carried out accurately an equal number of
cells were seeded onto 6-well polystyrene tissue culture plates (TCP) as above.
Viability of seeded cells was assessed using an Alamar blue™ assay following the
protocol described in Chapter 3. Following overnight seeding graft samples and controls
were washed with PBS and the washings collected for cell counting to assess seeding
efficiency. One millilitre of Alamar blue™ (10%) v/v in complete medium was added to
each graft/well and incubated for 4 hours. Duplicate 100 μl samples were then removed
and the absorbance's read spectroscopically at wavelengths of 570 nm and 630 nm.
4.2.3 RNA extraction
Prior to the extraction of the RNA using a “Qiagen RNeasy™” kit (method
outlined in Chapter 3, Section 3.6) cells were removed from the graft and wells of
polystyrene plate in one of the three ways detailed below:
(I) Trypsinisation: graft segments/wells were washed with PBS and 1 millilitre trypsin-
EDTA (0.25%) was added for 5 min.
(II) Cell scraping: graft segments/wells were washed with PBS and the graft segments
were then split lengthwise to expose the inner graft surface. One millilitre PBS was then
added and the graft segments/wells were scraped using a cell scraper.
(III) Direct lysis: graft segments/wells were washed with PBS and the graft segments were
then split lengthwise to expose the inner surface of the graft. One millilitre cell lysis
buffer was then applied directly to the cells on the graft and using a cell scraper the
lysates were collected.
4.2.4 Analysis of total RNA and mRNA
The RNA concentration and purity was calculated by measuring the absorbance
at 260 and 280 nm. The quality of the RNA was assessed by agarose gel electrophoresis
and the mRNA was used for PCR (see Chapter 3) of the housekeeping gene GAPDH
and the growth factor gene TGF-β1. For amplification this was carried out by a
MasterCycler Gradient PCR machine, RT-PCR was performed using a one-step PCR
kit. A master mix containing 10 μl 5× Qiagen one-step RTPCR buffer, 10 μl 5× Q-Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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Solution, 400 μM from each of the deoxynucleoside triphosphate, 2 μl Qiagen One-Step
RTPCR enzyme mix and 0.5 μM from each of the primers was added. For each sample,
0.5 μg of template RNA and RNase free water was added to make a total volume of
50 μl. Cycle conditions for GAPDH were 40 cycles (94, 50, 72 °C) and for TGF-β1
were 35 cycles (95, 55, 72 °C).
4.2.5 Scanning electron microscopy
Complete removal of cells from the polymer was difficult to assess visually
therefore trypsinising, scraping and direct lysing of cells from the polystyrene plates
allowed microscopic assessment that each technique applied was fully removing the cells
from the surface. Following removal of cells from the graft by the various methods,
representative graft samples were analysed with ScEM. This enabled the visualisation of
how efficient each isolation method was and enabled any damage to the graft by the
removal of cells to be monitored.
4.2.6 Data analysis and statistical methods
The experiments were repeated six times. Data are presented in mean ± SD.
Comparison between groups was made by one-way ANOVA (Kruskal–Wallis) test with
post comparison using Dunn's comparison test.
4.3 Results
4.3.1 Cell viability
The Alamar blue™ results demonstrated that viable HUVEC were present on all
the graft segments seeded as well as in the wells of the polystyrene plates (Figure 4-1).
There was no significant difference between the three groups within either the seeded
graft samples or the seeded plates. Significantly higher (P < 0.01) Alamar blue™ activity
was found where cells were seeded in the wells of the plate compared to the seeded
graft in all cases.Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
cardiovascular bypass grafts
132
Control PCU
0.0
0.5
1.0
1.5
Trypsin
Scraping
Direct Lysis
** ** **
A
b
s
(
5
7
0
-
6
3
0
n
m
)
Figure 4-1. Alamar blue™ viability assay test. Absorbance was measured in arbitrary units (AU)
at 570 and 630 nm wavelengths. The control groups represent cells seeded on polystyrene wells
and the PCU group are cells present on the graft. **P < 0.01 compared to control, Student's t-
test.
4.3.2 RNA quantity, purity and quality
The amount of RNA extracted by the three different isolation methods is shown
in Figure 4-2. In the case of RNA extracted from HUVEC seeded in the wells of the
plate, the trypsinisation method produced a significantly higher yield of RNA
(0.728 μg/μl) compared to cell scraping (0.445 μg/μl; P < 0.05) and directly lysing
(0.308 μg/μl; P < 0.01).
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Figure 4-2. Comparison of RNA yields in μg/μl isolated by different methods between the
control and PCU group. *P < 0.05, **P < 0.01 compared to trypsin, Student's t-test.Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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When extracting RNA from HUVEC seeded onto the graft segments again
trypsinising the cells produced the highest yield (0.13 μg/μl) of RNA compared to
scraping the cells (0.078 μg/μl) and directly lysing the cells (0.093 μg/μl) from the graft
surface. In this case, there was no significant difference in the yield of RNA obtained
between any of the three isolation methods from the graft material. In all cases purity
was greater than 95% (Figure 4-3).
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Figure 4-3. Comparison of RNA purity expressed as percentage for each sample. No significant
difference was observed in purity between any of the three isolation methods from the control
and graft material.
Figure 4-4 is a standard 2% agarose gel of the total RNA. This illustrates the
quality of total RNA obtained from each isolation method. In all cases the ribosomal
RNA can be clearly seen, demonstrating that there is little or no RNA degradation prior
to extraction. PCR conducted on all samples demonstrated equal levels/μg of RNA of
the housekeeping gene GAPDH (Figure 4-5). It can be seen that all isolation methods
produced mRNA suitable for further investigation by PCR and all samples were
comparable to those obtained from the control wells. Further studies of the RNA
isolated from each sample showed similar levels of expression of TGF-β1 (Figure 4-6).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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Figure 4-4. Total RNA of HUVEC from the control and PCU using the three isolation
methods. Two distinct 28S and 18S ribosomal RNA bands are shown on 2% agarose gel.
Intensity of 28S is two times as that of 18S band with no degrading. Total RNA integrity
showed no difference between the extraction methods.
Figure 4-5. Two percent agarose gel shows amplification of the house-keeping gene GAPDH
which was observed in all the RNA samples obtained from each sample. This indicates
functional mRNA was extracted.
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Figure 4-6. Two percent agarose gel demonstrating the expression of TGF-β1 amplicon from
HUVEC isolated from the extraction methods applied in the control and PCU group.
4.3.3 Efficiency of cell removal
From the assessment of representative graft sections prior to and after isolation
it was observed that in some cases cell removal from the graft was less complete than in
others. Figure 4-7 shows the graft segments post cell isolation. Figure 4-7 (A) and (B)
shows native PCU with honeycomb surface and seeded with HUVEC respectively.
Trypsinisation resulted in the majority of cells being removed from the graft surface
(Figure 4-7 C) and showed no apparent damage to the graft surface (Figure 4-7 D).
Mechanically scraping the cells from the graft did not result in the removal of all the
cells from the surface (Figure 4-7 E) and also caused damage to the graft surface (Figure
4-7 F). Furthermore, directly lysing the cells from the graft surface again showed visible
cells present after isolation (Figure 4-7 G) and also resulted in some damage to the
surface of the graft (Figure 4-7 H)
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B)
Figure 4-7. Typical ScEMs show native PCU with honeycomb surface (A) and seeded with HUVEC (B).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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C)
D)
Figure 4-7. ScEMs show high magnification of surface of PCU after trypsinisation (C) and low
magnification of PCU showing post trypsinisation (D).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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E)
F)
Figure 4-7. ScEMs show high magnification of PCU post-scraping (E) and low magnification
of PCU post-scraping (F).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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G)
H)
Figure 4-7. ScEMs show high magnification of PCU after directly lysing (G) and low
magnification of PCU post-lysing (H).Chapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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4.4 Discussion
No work has been conducted in order to develop quantifiable RNA extraction
methodology in the context of cardiovascular prostheses. The methodology of RNA
extraction that has been used to date from in vivo samples of seeded prosthetic grafts is
based on scraping cells from the inner surface (302;313). Despite other groups
demonstrating changes in gene expression they have not reported what efforts they have
made to ensure that the RNA extracted is a reliable indication of all the cells extracted
from the graft. Studies have investigated flat sheets of poly(ether)urethane used in
vascular grafts and a peptide based degradable urethane seeded with cells (314;315).
Gene expression in cylindrical vascular prosthesis is of interest as to date it has
not been possible to study the effects of shear stress on cellular/material interaction and
EC remodelling. Removing cells from a graft surface is more challenging than tissue
culture plastic. As an example, in Dacron grafts the surface consists of a complex
woven, knitted textile or mesh form. In ePTFE grafts the drawing and sintering process
used to extrude grafts produces a cylindrical tube with a highly porous wall consisting of
fibrils and nodules of different pore sizes. Extrusion of polyurethanes leads to solid
walls or if coagulating, into porous walled structures. PCU based vascular grafts have
spongy middles and a single skin structure that allows it to maintain compliance and
pulsatile flow in vivo (208;214) resulting in a significant proportion of the cells becoming
trapped in the spongy middle. This honeycombed surface structure is ideal for cell
seeding (199;214;314;422;444) but further complicates cell retrieval.
The tubular nature of the grafts makes application of trypsin in an aseptic
manner more difficult than in a culture flask. Direct lysis of the cells with the RNeasy
lysis buffer (containing guanidine isothiocynate) was included in this study as this buffer
stabilises the RNA and thus reduces degradation. Scraping is a physical method of
removing cells from the surface commonly used for routine tissue culture; it was used
here in case the chemical means of cell collection were effected by, or affected, the graft
material.
RNA isolation was examined from PCU vascular grafts using three methodologies to
assess how effective they were for extracting RNA from PCU vascular grafts. The
cellular metabolism was significantly greater in the control group (polystyrene tissueChapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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culture plates) compared to the PCU group. This suggests that fewer cells adhered to
the graft than the wells of the polystyrene plates. This was due to a leakage of cells
through the PCU graft pores during seeding, which resulted in a lower number of cells
on the graft. Fewer cells may also explain, in part, why there was a significant difference
in the RNA yield between PCU and control groups for each isolation method.
There was not a significantly greater amount of RNA extracted in the PCU group using
trypsin although this method did produce more RNA than either scraping or direct lysis.
We have found that trypsinisation is the best methodology for investigating gene
expression on cells grown on polymers, despite not showing a significantly higher yield.
The lysis and scraping methodologies used on the PCU graft presented many obstacles
which we postulated made them less suitable for obtaining reliable RNA from seeded
grafts for PCR.
Stable RNA is a prerequisite for reliable gene-expression analysis and the
extraction of RNA from cells or tissue must be performed rapidly. The greater the time
it takes to extract the RNA the higher the risk of RNA degradation, thus compromising
RNA quality and yield. Changes in the pattern of gene expression can occur due to
specific and non-specific RNA degradation. It was found that the lysis and scraping
procedures were more time consuming and technically more difficult than trypsinisation
and therefore more likely to result in changes of gene expression pattern during
isolation. Applying lysis buffer directly to the graft can also inhibit cell lysis due to the
potential presence of culture medium in the pores of the graft resulting in the entire cell
population not being obtained.
The ScEM images also provided evidence that there were cells still present on the graft
after lysing and scraping showing that most of the cell population was not extracted,
especially those cells that were embedded in the graft pores which are more likely to
undergo alterations in gene expression. Trypsinisation is significantly better on
polystyrene culture plates; resulting in higher total RNA from PCU graft and did not
damage the graft. The current in vitro model studying gene expression after shear stress
has been carried out on two dimensional cultures where the characteristics of the flow
and the interactions of the cells with the material are different from the clinical scenario.
The use of microarrays would be more complex given the reduced yield of RNA from
cylindrical grafts although PCR would be possible on carefully selected genes.
Amplification schemes are available to prepare small quantities of DNA for use onChapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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microarrays, these will allow the amounts of RNA isolated here to be suitable for these
studies (263;472).
In this experiment two genes were examined for potential use in future studies.
GAPDH is frequently used as the housekeeping gene of choice and was used as a
positive control for RNA quality. Similar levels of expression in each group suggested
that the RNA would be of good quality for subsequent genes expression investigation.
In addition, TGF-β1 has been demonstrated to be important in the production of ECM
(473) and is thought to be essential in remodelling of EC under shear flow (400). Similar
levels of expression of TGF-β1 were observed in all samples demonstrating that there
was no difference between the methods of isolation used on the graft and in the culture
plates. This indicates that the method applied on the graft in order to isolate RNA has
no effect on the RNA function. It was also important at this stage, as no flow was
applied, that we consider a gene demonstrated to be up-regulated by HUVEC prior to
flow. The use of genes such as collagen have been reported by some groups not to be
up-regulated until some time after the cells have been exposed to shear flow.
In addition to the studies of shear flow and EC, which have already been carried
out extensively it is fundamental that the interaction of cells and materials should be
studied using gene expression. The understanding of how cells interact with the graft
would open an array of possibilities to modify cellular behaviour by genetic modification
of these cells when used for tissue engineering; the use of haemodynamics may be better
adapted to promote cell adhesion, differentiation and proliferation. This study
demonstrates that the study of gene expression in tubular conduits of PCU is possible
and that the RNA extracted is reliable and reproducible.
4.5 Conclusion
This study demonstrates for the first time a quantitative methodology for the
isolation of RNA from PCU vascular grafts. Before embarking upon this project it was
very important to establish whether it was possible to extract RNA successfully from
cells seeded onto conduits. The final plan for this project was to study a novel
nanocomposite polymer which was being developed. When the project began thisChapter 4: Development of an RNA isolation procedure for the characterisation of human endothelial cell interactions with
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nanocomposite polymer was still undergoing further development (particulars of
conduit design can be found in Chapter 6) and thus was not available in conduit form to
study RNA extraction from cells seeded on it. In order to study a similar system and
progress the project whilst polymer development was taking place it was decided to
employ another porous polymer conduit previously investigated our group (PCU) to
study RNA extraction from cells seeded on a porous cylindrical conduit. As a result of
this the conclusions reached in this chapter are based on previously published data on
PCU seeding whereas the rest of the thesis is based on the employment of
nanocomposite.
Three methods of cell/RNA isolation from the graft were analysed and showed
that there were no significant differences between cell scraping, direct cellular lysis on
the graft and trypsinising the cells from the graft prior to RNA extraction with a
commercial RNA extraction kit. Despite this trypsinisation alone showed cell removal
without damage to the graft and provided higher levels of RNA. It can be concluded,
therefore, that RNA isolation from cells seeded onto PCU graft is best achieved by the
removal of cells from the graft by trypsin prior to RNA extraction.Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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In vitro cytotoxicity analysis of nanocomposite
5.1 Introduction
All natural and synthetic materials used as implantable devices (“biomaterials”)
must be screened for adverse effects on cells and tissues. Biocompatibility is the ability
of a material to perform with an appropriate host response in a specific application (1).
It is not possible to make a single test that determines whether a material is
biocompatible or not. This usually requires in vitro, animal and clinical testing.
The biocompatibility of a scaffold or matrix for a tissue-engineering products refers to
the ability to perform as a substrate that will support the appropriate cellular activity,
including the facilitation of molecular and mechanical signalling systems, in order to
optimise tissue regeneration, without eliciting any undesirable effects in those cells, or
inducing any undesirable local or systemic responses in the eventual host. Although
animal studies are ultimately required before a new material can be licensed for clinical
use, all potential materials are screened first in tissue culture systems.
While current prosthetic materials are not suitable for CABG, we believe that the
answer lies with a new generation of nanocomposite incorporating silicon in the form of
POSS molecules. The nanocomposite polymer used in this thesis has been extensivelyChapter 5: In vitro cytotoxicity analysis of nanocomposite
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characterised including the synthesis, mechanical and physical properties of the polymer
by researchers in our department (70;474). Given the importance of endothelialisation in
vascular grafts, this investigation sought to study the ability of this nanocomposite to
sustain endothelialisation. The properties engendered in the polymer were to achieve
both anti-platelet and protein inhibitory qualities coupled with the ability to demonstrate
cytocompatibility allowing cells to grow on its surface. The silsesquioxane being present
on the polymer surface permits the anti-platelet and anti-coagulant function but
prevents the cytotoxic effects associated with materials containing silicon. This allows
EC to grow on its surface as required in tissue-engineered of CABG. Apart from
indicating its safety as a biomaterial at the cellular level, such information would also
serve as a measure of its potential for developing bio-hybrid vascular grafts.
Current in vitro biocompatibility assays are based upon the exposure of cultured
cells to test materials, either as a solid sample or as particles. Previous studies into the
cytocompatibility of similar materials have investigated the effect on cells of either direct
contact with the material or indirect contact by utilising cell culture medium exposed to
material for a time prior to use. Techniques used to evaluate cytocompatibility include
examining cell morphology by light microscopy and ScEM, [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] (MTT) metabolic activity assays, neutral red
viability staining and cell counting by using Tryphan blue (2;3;5;18). In this study, both
the direct and indirect effects of the nanocomposite on HUVEC have been explored by
looking at the total amount of DNA present in the cells using a Pico green assay system,
examining cell metabolism using an Alamar blue™ metabolic assay and looking at cell
damage by measuring LDH release. Cell morphology was studied by staining with
Toluidine blue in the case of indirect contact and carrying out ScEM studies in the case
of direct contact.
5.2 Material and Methods
5.2.1 Polymer production
The synthesis of nanocomposite has been described in Chapter 3. The
nanocomposite was cast by pouring 3 ml of the polymer solution into a 10 cm diameterChapter 5: In vitro cytotoxicity analysis of nanocomposite
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glass dish and was left for 18 hours in a circulating air oven at 55 - 65 °C. Following
casting, the graft material was thoroughly washed with PBS. The polymer coated glass
dishes were sterilised by autoclaving prior to use.
5.2.2 Endothelial cell culture
HUVEC were isolated from human umbilical cord vein as described earlier. In
brief, cell numbers were amplified by tissue culture in cell culture medium (CCM). At
confluence, cells were removed using 0.25% trypsin-EDTA and split in a 1:2 ratio.
Confluent cultures at passage three were used in all experiments.
5.2.3 Assessment of cytocompatibility
5.2.3.1 Indirect effect of nanocomposite on HUVEC
A sample of the graft was powdered using a Mikro Dismembartor U (B. Braun
Biotech International, Melsungen, Germany). Following powdering, graft samples were
sterilised by autoclaving. Powdered graft was then added at concentrations of 1, 10 and
100 mg/ml to CCM and shaken for seven days at 37 °C in a shaker. Following exposure
to powdered nanocomposite the treated CCM samples were centrifuged to remove the
powdered nanocomposite.
Twenty-four-well plates were seeded with 1 ml HUVEC at a concentration of
2×10
5 cells/ml for 24 hours. Cells were then exposed to the following treatments:
untreated CCM (CCM0), 1 mg/ml treated CCM (CCM1), 10 mg/ml treated CCM
(CCM10), 100 mg/ml treated CCM (CCM100) and, in order to show the efficiency of the
assays used, 1 μM staurosporine (CCMST) which is a potent inhibitor of
phospholipids/calcium-dependant protein kinase and causes cell death. LDH, AB and
Pico green assays were carried out 24 and 96 hours post-exposure.
5.2.3.2 Direct effect of nanocomposite on HUVEC
Sections of graft material were cut into 16 mm diameter discs and autoclaved to
sterilise them. The discs were then placed into a 24-well plate. Twelve graft discs wereChapter 5: In vitro cytotoxicity analysis of nanocomposite
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seeded with 1 ml HUVEC at a concentration of 2 × 10
5 cells/ml for 24 hours
(nanocomposite-seeded). Twelve wells containing discs of graft were left unseeded with
only CCM in them as a control (nanocomposite-unseeded). LDH, Alamar Blue and Pico
green assays were carried out 24 and 96 hours post-seeding and samples of graft sent for
ScEM studies.
5.2.3.3 Assessment of cell proliferation on nanocomposite
Thin films of the nanocomposite were cast in 60 mm × 120 mm glass Petri
dishes and sterilised by autoclaving. 2 × 10
5 HUVEC were then seeded in six dishes
with a further six being left unseeded as a control. As a comparison, uncoated dishes
were seeded with the same number of cells. At 1, 3, 6, 10, 13 and 16 days post-seeding a
4 hours Alamar Blue and Pico green assay were carried out on all samples.
5.2.4 Lactate dehydrogenase assay to assess cell damage on nanocomposite
LDH was measured using a CytoTox 96
® non-radioactive cytotoxicty assay kit.
The amount of LDH released was measured using a 30 minutes coupled enzymatic
assay based on the conversion of a tetrazolium salt INT (2-p-iodophenyl-3-p-
nitrophenyl-5-phenyl tetrazolium chloride) into a red formazin product, with the
amount of colour formed being proportional to the number of lysed cells (refer to
Chapter 3).
Fifty microlitre CCM from each sample was transferred to a 96-well plate. Fifty
microlitre substrate mix (1 vial substrate plus 12 mls assay buffer) was added to each
well and the plate covered in foil to prevent light access. Samples were then incubated at
room temperature for 30 min after which the reaction was stopped by the addition of
50 μl stop solution (1 M acetic acid). Absorbance was then read at 450 nm using a
Multiscan MS UV visible spectrophotometer.Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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5.2.5 Alamar blue™ assay to assess cell viability and metabolism on
nanocomposite
Alamar blue™ as described earlier responds to chemical reduction resulting
from cell metabolism by changing colour. The advantages of this assay are that it is
soluble in media, stable in solution, minimally toxic to cells and produces changes that
are easily monitored (444). Alamar blue™ was added to CCM at a concentration of 10%
(v/v). At each AB assay time point grafts/wells were washed with 1 ml PBS and 1 ml of
the AB/CCM mixture added to each graft/well. One millilitre AB/CCM mixture was
placed into each of six empty wells as a negative control. After 4 hours, a 100 μl sample
of the AB/CCM mixture was removed and the absorbance at 570 and 630 nm measured
in a 96-well plate using a Multiscan MS UV visible spectrophotometer. The absorbance
at 630 nm (background) was subtracted from that at 570 nm.
5.2.6 Pico green assay to assess cell quantity on nanocomposite
The Pico green assay quantifies double-stranded DNA in solution using an
ultrasensitive fluorescent nucleic acid stain. Briefly, stock standard DNA solution
(100 μg/ml) was diluted in TE assay buffer to provide a standard curve of 0–
1000 ng/ml DNA. Cell samples were trypsinised as above and the cells disrupted by
being passed through a small-bore needle three times. Hundred microlitre of
standard/sample was added to a 96-well plate and 100 μl of diluted Pico green (Pico
green dimethylsulfoxide stock solution diluted ×200 in TE assay buffer) was added to
each standard/sample well. Plates were then incubated for 5 minutes in the dark.
Standards/samples were then excited at 480 nm and the fluorescence emission intensity
measured at 520 nm using a Fluroskan Ascent FL spectrofluorometer.
5.2.7 Assessment of cell morphology on nanocomposite
5.2.7.1 Toluidine blue staining
Cells were washed with PBS and then fixed in formaldehyde for 10 min at room
temperature. Five hundred microlitre of a 0.1% solution of Toluidine blue (see SectionChapter 5: In vitro cytotoxicity analysis of nanocomposite
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3.8.1) was then added to each well and incubated for 30 min at room temperature. Cells
were then destained in water and photographed.
5.2.7.2 Scanning electron microscopy
Sections of unseeded nanocomposite and nanocomposite seeded with HUVEC
were washed three times with PBS and prepared for ScEM. The specimens were then
attached to aluminium stubs and an SC500 (EM Scope) sputter coater used to coat them
with gold. The stubs were then examined and photographed using a Phillips 501
scanning electron microscope.
5.2.8 Data analysis and statistical methods
Data are presented in mean ± SD. Comparison between groups was made by
one way ANOVA (Kruskal-Wallis) test with post-comparison using Bonferroni's
Multiple Comparison test. *indicates p < 0.05 and *** that p < 0.001.
5.3 Results
5.3.1 Indirect effect of nanocomposite on HUVEC
5.3.1.1 Lactate dehydrogenase assay
After 24 hours indirect exposure there was no significant difference (p > 0.05)
between the CCM0 group and any of the nanocomposite-treated CCM groups. Cells
treated with CCMST had a higher level of LDH activity compared to the CCM0 group (p
< 0.001) (Figure 5-1 a.).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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Figure 5-1 a. LDH assay test on HUVEC exposed to nanocomposite-treated CCM for 24
hours. Absorbance was measured in arbitrary units at 450 nm wavelength. Data are mean ± SD
(n = 6).
5.3.1.2 Alamar blue™ assay
Indirect exposure to nanocomposite for 24 hours showed no significant
difference between the CCM0 group and the three nanocomposite-treated CCM groups.
The cells treated with CCMST showed significantly less AB activity than the CCM0 group
(p < 0.001) (Figure 5-1 b.). In the case of the indirectly exposed 96 hours cells there was
no significant difference in AB activity between the CCM0 cells and the CCM1 or CCM10
groups; however, there was a significant reduction in AB activity in the case of the
CCM100 sample (p < 0.05). After 96 hours exposure to CCMST no viable cells were
present (Figure 5-1 c.).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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Figure 5-1 b. Alamar blueTM viability assay test on HUVEC exposed to nanocomposite-treated
CCM for 24 hours. Absorbance was measured in arbitrary units at 570 nm wavelength and
background at 630 nm subtracted. Data are mean ± SD (n = 6).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Blank
CCM0
CCM1
CCM10
CCM100
CCMST
***
*
Treatment
A
b
s
o
r
b
a
n
c
e
(
5
7
0
-
6
3
0
n
m
)
Figure 5-1 c. Alamar blueTM viability assay test on HUVEC exposed to nanocomposite-treated
CCM for 96hours. Absorbance was measured in arbitrary units at 570 nm wavelength and
background at 630 nm subtracted. Data are mean ± SD (n = 6).
5.3.1.3 Pico green assay
After 24 hours indirect exposure to nanocomposite-treated CCM between 780.1
± 55.3 and 916.9 ± 38.0 μg/ml DNA was extracted, with no significant difference being
observed between the CCM0 cells and any of the test groups (Figure 5-1 d.). In the case
of the 96 hours indirect exposure experiment again there was no significant differenceChapter 5: In vitro cytotoxicity analysis of nanocomposite
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between the CCM0 cells and the three different concentrations of nanocomposite-
treated medium exposed cells. However, there was significantly less DNA in the
staurosporine exposed group (Figure 5-1 e.).
0
200
400
600
800
1000
1200
CCM0
CCM1
CCM10
CCM100
CCMST
*
Treatment
D
N
A
(
µ
g
/
m
l
)
Figure 5-1 d. Pico Green assay test on HUVEC exposed to nanocomposite-treated CCM for
24 hours. Data is presented as DNA amount in µg/ml. Data are mean ± SD (n = 5).
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Figure 5-1 e. Pico Green assay test on HUVEC exposed to nanocomposite-treated CCM for 96
hours. Data is presented as DNA amount in µg/ml. Data are mean ± SD (n = 5).
5.3.1.4 Toluidine blue staining
The results from the Toluidine blue staining can be seen in Figure 5-2. It can be
seen that at both 24 and 96 hours post-exposure to CCM100 cell appearance andChapter 5: In vitro cytotoxicity analysis of nanocomposite
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numbers are comparable to cells exposed to untreated CCM (Figure 5-2 a, b, d and e.).
However, exposure to CCMST clearly results in cell damage at both time points (Figure
5-2 c and f.).
a) 24 hours CCM0
b) 24 hours CCM100Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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c) 24 hours CCMST
d) 96 hours CCM0Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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e) 96 hours CCM100
f) 96 hours CCMST
Figure 5-2. Toluidine blue staining of HUVEC exposed to nanocomposite-treated CCM for
24 hours (a, b and c). Toluidine blue staining of HUVEC exposed to nanocomposite-treated
CCM for 96 hours (d, e and f).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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5.3.2 Direct effect of nanocomposite on HUVEC
5.3.2.1 Lactate dehydrogenase assay
After 24 hours direct exposure a significantly higher level (p < 0.001) of LDH
activity was found from the nanocomposite-seeded group compared to the CCM0 group
(Figure 5-3 a.).
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Figure 5-3 a. LDH assay test on HUVEC seeded directly onto nanocomposite for 24 hours.
Absorbance was measured in arbitrary units at 450 nm wavelength. Data are mean ± SD (n =
6).
5.3.2.2 Alamar blue™ assay
Direct exposure to nanocomposite for 24 hours showed viable cells present,
though at a lower level of Alamar Blue activity compared to the CCM0 group (p < 0.001)
(Figure 5-3 b.). After 96 hours direct exposure viable cells were still present on the
nanocomposite-seeded, again at a lower level compared to the CCM0 cells (p < 0.001)
(Figure 5.3 c.).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
157
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Blank
CCM0
***
nanocomposite-unseeded
nanocomposite-seeded
Treatment
A
b
s
o
r
b
a
n
c
e
(
5
7
0
-
6
3
0
n
m
)
Figure 5-3 b. Alamar blueTM viability assay test on HUVEC seeded directly onto
nanocomposite for 24 hours. Absorbance was measured in arbitrary units at 570 nm wavelength
and background at 630 nm subtracted. Data are mean ± SD (n = 6).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Blank
CCM0
***
nanocomposite-unseeded
nanocomposite-seeded
Treatment
A
b
s
o
r
b
a
n
c
e
(
5
7
0
-
6
3
0
n
m
)
Figure 5-3 c. Alamar blueTM viability assay test on HUVEC seeded directly onto
nanocomposite for 96 hours. Absorbance was measured in arbitrary units at 570 nm wavelength
and background at 630 nm subtracted. Data are mean ± SD (n = 6).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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5.3.2.3 Pico green assay
Direct exposure for 24 hours to nanocomposite resulted in the presence of 417.3
± 50.4 μg/ml DNA. After 96 hours direct exposure 323.6 ± 232.9 μg/ml of DNA was
extracted from the graft samples.
5.3.2.4 ScEM studies
ScEM studies showed that the surface of the nanocomposite graft material was
uniform and demonstrated that EC were present on the graft material at both 24 and
96 hours post-seeding (Figure 5-4).
Unseeded Graft
Figure 5-4 a. ScEM of surface of nanocomposite graft (×640).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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Unseeded Graft
Figure 5-4 b. ScEM of surface of nanocomposite graft (×160).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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Seeded Graft 24 hours
Figure 5-4 c. ScEM of HUVEC seeded directly onto nanocomposite after 24 hours (×160).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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Seeded Graft 96 hours
Figure 5-4. d. ScEM of HUVEC seeded directly onto nanocomposite after 96 hours (×160).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
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5.3.3 Assessment of cell proliferation on nanocomposite
Figure 5-5 and 5-6 shows the results from the proliferation study. It can be seen
that the HUVEC exhibit a typical growth curve on both nanocomposite and glass, with
confluence being reached at day 10. Again the AB results are lower for the cells seeded
on nanocomposite compared to those seeded on glass.
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Figure 5-5 Alamar blue™ viability assay test on HUVEC seeded directly onto nanocomposite
for 16 days. Absorbance was measured in arbitrary units at 570 nm wavelength and background
at 630 nm subtracted. Data are mean ± SD (n = 6).
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Figure 5-6. Pico Green assay on HUVEC seeded directly onto nanocomposite for 12 days.
Data is presented as DNA amount in µg/ml (n = 6).Chapter 5: In vitro cytotoxicity analysis of nanocomposite
163
5.4 Discussion
The improvement and understanding of surface thrombogenicity has become an
important field of research. In tissue engineering it has been found that silicon and its
analogues, such as oxides, dramatically reduce protein adsorption and platelet adhesion
(6). The mechanism has been hypothesised to be related to the surface charge (7);(8)
causing structural changes to the blood proteins (9);(14) such as fibrinogen (59). Silicon
itself is very un-reactive and therefore research has been focused on moieties such as
siloxane, in particular PDMS especially when combined with polyurethanes, rubbers or
on its own (190-192). PDMS on its own or with rubbers is mechanically very weak and
therefore cannot be used in bio-medical devices. As a result various methodologies have
been attempted in order to combine it with polyurethane. To date the results in vivo have
been very poor due to dramatic losses in bio-stability caused by the non-reaction of
PDMS with either the soft or hard segments resulting in two separate polymers
(193;194). Until now silicon and siloxane-based materials possessed poor growth
characteristics for human cells such as EC (209) making them unsuitable for tissue
engineering.
It was therefore felt that a need still existed for a polyurethane containing silicon that is
mechanically strong and so bio-stable, but in addition possesses the advantageous
qualities of reduced protein and platelet adsorption and most importantly would still
allow the growth of cells such as EC without causing related cytotoxic effects. The
original hypothesis was that the synthesis of a polyurethane containing silsesquioxane
would result in a class of inorganic-polymers (nanocomposite) that would possess all the
desirable attributes described above (210).
In the clinical scenario the choice of a material to be used for CABG prostheses
must incorporate cytocompatibility to EC in two areas; indirect and direct contact of EC
with the material. In this study in the case of indirect contact an initial exposure for
24 hours to CCM treated with powdered nanocomposite produced no significant effect
on either cell metabolism or cell numbers compared to the CCM0 as shown by the
results of the AB and PG assays. The use of Staurosporine as a positive control proves
the principle that these assays are capable of demonstrating cell damage and further
suggests that the toxicity of nanocomposite is low. A longer 96 hours exposure again
produced no significant change in cell numbers though metabolism was reducedChapter 5: In vitro cytotoxicity analysis of nanocomposite
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significantly in the case of the CCM100 group. In contrast by 96 hours post-exposure the
CCMST group showed no cell metabolism and extremely low cell numbers. This
indicated that toxicity by nanocomposite on EC was not apparent other than mildly at
CCM100.
Twenty four hours of post-seeding, of EC onto nanocomposite showed the
presence of viable EC from the PG results and ScEM analysis and that the cells were
metabolising (as shown in Figure 5-4). Whilst both the cell numbers and metabolism
were significantly less than for the CCM0 cell group this may be due to improved
seeding and attachment on TCP (which is optimal for cell attachment and growth)
compared to nanocomposite and is similar to the results obtained in previous studies on
ePTFE and compliant PCU (444). There was a significantly increased level of LDH
activity compared to the CCM0 cells suggesting that seeding efficiency on
nanocomposite was lower than on TCP or glass or that initial cell damage had occurred.
Extended 96 hours direct exposure showed similar results to the 24 hour period and
again demonstrated the presence of viable cells on the material. The cell proliferation
study showed that HUVEC can be maintained on nanocomposite for an extended
period (16 days) and that the growth pattern is similar to that for HUVEC grown on a
glass surface.
5.5 Conclusion
In conclusion it can be said that the results obtained in this study demonstrate
that indirect exposure to nanocomposite does not result in serious damage to EC at
concentrations likely to be encountered in a clinical situation. Furthermore, the
nanocomposite can be successfully seeded with EC and indicates that, once seeded, the
EC remain viable and proliferate for a period of days. This combined with its other
advantages suggests that nanocomposite is suitable for further development in the
development of a coronary bypass graft.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
165
Fabrications of a small diameter compliant nanocomposite coronary
artery bypass graft
6.1 Introduction
Advanced novel fabrication methods are needed to build three-dimensional
scaffolds that incorporate multiple functionally graded biomaterials with a porous
internal architecture that will enable the simultaneous growth of multiple tissues, tissue
interfaces and blood vessels. Various methods have been utilised to manufacture porous
grafts for vascular bypasses. These include electrospinning (475), electrospraying, dip-
coating (476) and extrusion (477).
Electrospinning of polymer is an approach for the production of much smaller
diameter fibers which are of interest for tissue engineering. While electrospinning has
been known for some time and attempts have been made to produce vascular grafts by
this technique, only recently has interest in electrospinning for polymer biomaterial
processing been revived (475). In electrospinning highly viscous polymers are able to
‘spin’ into a flowing fibre from the ‘Taylor Cone’. This cone is generated by an electric
field applied to a metal capillary through which the polymer extrudes. The electrostatic
repulsion effect due to the electric field allows the spun fibres to be whipped and
thinned simultaneously to be collected on a surface (see Figure 6-1). The degree of
thinning can thus be accurately controlled. If a low viscosity polymer is subjected to theChapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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same electric field, a spray effect is generated as the electrostatic repulsion forces the
droplets to disperse in an aerosol - this is known as electrospraying (476).
The basic elements of a laboratory electrospraying system are simply a high voltage
supply, collector (ground) electrode/mold, source electrode, and a solution or melt to be
sprayed or spun. The sample is confined in any material formed into a nozzle with
various tip bore diameters (such as a disposable pipette tip) with a thin source electrode
immersed in it. The collector can be a flat plate wire mesh or, in more sophisticated
modifications, a rotating metal drum or mandrel on which the polymer is wound.
Dip-coating refers to the immersion of a scaffold into polymer solution in order
to coat it. An additional process is required to solidify the result. This may be by casting
(i.e. heating the polymer so that the solvent evaporates) or phase inversion by swapping
the solvent for a non-solvent (477). Freehand dip-coating can cause great variability
between grafts produced, and for adequate control, a mechanised dipping process is
necessary. Kannan et al has produced microvessels from the nanocomposite using a
semi-mechanised dip-coating followed by phase inversion (478). His work involved
dipping needles via a mechanical arm into polymer solution, then allowing a capillary
action to act and distribute thin coating of polymer uniformly before dropping into a
coagulant. Using this technique gave good results in terms of wall uniformity and
mechanical properties. One of the techniques assessed in this chapter used for
manufacture of small diameter vascular grafts was essentially a modification of this
method called extrusion-phase inversion.
The extrusion technique refers to the pressured drawing of a material (usually a
polymer) through a template to form a three dimensional model with a cross section
mirroring the template. This requires a highly viscous polymer which will hold its shape
after drawing out. The pressure is usually provided by a screw system pump. The
technique used here depends on a layer of polymer coating a mandrel as it passes
through it, with shape being given by the exit aperture; this method is extrusion.
However, the viscosity of the polymer is much lower than that used in typical extrusion.
Therefore, phase inversion must be commenced immediately to prevent the polymer
flowing off the mandrel. A vertical dip-coating coagulative extruder has been used to
manufacture uniform walled porous 5 mm internal diameter conduits. The porosity
imparts compliance which would ideally match that of a native artery.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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The concept of phase inversion can be explained by consideration of the
nanocomposite as a pure polymer with a variable amount of solvent in which it is
dissolved. The higher the amount of solvent, the higher the viscosity (i.e. the more
solid). Phase inversion relates to the controlled removal of solvent by swapping it for a
non-solvent. Previous studies have proven that polyurethanes may be made porous by
placing the polymer solution in a non-solvent solution such as water which leach into it
and forms porous materials as a result of the release of DMAC from the polymer
solution into the water. This technique depends upon the homogeneity, viscosity and
concentration of the coating polymer as well as the type of mandrel used (479). When
using this method, achieving a uniform coating on the mandrel depends upon consistent
polymer flow patterns on the mandrel. Extruding these polymers solutions have proved
successful in vessels of above 3 mm in internal diameter and dip-coating remains the
primary method of fabricating smaller vessels (479).
The objective of this study was to determine the ideal method of fabricating
small diameter nanocomposite vascular grafts with similar compliance characteristics to
native arteries using phase inversion. The parameters assessed were method of polymer
deposition namely electrospraying or extrusion. In this study basic compliance and burst
pressure was measured in order to determine a suitable conduit for progression to in
vitro shear stress work.
6.2 Materials and Methods
6.2.1 Nanocomposite synthesis
The synthesis of nanocomposite polymer solution has been described in Chapter 3.
6.2.2 Nanocomposite deposition onto mandrels and formation of porous
nanocomposite vascular grafts
6.2.2.1 Electrospraying-phase inversion
Using a 10
-5 m
3 syringe on an infusion system; Semat A99FMZ syringe pump
(Semat International Ltd., St. Albans, Hertfordshire, UK) with a silicone rubber tube,Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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the polymer was made to flow at a rate (FR) of 1.338 x 10-9 m
3/s through a point
needle (1070 μm diameter) held in an epoxy resin. The polymer solution was passed
through an electric field of 6.2 kV to form a stable cone jet (Figure 6-1) with the ground
electrode being placed at a distance of 10 mm from the needle tip. The electrical field
was supplied by a high voltage supply (Glassman Europe Ltd., Tadley, Hampshire,
U.K.) while illumination was provided by a LED and a signal generator. The polymer
droplets were deposited onto cylindrical 5 mm diameter stainless steel rotated mandrels
(Venflon BD systems, U.S.A) so as to form a thin film on its surface. The
polymer/mandrel was set in deionised water at 0 °C for the phase inversion step.
Figure 6-1. Using electrospinning as a method of producing a porous graft from a liquid
polymer.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.2.2.2 Extrusion-phase inversion
The extrusion device (referred to as an automated bio-processor) contains a
mechanical arm, polymer chamber and coagulant reservoir (Figure 6-2). A mechanical
arm capable of descending vertically downwards at 10 mm/sec was positioned such that
it held a 5 mm diameter stainless steel cylindrical mandrel within the exit aperture of a
polymer chamber (Figure 6-2 A). This latter structure, encased within a perpex block,
was also made from stainless steel, comprising of a circular 5 mm entry aperture
superiorly; a luer-lock syringe compatible polymer introduction channel laterally (Figure
6-2 B); a 6 mm circular exit aperture inferiorly which could be surplanted by other
aperture adapter (Figure 6-2 C); and a PTFE sliding cover for the exit aperture (Figure
6-2 D and E). The Perspex block was held in a bracket such that the mandrel cross-
section was aligned perfectly concentric with respect to the exit aperture.
With the mandrel’s base centrally placed and level with the exit aperture, the PTFE
sliding cover was closed before 3.0 ml of nanocomposite polymer solution was injected
slowly into the polymer chamber. For the first step it was very important that the
syringe contained no air bubbles. This was allowed to settle for 15 minutes to ensure
that any small air bubbles that were present could rise to the nanocomposite surface.
A vertical column of coagulant solution was placed directly below the sliding cover
leaving a 5 mm gap between the two. The coagulant solution was deionised water at 0
°C. This coagulation step has been investigated in our laboratory to be the condition for
extruding porous nanocomposite conduits. The relative importance of porosity of grafts
have been extensively explored with groups investigating pore sizes of 10 to 45 microns
that is required for spontaneous endothelialisation (480).
The cover was opened and the mandrel driven downwards vertically into the
coagulant at 10 mm/sec immediately afterwards (Figure 6-2 F). A pressure switch on
the mechanical arm ensured it stopped descending when it reached the polymer
chamber. The alignment was checked during this extrusion by visually comparing the
layers of nanocomposite coating either side of the mandrel within the coagulant solution
in the moments before coagulation occurred. This was undertaken in two planes
perpendicular to each other about the longitudinal axis of the mandrel, and was
facilitated by viewing against a natural light background.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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The column was undisturbed for 20 minutes after which time the mandrel was
disconnected from the mechanical arm and placed in coagulant solution and left at 5
0C
for a minimum of 12 hours. Thereafter, the mandrel was removed from the coagulant
and dried with paper towels, before transferring to an absolute ethanol bath for
degassing over 10 minutes, thereby facilitating removal of the formed tube from the
mandrel. This latter step was carried out by gently loosening the conduit from the rod
along its whole length with small circular and longitudinal stresses after which the whole
tube easily slid off without excessive strain. Each extruded tubes was produced with an
overall length of 18 cm.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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A
Figure 6-2. An automated bio-processor used to extrude polymer into conduits. A) The device
consists of a mechanical arm that travels vertically at 10 mm/s, polymer chamber and coagulant
reservoir containing 0 °C deionised water.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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Figure 6-2. B) Shows polymer chamber with mandrel entering superiorly and polymer
introduction channel laterally, C) Under surface of polymer chamber showing adaptors enabling
control of exit aperture size, D) Exit aperture cover closed and E) Exit aperture cover open.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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E
Figure 6-2. E) Extrusion performed by driving mandrel through polymer chamber and then
into coagulant.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.2.3 Reproducibility of conduit
Six conduits were fabricated with no selection of ‘best specimen’. The image
analysis software was used to measure the uniformity of wall thickness at 72 points
distributed equally around the circumference, so assessing the reproducibility of the
electrospraying and extrusion process.
6.2.4 Compliance
Fifty millimetre lengths were taken from the midsection of the extruded and
electrosprayed tubes, so as to harvest the most uniform part, leaving the bulbous ends.
The grafts remained in deionised water, rather than dry storage to ensure no shrinkage
or changes to the mechanical properties due to graft dehydration. Intraluminal pressures
were measured in mmHg. The segments of the conduits were then longitudinally
stretched by 10 %, so as to mimic conformational changes expected within an in vivo
system, before being connected to the flow circuit using commercially available 21G
intravenous cannulae (Venflon BD Ltd, UK) and placed in a water bath. The flow
circuit was then filled with clinical-grade native citrated blood (0.40 haematocrit) at 37
ºC maintained using a heat exchanger (Portex, Hythe, UK) taking care to evacuate any
air within the system which could cause damping. On initiating pulsatile flow at a
frequency of 1 Hz, physiological mean pressures of 30 to 70 mmHg were achieved
whilst maintaining the pulse pressure at 39.633 (± 3.952) mmHg throughout the tests.
Both anterior and posterior vessel wall motion with each pulse was assessed using a 7.5
MHz linear array Duplex probe and an echo-locked wall tracking system (Walltrack; Pie
Medical Systems). The data was then interpreted using analogue-to-digital data
acquisition recording system (ADC/Maclab; AD Instruments, Hastings, UK).
As the control, freshly harvested human iliac arteries and femoral vein from
cadaveric rats were used in comparison to these nanocomposite conduits. These grafts
were obtained in accordance with human and animal research guidelines. Also as a
comparison the compliance of ePTFE was measured. All experiments were repeated 6
times for each pressure range using different sets of vessels (n = 6). Unlike previous
experiments with the PCU vascular grafts (57;481), there was no need to pre-clot these
nanocomposite conduits as there was no significant leakage of blood through their
walls. This may be explained by the microporous nature of the conduits walls.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.2.5 Burst strength
To measure burst pressure of the conduits high pressure syringe pump (Harvard
Apparatus PHD 2000 Programmable) containing freshly deionised water (pH 7.0) was
connected via a transducer (Honeywell Component No. 22PCCFB6G) to unused fifty
millimetre lengths of conduits fabricated in the same manner as those used for
compliance study (Figure 6-3). This was vertically suspended with distal clamping and
weighted to ensure 10 % longitudinal stretch. The transducer was precalibrated by
connecting it to a standard clinical sphygmomanometer and a voltmeter to record
voltage readings at 0 mmHg, 100 mmHg and 200 mmHg from which offset and gain
Figures were calculated and entered into a personal computer with bespoke software for
recording the pressure at a sample rate of 10 Hz.
The transducer was connected via a 10 v power source to the personal computer. Water
was expelled from the pump with the graft unclamped to allow the apparatus to be filled
completely, whilst ensuring all air was eliminated from the apparatus. The clamp and
weight was applied and an initial infusion rate of 0.2 ml/min was commenced, and this
was gradually increased to take account of the percolation of water through the wall at
high pressure and ensure an increasing intraluminal pressure. The infusion was
continued until the graft material burst, and the burst pressure recorded. Six graft
conduits were subjected to assess burst pressure.
Figure 6-3. High pressure syringe pump used to measure burst pressure.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.2.6 Scanning electron microscopy
The fabricated conduits were assessed by ScEM to visualise the detail of the wall
cross section and pores.
6.3 Results
6.3.1 Electrospraying-phase inversion
6.3.1.1 Assessment of reproducibility of electrosprayed conduits
Table 6-1 shows the measurements of wall thickness of the six independent
conduits fabricated using the electrospraying-phase inversion technique. The wall
thickness of each conduit measured was found to widely vary where the lowest mean
pressure was 0.002 mm and the highest being 0.31 mm. A high variation in mean wall
thickness can be seen in Figure 6-4.
Table 6-1. Measurement of wall thickness in mm from conduits fabricated by electrospraying-
phase inversion. The image analysis software was used to measure the uniformity of wall
thickness at 72 points distributed equally around the circumference, so assessing the
reproducibility of the cylindrical graft conduits.
Graft Mean wall
thickness
(mm)
Minimum
(mm)
Maximum
(mm)
Standard
Deviation
1 0.23 0.11 0.45 0.0574
2 0.05 0.006 0.35 0.0141
3 0.11 0.02 0.29 0.0054
4 0.31 0.22 0.63 0.0214
5 0.008 0.001 0.20 0.0132
6 0.002 0.0009 0.007 0.0356Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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Figure 6-4. Mean wall thickness in mm of six independent fabrications of cylindrical graft
conduits using electrospraying-phase inversion.
6.3.1.2 Measurement of compliance
The compliance of conduits produced by electrospraying was unsuccessful. This
is because all the grafts placed in the flow circuit were found to burst when pulsatile
flow was applied. As a control, the compliance of artery, vein and ePTFE can be found
in Figure 6-8. This demonstrates that compliance measurements were carried out
successfully even though no data were obtained for electrosprayed conduits.
6.3.1.3 Measurement of burst pressure
Conduits that were produced by electrospraying-phase inversion burst within the
initial flow rate were applied at an infusion rate of 0.2 ml/min. The conduit measured
with a mean wall thickness of 0.31 mm (see Table 6-1, graft 4) was the only conduit
found to burst at 100 mmHg.
6.3.1.4 Scanning electron microscopic observations of electrosprayed grafts
Figure 6-5 shows ScEM of a typical conduit that has been fabricated using the
electrospraying-phase inversion technique. As can be seen, although there is a uniform
layer of polymer around the conduit, the nanocomposite conduit seems to be relativelyChapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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weak, indicating its pore activity when physiological flow was applied. There are also
large gaps within the conduit, making them leak.
Figure 6-5. ScEM of the electrosprayed conduit on 5 mm internal diameter mandrels. The
sprayed conduit was then immersed into a coagulant solution to form a porous graft.
6.3.2 Extrusion-phase inversion
6.3.2.1 Assessment of reproducibility of extruded conduits
Figure 6-6 shows the nanocomposite polymer extruded using the automated bio-
processor (as shown in Figure 6-2) with phase inversion into small diameter
nanocomposite conduit. The wall thickness for conduits produced by extrusion-phase
inversion is shown in Table 6-2. The mean wall thickness was obtained by measuring
the wall thickness over 72 points around the circumference of the graft. The mean
lowest wall thickness was 0.47 mm and the highest was 0.56 mm. In Figure 6-7 theChapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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mean wall thickness is plotted vs. graft. The average mean wall thickness of the six
extruded grafts was 0.507 mm.
Figure 6-6. Photograph of five millimeter internal diameter nanocomposite conduit using
extrusion-phase inversion.
Table 6-2. Wall thickness measurements for each extruded conduit based on image analysis
software at 72 points distributed equally around the circumference, so assessing the
reproducibility of the cylindrical graft conduits.
Graft Mean wall
thickness
(mm)
Minimum
(mm)
Maximum
(mm)
Standard
Deviation
1 0.47 0.37 0.65 0.06541
2 0.56 0.39 0.77 0.03212
3 0.50 0.44 0.61 0.01323
4 0.51 0.32 0.71 0.12154
5 0.48 0.43 0.66 0.12145
6 0.52 0.44 0.68 0.01436Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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Figure 6-7. Mean wall thickness in mm of six independent fabrications of cylindrical graft
conduits using extrusion-phase inversion.
6.3.2.2 Measurement of compliance
The compliance as well as the pressure ranges over which they are determined is
shown in Figure 6-8 for nanocomposite conduits, artery, vein and ePTFE grafts.
The compliance of human external iliac artery was found to range from 30 %/mmHg x
10
-2 at a mean pressure of 40 mmHg to less than 5 %/mmHg x 10
-2 at 120 mmHg mean
pressure. The compliance of ePTFE was found to be in the region of 1 %/mmHg x 10
-
2. A compliance of 7 – 10 %/mmHg x 10
-2 was measured for the nanocomposite graft.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
181
40 50 60 70 80 90 100 110 120 130
0
5
10
15
20
25
30
Nanocomposite
Artery
Vein
ePTFE
Pressures (mmHg)
C
o
m
p
l
i
a
n
c
e
(
%
m
m
H
g
x
1
0
-
2
)
Figure 6-8. Measure of compliance vs. mean pressure for different conduits. The compliance
characteristics on human external iliac artery, femoral vein, ePTFE and extruded nanocomposite
conduits. The pulse pressure was 60 mmHg. Nanocomposite conduit is compliant unlike
ePTFE.
6.3.2.3 Measurement of burst pressure
The burst pressure of extruded conduits can be found in Table 6-3. The lowest
burst pressure was shown to be 420 mmHg and the highest at 475 mmHg. The average
burst pressure of the nanocomposite conduits was 450 mmHg.
Table 6.3. Shows the burst pressures in mmHg for nanocomposite conduits fabricated by
extrusion-phase inversion.
Tube Burst pressure
mmHg
1 450
2 475
3 460
4 445
5 420
6 450Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.3.2.4 Scanning electron microscopic observations of extruded grafts
Figure 6-9 shows ScEMs of extruded-phase inversion nanocomposite conduits.
The conduits extruded demonstrated uniformity as well as a microporous structure ideal
for seeding.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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Figure 6-9. ScEM images of conduits produced using the extrusion-phase inversion technique
where a) internal view and b) microporous layers.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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6.4 Discussion
The objective of this chapter was aimed at developing compliant small diameter
conduits for use as a coronary bypass grafts with similar compliance characteristics to
native small diameter arteries using the techniques, electrospraying and extrusion (based
on the dip coating method), both with the phase inversion step.
Electrospraying has been represented previously as an attractive means to
achieving small diameter conduits (476). In electrospraying charged droplets are
generated at the tip of a metal needle with a several kV dc field, and are subsequently
delivered to a grounded target. The droplets are derived by charging a liquid to 5-20 kV,
which leads to charge injection into the liquid from the electrode. Attempts at
electrospraying the nanocomposite onto mandrels as a technique proved futile as
polymer deposition was uneven. After phase-inversion the conduit was relatively weak.
The conduits showed to burst when initial pressure was applied. When tested for
compliance all the conduits failed within the initial application of physiological flow. In
this study, it was proved that the electrospinning application did not produce compliant
conduits with sufficient strength for future flow studies.
The drawback with freehand dip coating is that it can cause great variability
between grafts produced, and for adequate quality control, a method based on the
mechanised dipping process was assessed. This technique of extrusion combined with
phase inversion is not novel-it is used to manufacture of the Chronoflex graft which is
commercially available as a vascular access graft, utilising the patented method of
Charlesworth (482). However, this is a horizontal extruding system that requires a
constant rotational torque during phase inversion to ensure evenness of the graft walls.
The idea of using a vertical extruding system relying on gravity for a uniform graft wall
thickness, lead to the development of a novel bench-top extruding device. The extrusion
technique used in this thesis was devised by a fellow Ph.D. student, Dr. Sandip Sarkar in
order to achieve tubular conduits with sufficient integrity for subsequent in vitro
research.
The compliance and burst pressure was measured for each fabricated conduit in
order to determine a suitable model. The compliance for an artery is used to describe itsChapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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distention in response to applied pressure. Compliance is expressed in % per mmHg x
10
-2. A vessel’s compliance is a measure of how easily it dilates in response to internal
pressure increases (483). Physiological flow in a healthy human achieves a typical mean
pressure of 80 to 100 mmHg with a pulsatile pressure of 40 mmHg, suggesting that
matching arterial compliance would require a value nearer 3-5 % mmHg x 10-2. In
human femoral arteries a compliance value of 5.3 %/mmHg x 10
-2 has been reported
(484). Another documented value for arterial compliance is 8.1 ± 5.9 %/mmHg x 10
-2
over the pressure range 30 to 100 mmHg, but the position of the artery is not
documented (481). The compliance of the human vein is shown as 4.4 ± 0.8 %/mmHg
x 10-2 in the SV over an unknown pressure range (484) and 5.0 ± 6.7 %/mmHg x 10-2
over passage range 30 to 100 mmHg at an unknown position (481). As veins consist of
the same material as arteries they will undergo a similar response. Veins however consist
of different proportions of the material (more collagen, less elastin) because they have to
operate at different pressures in vivo. The collagens properties will be recruited at much
lower pressures.
Compliance test was measured by an in vitro flow circuit to show the strength,
endurance and viscoelasticity of the conduits. In addition, it also demonstrates the
reproducibility of graft performance between the various conduits, thereby serving a
quality control function. Although the compliance of nanocomposite conduits
fabricated by electrospraying was unsuccessful, those that were fabricated by extrusion
showed superb results. The compliance of extruded nanocomposite conduit was
measured at 7 – 10 %/mmHg x 10
-2. As the compliance of the iliac artery measured was
5 %/mmHg x 10
-2 at 120 mmHg, this suggests that the extrusion based nanocomposite
conduit would match the arterial compliance in vivo. In comparison, the compliance of
ePTFE was shown to be very low. The graft would not be able to successfully dilate
during pulsatile flow with consequences on both blood flow profile as well as wall
stress. Firstly the flow of blood from the artery into the relatively stiff graft would cause
a calibre mismatch, concentrating stress at the anastomosis.
The burst pressure for the internal carotid artery is approximately 5000 mmHg (485).
PTFE as a vascular prosthesis has a burst pressure of 600 mmHg (485). One way to
strengthen the conduits is to increase their wall thickness. However, in this study the
concept of measuring the burst pressure of these conduits was to assess whether they
could withstand physiological stress.Chapter 6: Fabrications of a small diameter compliant nanocomposite coronary artery bypass graft
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The ideal graft would conform to arterial compliance at all physiological
pressures, not just for reasons of compliance matching but also to prevent over-
distention. The bypass prosthesis in current use does not have the problem of over-
distention due to their inelastic status. However, development of elastic alternatives
requires incorporation of the composite model demonstrated in arteries by way of the
complementary systems of elastin and collagen.
6.5 Conclusion
This study has demonstrated the development of compliant nanocomposite
conduits using extrusion-phase inversion technique, with a burst pressure able to
withstand physiological flow. As mentioned in Chapter 4 extrusion of polyurethanes
leads to solid walls or if coagulating, into porous walled structures. PCU based vascular
grafts have spongy middles and a single skin structure that allows it to maintain
compliance and pulsatile flow in vivo (208;214). The mechanical characterisation
described in this chapter affords a description of how the nanocomposite material
behaves under stress. Although this information is essential for a baseline in developing
any new material the results do not immediately translate to an indication of EC-graft
behaviour under the physiological stresses of pulsatile flow. In order to undertake this
translation, understanding of the stresses acting on the graft wall is desirable, and this
has been reviewed in Chapter 2. However, analysis of EC interaction with the compliant
graft would be required to quantify the action of stress. Each of these is in itself a
complex field requiring sophisticated theoretical models and models have been sought.
One way is by stimulating the potential stress on the wall by mimicking pulsatile flow.
The flow circuit described in Chapter 3 and used in measuring graft compliance in this
Chapter does this.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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EC & nanocomposite hybrid grafts: seeding and culture
7.1 Introduction
An important aspect of the development of a successful synthetic CABG is to
investigate the possibility of carrying out EC seeding of an artificial conduit. Evidence
for the requirement of a luminal EC lining is provided by the poor patency observed
when unseeded synthetic grafts with diameters less then 6 mm are employed (486).
These grafts exhibit extremely poor, clinically unacceptable long term patency when
compared to the ‘gold standard’ use of autologous grafts. The predominant reason for
this is that blood contact with the artificial graft surface results in the potential
formation of blood clots which cause a loss of patency (197). Thus an ideal clinically
acceptable artificial bypass graft would be to develop a conduit that allows seeding with
an achievable density of cells and be able to stimulate these cells under physiological
flow to proliferate, support and develop a stable and functional graft reducing the
likelihood of blood clots forming. Previous studies have demonstrated that many of
these problems can be overcome if the graft is seeded with EC prior to implantation but
take-up of this process has, to date, been limited due to the technical expertise required
to extract and seed the graft and the additional expense incurred in the process
(230;329;487).Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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As discussed in Chapter 4, polymers can differ greatly in their interactions with
cells seeded on them. This can affect factors such as the time required for cells to
adhere to the material, the number of cells required to obtain a confluent cell layer, the
ability of cells to withstand physiological flow when exposed to blood flow and the
ability of the cells to survive and proliferate on the material. The PCU graft employed in
this study to investigate the optimal method for isolating RNA from EC seeded on an
artificial graft has been shown to have a honeycomb structure (199;422;444) which
results in a greater potential surface area available for cell attachment when compared to
materials such as ePTFE which do not have a honeycomb structure and therefore leads
to the possibility of higher seeding densities being employed (199). When developing an
EC seeded nanocomposite hybrid graft an important initial stage is to determine the
optimal seeding efficiency of the graft. Seeding a high density of EC onto a graft surface
not only requires a large amount of initial tissue to isolate the cells from but also
extensive cell culture to generate the large number of cells required. At very high
seeding densities many of the cells seeded may be wasted as the excess cells do not
adhere to the surface resulting in cell death. Alternately utilising a seeding density which
is too low will not result in a confluent layer of EC on the graft and may increase the
chance of cells being washed away when exposed to flow. Previous work on lining PCU
and ePTFE vascular grafts with EC have established the optimal seeding conditions
(197;199) under various conditions for these materials. The optimal cell density required
is determined by a variety of factors such as the availability of cells, the type of graft
being seeded and the seeding time employed. To determine the optimal seeding density
a broad range of cell concentrations are assessed and then narrowed down to the
optimal cell number for the graft of choice and the seeding time employed. For example
in the case of PCU initial seeding density saturation occurred at 16 x 10
5cells/cm
2 when
seeded for 4 hours and these conditions resulted in a confluent EC layer (199). This was
therefore determined as the optimal conditions for seeding PCU graft conduits.
In order to determine if there were any significant differences between the
optimal seeding density for PCU and the nanocomposite conduits employed for the
flow studies this study was repeated to determine the optimal seeding conditions for the
nanocomposite. In addition to examining cell confluence and metabolism at each
seeding density two further important factors were investigated, RNA yield from cell
extraction (vital to later gene expression studies) and cytotoxicity. To assess cell seedingChapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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concentrations, HUVEC were seeded on nanocomposite conduits at achievable cell
densities; 6.3 x 10
3 cells/cm
2, 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4 cells/cm
2. To assess the
optimal seeding time, after 4, 8, 12 and 24 hours of incubation at 37°C cell seeding
efficiency and viability was assessed using Alamar blue
TM. An LDH assay was used to
monitor cell death. For each seeding density and incubation time the total RNA was
extracted and the purity measured.
Secondly the question of the stability of gene expression of the HUVEC
employed for cell seeding was addressed. There is phenotypic variation between ECs in
different portions of the vascular tree, and between arterial and venous cells. Cells from
different locations within an individual not only express different markers but can also
generate different responses to the same stimilus. Cells from different individuals can
vary in the responses to stilmuli, even when obtained from the same portion of the
vasculature. Due to the high numbers of cells required for successful seeding of the
nanocomposite conduits and the large numbers of conduits required for the exposure to
flow experiments it was recognised that there would be a necessity to utilise cells from
several different HUVEC isolations and, perhaps, different passage numbers in the
course of the study envisaged. In order to investigate the effects of passage number (and
time) on gene expression HUVEC were investigated from the initial cell isolation to
passage 11 by extracting RNA at each passage, examining the quality of RNA extracted
and carrying out RT-PCR analysis for GAPDH, TGF-β1, COL-1 and PECAM-1 at each
stage.
The aim of this part of the study was to validate the proposed model employed
for the shear stress studies by analysing the most suitable cell density and conditions for
EC seeding to obtain a sufficient amount of RNA for further studies and to ensure that
the ideal culture passage number was employed in order to investigate changes in gene
expression.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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7.2 Materials and Methods
7.2.1 Assessment of seeding efficiency and seeding time
7.2.1.1 Conduit seeding
HUVEC were cultured to passage three and seeded in 5 cm length with 5 mm
internal diameter tubular nanocomposite conduits prepared using the extrusion-phase
inversion method as described in Chapter 6. All conduits were autoclaved prior to use.
Following trypsinisation, and resuspension in complete tissue culture medium, a cell
count was obtained and diluted in 1ml of complete medium to three cell seeding
concentrations; 6.3 x 10
3 cells/cm
2, 1.2 x 10
4cells/cm
2 and 2.5 x 10
4 cells/cm
2.
For conduit seeding the cells were added as a suspension to each graft segment. The
ends of the graft were plugged, and the graft segments rotated 90° every 15 minutes for
the first two hours to achieve an even covering of HUVEC on each graft.
To assess the efficiency of cell adhesion on the nanocomposite, grafts were incubated
for 4, 8, 12 and 24 hours at 37 °C. Unseeded grafts were placed with complete medium
and incubated at 37°C. As a comparison and to ensure each technique was carried out
accurately the same densities of cells were seeded onto 6-well polystyrene tissue culture
plates (TCP) as above.
7.2.1.2 Cell viability
Grafts and control tissue culture plates were washed twice with PBS and the
viability of seeded cells was assessed using an Alamar blue™ assay. One millilitre of
Alamar blue™ (10%) in complete medium was added to each graft/well and incubated
for 4 hours. Duplicate 100 μl samples were then removed and the absorbance's read
spectroscopically at wavelengths of 570 nm and 630 nm.
7.2.1.3 Cell damage
To assess cell damage over seeding conditions, LDH assay was measured as
previously described. Fifty microlitres cell culture medium from each sample was
transferred to a 96-well plate. Fifty microlitres substrate mixes (1 vial substrate plusChapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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12 mls assay buffer) was added to each well and the plate covered in foil to prevent light
access. Samples were then incubated at room temperature for 30 minutes after which
the reaction was stopped by the addition of 50 μl stop solution (1 M acetic acid).
Absorbance was then read at 450 nm using a Multiscan MS UV visible
spectrophotometer.
7.2.1.4 RNA extraction
Total RNA from each graft and 6-well plate was extracted using the method
described in Chapter 3. Cells were trypsinised to remove them from the surface and
centrifuged to obtain a cell pellet. Cells were lysed with RLT lysis buffer and RNA
extracted as previously described. The yield and purity for each sample was measured at
260 and 280 nm using GeneSpec.
7.2.1.5 Cell staining
Cells seeded in grafts were stained using the Toluidine blue method. Following
seeding at 6.3 x 10
3 cells/cm
2, 1.2 x 10
4cells/cm
2 and 2.5 x 10
4 cells/cm
2 per conduit for
24 hours, nanocomposite conduits were washed in sterile PBS and stained using the
method outlined in Chapter 3, Section 3.8.1.
7.2.2 Assessment of genotype stability
7.2.2.1 Cell culture and RNA extraction
HUVEC were isolated from human umbilical cord vein as described earlier. The
initial cell isolation was called P0 for RNA extraction purposes and was taken as a
control. HUVEC were cultured in 75 cm
2 tissue culture flasks from passage 1 to 11.
Cultures were passaged every one to two weeks at a ratio of 1:2 and fed every 48 hours
as described in Chapter 3. Once a confluent monolayer was achieved cells were
removed by washing with 8 ml of PBS and then adding 3 ml of 10 % trypsin-EDTA
solution. The flasks were incubated for 3 minutes prior to gentle tapping in order to
loosen all the cells. The trypsin was then neutralised by the addition of 10 mls of
complete medium. The cell suspension was spun at 300 g for 7 minutes, supernatantChapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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discarded and cell pellet collected. At each passage split, confluent cells from one flask
were isolated for RNA extraction and the rest were resuspended in 10 ml of complete
medium to continue culturing.
7.2.2.2 Analysis of gene expression at each passage
RT-PCR was conducted for the expression of GAPDH, TGF-β1, COL-1 and
PECAM-1. 0.5μM from each of the primers was added to the PCR mix. For each
sample, 0.5μg of template RNA was employed with RNase free water added to make a
total volume of 50μl. Cycle conditions for all PCR reactions are described in Chapter 3.
All PCR products were run on a 2 % agarose gel and the intensity was measured for
each band.
7.2.3 Data analysis and statistical methods
Assessment of genotype stability study was repeated four times for each passage
number. Concentrations of RNA obtained are presented in mean ± SD. Comparisons
of gene intensity between groups were made by one-way ANOVA (Kruskal–Wallis) test
with post comparison using Dunn's comparison test.
The assessment of seeding efficiency and seeding time was repeated six times for each
cell density/seeding time measured. Statistical analysis used one-way ANOVA with
Tukey’s multiple comparison tests.
7.3 Results
7.3.1 Assessment of seeding and seeding time
7.3.1.1 Cell viability
Figure 7-1-1 shows Alamar blue
TM cell viability assay post HUVEC seeded on
TCP and nanocomposite conduits at cell densities of 6.3 x 10
3 cells/cm
2, 1.2 x 10
4
cells/cm
2 and 2.5 x 10
4 cells/cm
2 per conduit after a) 4 hours, b) 8 hours, c) 12 hours
and d) 24 hours of seeding time.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Significant differences (p < 0.001) in cell viability were observed between the TCP and
nanocomposite groups at all seeding time points. There were no significant differences
in cell viability between any of the cell densities seeded in nanocomposite conduits that
were seeded for 4, 8 or 12 hours (Figure 7-1-1 a, b and c respectively). Significant
increases in viability were only seen at 24 hours in nanocomposite conduits seeded with
1.2 x 10
4 cells/cm
2 (p < 0.01) and 2.5 x10
4 cells/cm
2 (p < 0.001) compared to 6.3 x 10
3
cells/cm
2. At 24 hours post seeding, no differences were observed in cell viability in
nanocomposite conduits seeded with 1.2 x 10
4 cells/cm
2 compared to 2.5 x 10
4
cells/cm
2.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-1-1. Alamar blueTM cell viability of HUVEC at 6.3 x 103 cells/cm2, 1.2 x 104cells/cm2
and 2.5 x 104 cells/cm2 seeded on tissue culture plates (TCP) and nanocomposite conduits post
a) 4 hours, b) 8 hours, c) 12 hours and d) 24 hours incubation time.
Absorbance was measured in arbitrary units at 570nm wavelength and background at 630 nm
subtracted. Data are n = 6. *P < 0.05, **P < 0.01 and ***P < 0.001. All statistical analysis
utilised one way ANOVA with Tukey’s multiple comparison test.
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Figure 7-1-2 shows Alamar blue
TM cell viability results of nanocomposite
conduits seeded at three cell densities of a) 6.3 x 10
3 cells/cm
2, b) 1.2 x 10
4cells/cm
2 and
c) 2.5 x 10
4 cells/cm
2 comparing against 4, 8, 12 an 24 hours seeding time. Conduits
seeded with 6.3 x 10
3 cell/cm
2 (Figure 7-1-2 a) showed significant increases (p < 0.05) in
cell viability at 12 and 24 hours only compared to 4 hours seeding time. There was no
significant difference between any other seeding time points at this seeding density. At
1.2 x 10
4 cells/cm
2 (Figure 7-1-2 b) and 2.5 x 10
4 cell/cm
2 (Figure 7-1-2 c),
nanocomposite conduits showed a significant increase in cell viability post 12 (p < 0.05)
and 24 hours (p < 0.001) of seeding compared to 4 hours. Increases were also observed
after 24 hours (p < 0.001) seeding compared to 8 hours. At 1.2 x 10
4 cells/cm
2 (Figure
7-1-2 b) and 2.5 x 10
4 cell/cm
2 (Figure 7-1-2 c) a significant difference (p < 0.01) in cell
viability was seen at 24 hours compared to 12 hours.
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Figure 7.1.2 a. Alamar blueTM cell viability of HUVEC seeded at 6.3 x 103 cells/cm2 on
nanocomposite conduits for 4, 8, 12 and 24 hours. Absorbance was measured in arbitrary units
at 570 nm wavelength and background at 630 nm subtracted. Data are n=6. *P < 0.05, all
statistical analysis utilised one way ANOVA with Tukey’s multiple comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-1-2 b. Alamar blueTM cell viability of HUVEC seeded at 1.2 x 104 cells/cm2 on
nanocomposite conduits for 4, 8, 12 and 24 hours. Absorbance was measured in arbitrary units
at 570 nm wavelength and background at 630 nm subtracted. Data are n=6. *P < 0.05, **P <
0.01 and ***P < 0.001, all statistical analysis utilised one way ANOVA with Tukey’s multiple
comparison test.
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Figure 7-1-2 c. Alamar blueTM cell viability of HUVEC seeded at 2.5 x 104 cells/cm2 on
nanocomposite conduits for 4, 8, 12 and 24 hours. Absorbance was measured in arbitrary units
at 570 nm wavelength and background at 630 nm subtracted. Data are n=6. *P < 0.05, **P <
0.01 and ***P < 0.001, all statistical analysis utilised one way ANOVA with Tukey’s multiple
comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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7.3.1.2 Cell damage
Figure 7-2-1 shows the LDH assay for cells seeded on nanocomposite conduits
and TCP at 6.3 x 10
3, 1.2 x 10
4 and 2.5 x 10
4 cells/cm
2 for a) 4 hours; b) 8 hours; c) 16
hours and d) 24 hours of seeding time.
HUVEC seeded on TCP was used as a control. Differences in LDH activity were
observed in all cell densities seeded in TCP compared to those seeded in nanocomposite
conduits at 4, 8, 12 and 24 hours of seeding.
There was a significant difference between 6.3 x 10
3 and 1.2 x 10
4cells/cm
2 post 4 hours
(p < 0.001), 8 hours (p < 0.01), 12 hours (p < 0.01) and 24 hours (p < 0.001) seeding
time on the nanocomposite conduits. After 4 hours of seeding time there was no
significant difference between 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4 cells/cm
2 seeded on
nanocomposite conduits. This was significant post 8, 12 hours (p < 0.01) and 24 hours
(p < 0.001).Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-2-1. LDH assay test measuring cell toxicity on HUVEC seeded on TCP and
nanocomposite conduits at 6.3 x 103, 1.2 x 104 and 2.5 x 104 cells/cm2for a) 4 hours, b) 8 hours,
c) 12 hours and d) 24 hours of seeding time. *P < 0.05, **P < 0.01 and ***P < 0.001 using one-
way ANOVA with Tukeys’s multiple comparison test.
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Figure 7-2-2 shows the LDH assay for cells seeded on nanocomposite conduits
at a) 6.3 x 10
3 cells/cm
2; b) 1.2 x 10
4cells/cm
2 and c) 2.5 x 10
4 cells/cm
2for 4, 8, 12 and
24 hours.
Cells seeded on nanocomposite conduits at a density of 6.3 x 10
3 cells/cm
2 (Figure 7-2-2
a) showed a significant difference between 4 and 24 hours (p < 0.01); 4 and 12 and 8
and 24 hours (p < 0.05) of seeding time. There was no significant difference in seeding
time between 12 and 24 hours of incubation at this cell density.
Nanocomposite conduits seeded with HUVEC at 1.2 x 10
4 cells/cm
2 (Figure 7-2-2 b)
showed a higher level of LDH activity at 4 hours compared to 12 and 24 hours (p <
0.01). This was also significant for 8 hours compared to 12 hours (p < 0.05) of seeding
incubation time on the nanocomposite conduits.
HUVEC seeded at 2.5 x 10
4 cells/cm
2 (Figure 7-2-2 c) on nanocomposite conduits
showed a significant higher (p < 0.001) LDH activity at 4 hours compared to 12 and 24
hours of seeding. Significant differences were also observed at 8 hours of seeding
compared to 12 (p < 0.001) and 24 hours (p < 0.01) seeding time on the conduits.
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Figure 7-2-2 a. LDH assay test on HUVEC seeded onto nanocomposite conduits at 6.3 x 103
cells/cm2 for 4, 8, 12 and 24hours. Absorbance was measured in arbitrary units at 450 nm
wavelength. *P < 0.05 and **P < 0.01 using one-way ANOVA with Tukey’s multiple
comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-2-2 b. LDH assay test on HUVEC seeded onto nanocomposite conduits at 1.2 x 104
cells/cm2 for 4, 8, 12 and 24hours. Absorbance was measured in arbitrary units at 450 nm
wavelength. *P < 0.05 and **P < 0.01 using one-way ANOVA with Tukey’s multiple
comparison test.
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Figure 7-2-2 c. LDH assay test on HUVEC seeded onto nanocomposite conduits at 2.5 x 104
cells/cm2 for 4, 8, 12 and 24hours. Absorbance was measured in arbitrary units at 450 nm
wavelength. **P < 0.01 and ***P < 0.001 using one-way ANOVA with Tukey’s multiple
comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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7.3.1.3 RNA yield
Figure 7-3-1 shows the RNA yield obtained from HUVEC seeded in TCP and
nanocomposite conduits at 6.3 x 10
3 cells/cm
2, 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4
cells/cm
2 for a) 4 hours; b) 8 hours; c) 12 hours and d) 24 hours of seeding time.
A significant difference (p < 0.001) in RNA yield was observed in all the control groups
(TCP) and nanocomposite conduits. After 4 and 8 hours (Figure 7-3-1 a and b
respectively) of seeding time, there was no significant difference in RNA yield between
all seeding densities. A significant difference was observed at 12 hours (p < 0.01) and 24
hours (p < 0.001) (Figure 7-3-1 c and d respectively), where an increase in RNA yield
was obtained with a cell density of 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4 cells/cm
2 compared
to 0.5 x 10
6 cells/cm
2 seeded on nanocomposite conduits. There was no significant
difference in RNA yield at 12 hours or 24 hours (Figure 7-3-1 c and d respectively) of
seeding time between 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4 cell/cm
2 seeded on
nanocomposite conduits.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-3-1. shows comparison of RNA yield measured at absorbance of 260 nm and 280 nm
obtained from conduits seeded at 6.3 x 103 cells/cm2, 1.2 x 104 cells/cm2 and 2.5 x 104 cells/cm2
on TCP and nanocomposite conduits for a) 4 hours, b) 8 hours, c) 12 hours and d) 24 hours of
seeding time. *P < 0.05, **P < 0.01 and ***P < 0.001 using one-way ANOVA with Tukey’s
multiple comparison test.
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Figure 7-3-2 represents RNA yield obtained from conduits over seeding time
(hours) for a) 6.3 x 10
3 cells/cm
2; b) 1.2 x 10
4 cell/cm
2 and c) 2.5 x 10
4 cells/cm
2 seeded
on nanocomposite conduits.
Conduits that were seeded with 6.3 x 10
3 cells/cm
2 (Figure 7-3-2 a) showed a significant
increase in RNA yield at 24 hours of seeding time compared to 4, 8 (p < 0.01) and 12
hours (p < 0.05). A significant difference (p < 0.001) in RNA yield was observed in all
seeding time points (except at 4 hours when compared to 8 hours) in nanocomposite
seeded with 1.2 x 10
4 cells/cm
2 (Figure 7-3-2 b).
Nanocomposite conduits seeded with 2.5 x 10
4 cells/cm
2 (Figure 7-3-2 c) showed a
significant increase in RNA yield post 24 hours (p < 0.001) of seeding time compared to
all time points but was less significant (p < 0.01) compared to 12 hours of seeding time
on the nanocomposite conduits.
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Figure 7-3-2 a. shows RNA yield measured at absorbance of 260 nm and 280 nm obtained
from nanocomposite conduits seeded at 6.3 x 103 cells for 4, 8, 12 and 24 hours of seeding time.
*P < 0.05 and **P < 0.01. Statistical analysis utilised one-way ANOVA with Tukey’s multiple
comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-3-2 b. shows RNA yield measured at absorbance of 260 nm and 280 nm obtained
from nanocomposite conduits seeded at 1.2 x 104 cells for 4, 8, 12 and 24 hours of seeding time.
***P < 0.001 using one-way ANOVA with Tukey’s multiple comparison tests.
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Figure 7-3-2 c. shows RNA yield measured at absorbance of 260 nm and 280 nm obtained
from nanocomposite conduits seeded at 2.5 x 104 cells for 4, 8, 12 and 24 hours of seeding time.
**P < 0.01 and ***P < 0.001 using one-way ANOVA with Tukey’s multiple comparison test.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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7.3.1.4 RNA purity
The purity of RNA was obtained for each cell density and seeding time. Figure
7-4 shows the RNA purity measured for HUVEC seeded on TCP and nanocomposite
conduits at three cell seeding densities of 6.3 x10
3 cells/cm
2, 1.2 x 10
4 cells/cm
2and 2.5
x 10
4 cell/cm
2 incubated at a) 4 hours; b) 8 hours; c) 12 hours and d) 24 hours.
No significant difference in RNA purity was observed in any of the groups (TCP and
nanocomposite conduits).Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-4. Comparison of RNA purity obtained from TCP and nanocomposite conduits
seeded at 6.3 x 103, 1.2 x 104and 2.5 x 104 cells/cm2 for a) 4 hours; b) 8 hours; c) 12 hours and
d) 24 hours seeding time. There was no significant difference in RNA purity between any of the
seeding densities and seeding times.
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7.3.1.5 Cell staining
The Toluidine blue images below (Figure 7-5) show HUVEC staining on
nanocomposite conduits seeded at a) 6.3 x 10
3 cells/cm
2, b) 1.2 x 10
4 cells/cm
2 and c)
2.5 x 10
4 cells/cm
2 for 24 hours. As can be seen differences were observed at cell
densities. Greater numbers of cells seem to be present in conduits seeded at 1.2 x 10
4
cells/cm
2 and 2.5 x 10
4 cells/cm
2 compared to 6.3 x 10
3cells/cm
2 over 24 hours seeding
time.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-5. Toluidine blue staining represents HUVEC seeded on nanocomposite conduits at
a) 6.3 x 103cells/cm2, b) 1.2 x 104cells/cm2and c) 2.5 x 104 cells/cm2for 24 hours.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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7.3.2 Assessment of genotype stability
7.3.2.1 RNA quantity and purity
The quantity and purity of the RNA isolated at each passage is shown in Table 7-
1. The amount of RNA isolated varied between 254 and 575 ng/µl and the ratio
A260/A280 between 1.90 and 2.20. The purity of total RNA achieved was good in all
cultured passages.
Table 7-1. RNA quantity and purity measured at absorbance of 260 nm and 280 nm.
Passage P0 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Concn(ng/µl)
(mean ±
SEM)
547
± 2.8
479
± 2.6
575
± 1.1
421
± 3.9
382
± 4.0
426
± 1.8
495
±4.4
274
± 5.0
277
±1.3
343
± 2.8
484
± 4.6
254
± 3.2
Ratio
(260nm/280
nm
1.92 1.97 1.98 1.93 1.90 1.96 1.92 2.20 2.12 1.90 1.92 1.95
7.3.2.2 Analysis of GAPDH, TGF-β1, COL-1 and PECAM-1 PCR products
All PCR products from each passage were loaded on a 2 % agarose gel. Figure 7-
6 shows 2 % agarose gels of PCR products for GAPDH, TGF-β1, COL-1 and
PECAM-1 expression over passage 0 to 11.
The mRNA levels of GAPDH remained relatively constant in the passage study
however slight changes were observed for the expression at passages 8, 9 and 10 (Figure
7-6 e & f).Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-6. PCR products of GAPDH, TGF-β1, COL-1 and PECAM-1 mRNA expression on
a 2 % agarose gel. The gel images show gene expression for HUVEC cultured where
(a) P0 and P1, (b) P2 and P3 (c) P4 and P5, (d) P6 and P7, (e) P8 and P9 (f) P10 and (g) P11.
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7.3.2.3 Analysis of gene intensity
Relative levels of GAPDH, TGF-β1, COL-1 and PECAM-1 over culture
passages 0 to 11 were determined using Syngene. The intensity of GAPDH was
determined for each band. As the products were loaded on different gels the intensity of
TGF-β1, COL-1 and PECAM-1 mRNA levels were normalized by GAPDH mRNA
level measured from the equivalent gel.
Figure 7-7 shows the intensity of gene expression from HUVEC at passage 0 to 11, for
a) GAPDH, b) TGF-β1, c) COL-1 and d) PECAM-1. Statistical analysis was assessed for
TGF-β1, COL-1 and PECAM-1 using the Kruskal-Wallis test. There was no significant
difference in any of the genes between the initial extractions, P0 to HUVEC cultured to
passage 11.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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Figure 7-7. Intensities of gene expression in arbitrary unit (AU) from RNA obtained from
passage 0 to 11 for a) GAPDH, b) TGF-β1, c) COL-1 and d) PECAM-1.
GAPDH gene intensity was measured for each band. TGF-β1, COL-1 and PECAM-1 mRNA
levels were normalized by GAPDH mRNA level. No significant increases in expression were
observed in any of the genes comparing between passages 0 to 11. Statistical analysis was
performed for TGF-β1, COL-1 and PECAM-1 using Kruskal-Wallis test. (n = 6).
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7.4 Discussion
Before embarking on shear stress and gene expression studies it was felt that this
investigation was a prerequisite in the stages of development of a model for studying
gene expression in EC-seeded conduits for small diameter coronary bypass graft. The
purpose of this chapter was to determine the cell concentration/seeding time
combination that produced the maximum number of adhered EC, maximum viable
graft surface coverage, and minimal cell number needed in terms for culture time whilst
at the same time producing sufficient RNA following extraction to permit gene
expression studies to be carried out. This is a fundamental requirement prior to flow
studies.
Nanocomposite conduits with an internal diameter of five millimetres and fifty
millimetres in lengths were fabricated and the seeding conditions were assessed. Using a
model previously utilised for lining vascular grafts with EC as a basis, cells were seeded
at 6.3 x 10
3 cells/cm
2, 1.2 x 10
4 cells/cm
2 and 2.5 x 10
4 cells/cm
2 per conduits. Equal
numbers were also seeded in TCP as a control. Grafts and TCP were incubated for 4, 8,
12 and 24 hours to assess seeding time. Examining seeding time first, both TCP and
nanocomposite demonstrated a time-dependent seeding efficiency. In the case of
nanocomposite in all cases (apart from 4 and 8 hours at the lowest seeding density) an
increase in seeding time resulted in an improved seeding density reflected in significant
increases in cell metabolism when measured by Alamar blue
TM. As regards initial seeding
density in general 6.3 x 10
3 cells/cm
2 resulted in significantly lower seeding compared to
the two higher cell densities for the cells seeded on nanocomposite. As a result of this
investigation it was decided to employ an initial seeding density of 1.2 x 10
4 cells/cm
2
with a 24 hour seeding time as the conditions for cell seeding in the following flow
studies. Whilst there was a slight increase in seeding efficiency using the higher initial
seeding density of 2.5 x 10
4 cells/cm
2 it was not felt that the increase in efficiency was
sufficient to overcome the difficulty of requiring twice as many cells for the studies.
Examination of the RNA yield at each time point confirmed the results obtained in the
cell metabolism studies and the advisability of using 1.2 x 10
4 cells/cm
2 with a 24 hour
seeding time which resulted in an adequate yield of RNA from the nanocomposite. The
RNA purity was unaffected by either the initial seeding density or the seeding time.Chapter 7: EC & nanocomposite hybrid grafts: seeding and culture
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The large number of cells needed to seed such grafts meant that alterations in
phenotype were a concern in this study. Primary cells in particular have a tendency to
change in phenotype in a number of ways with an increasing number of passages. Gene
expression is one of the factors that may be affected by changes over time in culture and
can be further influenced by the conditions under which the cells are maintained. Stable
gene expression under controlled conditions allows changes to be monitored. The
results obtained from the RNA extraction from HUVEC over 11 passages demonstrate
that levels of expression for GAPDH, TGF-β1, COL-1 and PECAM-1 remained stable
indicating that it would be possible to employ cells from different passages in the cell
seeding of nanocomposite conduits without compromising the results obtained from
later investigations into gene expression
7.5 Conclusion
The results obtained in this part of the study determined that the nanocomposite
could be successfully seeded with HUVEC using an achievable cell density and a 24
hour seeding period. Furthermore the use of different passage numbers of HUVEC to
achieve adequate numbers of cells should not result in a problem when investigating
gene expression as the expression was demonstrated to be stable over a wide passage
number. These studies validated the proposed model for seeding nanocomposite
conduits and provided a base from which to carry out the investigations into the effect
of flow to be carried out.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
An investigation of gene expression
215
The effect of shear stress on human endothelial cells seeded on
cylindrical conduits: An investigation of gene expression
8.1 Introduction
Steady progress in tissue engineering has produced a range of materials that are
capable of sustaining tissue ingrowth and limited regeneration. Artificial skin for the
healing of chronic wounds or burns is the most marked success (488-490). The
engineering of more complicated three-dimensional tissues and organs has been a
greater challenge (491;492). Many of the materials aimed for these applications are well
characterized chemically and mechanically (493;494). Modulus, strength and fatigue
properties can be modelled and predicted for numerous polymers (493;495-497).
Degradation rates and corrosion resistance can be tailored by alterations in composition.
Little is known, however, about the physiological impact of these materials on the cells
they contact in the body. Cells interacting with novel biomaterials may exhibit distinct
patterns of gene expression depending on the molecular nature of the surface they are
contacting. Little is known about how cells respond on a molecular level to tissue
engineering materials.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
An investigation of gene expression
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At present, attempts to seed EC on vascular prosthesis materials are problematic
with the major concern being the low number of EC that remain on the graft surface
after exposure to in vivo shear stress. As reviewed in Chapter 2, conditioning of seeded
EC by applying in vitro shear stress prior to implantation has been demonstrated to
improve cell retention (214) and decrease cell loss post implantation (338). Laminar
shear stress maintains normal endothelial structure and function. Turbulent flow and
local shear gradients activate endothelial cells and induce a pro-atherogenic state. This
reduces expression of eNOS and causes increased expression of vasoconstrictor and
pro-inflammatory factors. The pulsatile pattern of shear stress also affects the
endothelium. Thus, rapidly changing flow and oscillatory flow with flow reversal and
low net flow tends to induce a more pathologic state compared with laminar flow or
oscillatory flow that remains unidirectional. The precise molecular mechanisms that
mediate the shear stress response are unknown. Many in vitro studies of gene expression
have been carried out on monolayer’s of EC cultured on flat glass or polystyrene and
exposed to shear stress (263;498;499). These studies are two-dimensional models where
the characteristics of the flow and the interactions of the cells with the material are likely
to be very different from the clinical scenario in which a cylindrical graft is employed.
As evaluated previously, the major reason for the lack of such studies has been
due to the difficulty in extracting mRNA from EC seeded on a cylindrical graft surface.
In Chapter 5, this problem was examined and a suitable method of extracting functional
and viable mRNA from cell seeded cylindrical vascular grafts was identified (500). So
far, this thesis has also gone through evaluating the biocompatibility of the
nanocomposite as well as the design of compliant cylindrical nanocomposite grafts and
determining hybrid-grafts. Using these established systems, this chapter progressed onto
assessing, the effects of physiological flow on seeded cylindrical grafts. There are no
other reports in the literature of this being investigated apart from this study (501).
The aim of this study was to first time assess the effects of physiological shear
stress on the gene expression of human EC seeded in a cylindrical vascular graft. Gene
expression was investigated in HUVEC seeded onto nanocomposite conduits following
the application of physiological shear stress for one and four hours. In a further
investigation conduits exposed to flow were allowed to remain static for four hours toChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
An investigation of gene expression
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determine if expression returned to pre-flow levels. To validate the methods employed
identically sized and seeded glass conduits were also examined.
The genes chosen for study were GAPDH, TGF-β1, COL-1 and PECAM-1. As
reviewed in Chapter 2, GAPDH is a constitutively expressed house keeping gene that
has been well characterised has been shown to be expressed in constant amounts across
cell lines. TGF-β1 is involved in diverse biological processes, such as cell proliferation,
migration, differentiation, survival, and cell-cell and cell-matrix interaction and has been
demonstrated to be key to the formation of ECM by EC under flow (399;502). The
endothelial marker, PECAM-1 is expressed on EC and functions as an adhesion and
signalling molecule between adjacent endothelial cells and between endothelial cells and
circulating blood elements (503;504). The expression of COL-1 was studied as collagens
play a role in cell adhesion that is important for maintaining normal tissue architecture
and function (505).
8.2 Materials and Methods
8.2.1 Preparation of nanocomposite polymer conduits
The synthesis of nanocomposite has been described in Chapter 3 (70). The
nanocomposite was extruded into tubes of 5 mm internal diameter and 5 cm in length
using the extrusion-phase inversion protocol described in Chapter 6.
8.2.1.2 Glass conduits
Glass conduits of 5 cm length and 5 mm internal diameter were manufactured to
order (Scientific Laboratory Supplies, Wilford, U.K.). Conduits were sterilised by
autoclaving prior to use.
8.2.2 Human umbilical vein cell culture
HUVEC at passage three were used in this experiment as described in Chapter 3
(444).Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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8.2.3 Conduit seeding
Glass and nanocomposite conduits were seeded with HUVEC at 1.2 x 10
4
cells/cm
2, as assessed in Chapter 7. Cells were added as a suspension to each conduit,
the ends of the conduit plugged, and the conduits rotated 90° every 15 minutes for 2
hours to achieve an even covering of HUVEC on each conduit. Conduits were then left
overnight at 37 ° C and 5 % CO2/95 %O2for efficient cell adhesion and used the next
day.
8.2.4 Assessment of seeding efficiency and cell viability
Viability of seeded cells was assessed using an Alamar blue
TM assay as described
previously. Following overnight seeding conduits were washed with PBS and the
washings collected for cell counting to assess seeding efficiency. 1 ml of Alamar blue
TM
(10 %) in complete medium was added to each conduit and incubated for four hours at
37° C and 5 % CO2/95 %O2. Duplicate 100 μl samples were then removed and the
absorbance’s read spectroscopically. Cell viability on glass and nanocomposite was also
assessed following exposure to one or four hours of physiological shear stress or static
conditions.
8.2.5 Application of physiological pulsatile shear stress on cell
To test the flow shear stress on the EC, a physiological pulsatile flow circuit was
used to simulate the cardiovascular system (as described in Chapter 3). The system has
been validated extensively for physiological parameters (214) and has been described in
used in previous studies of flow (36). In brief the model simulates specifically a given
artery such as coronary or lower limb flow waveforms (See caption of Figure 3-2 in
Chapter 3 for further details). The flow circuit was primed with cell culture medium
adjusted for viscosity. The whole circuit was kept in sterile conditions. The experimental
protocol carried out is summarised in Figure 8-1. Seeded conduits were randomly split
into two groups, static and flow exposed. Static conduits were placed in fresh medium
and incubated at 37°C for either one or four hours. Flow exposed conduits were placed
in the flow system and a set flow rate of shear stress was applied for either one or four
hours. In a further study following one and four hours of flow or static exposure, aChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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subset of conduits were washed with PBS and placed in fresh medium and incubated
under static conditions for a further four hours. This group was labelled as the recovery
period group.
Figure 8-2 shows a typical distension and pressure waveform generated from
measuring distension and pressure versus time using an ultrasound artery wall tracking
system (Wall Track, Pie Medical Systems, Maastricht, Netherlands) and Millar catheter
(Millar Instruments, Houston, TX, USA). Examples of previously generated plots of the
velocity profile inside the artery and shear rate on the wall is shown in Figure 8-3. The
haemodynamic data including peak and mean shear stresses are computed and recorded
in Table 8-1.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Figure 8-1. Flow chart representing the experimental protocol carried out. Glass and
nanocomposite conduits were exposed to 1 or 4 hour of static or physiological flow exposure. A
further subset to this experiment includes a recovery period of 4 hour static of conduits prior to
1 or 4 hour static or flow.
Flow Static Flow Static
1 Hour 4 Hour 1 Hour 4 Hour 1 Hour 4 Hour 1 Hour 4 Hour
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
Alamar Blue
or
RNA
or
4 hour Recovery period (static)
or or or or
4 hour Recovery period (static)
RNA
Extraction
or or or
GLASS NANOCOMPOSITE
HUVEC SEEDED &
INCUBATED FOR 24
HOURS
HUVEC SEEDED &
INCUBATED FOR 24
HOURS
Alamar
Blue
(Pre-flow)
Alamar
Blue
(Pre-flow)
RNA
Extraction
RNA
Extraction
RNA
Extraction
RNA
Extraction
RNA
Extraction
RNA
Extraction
RNA
ExtractionChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
An investigation of gene expression
221
Figure 8-2. Vessel distension detected using an ultrasound wall tracking system and pressure
determined using a Millar Mikro-tip catheter transducer from circuit in Figure 3-2 (see Chapter
3).
Figure 8-3. A typical time dependent velocity (a) and shear rate distribution (b) acquired by the
duplex ultrasound coupled with on-line vessel wall tracking system.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Table 8-1. Summary of haemodynamic parameters measured.
Input parameters Value Computed parameters Value
Frequency of pulsatile cycle 1 Hz Inlet length (mm) 60
Internal diameter of conduit 5 mm Peak Reynolds number 512
Temperature 37 ± 1.4 Mean shear stress (dyn/cm2) 14.0 ± 3.2
Seeded graft length (mm) 50 Systolic shear stress (dyn/cm2) 30.4 ± 5.8
Seeded density (cells/cm2) 1.2 x 104 Diastolic shear stress (dyn/cm2) 62.7 ± 9.7
Pressure systolic (mmHg) 120 ± 5 Mean velocity (mm/sec) 436 ± 20
Pressure diastolic (mmHg) 70 ± 6
pH 7.3 ± 0.1
pO2 (kPa) 21 ± 2
pCO2 of solution (kPa) 4.2 ± 0.2
Viscosity of solution (poise) 0.035 ± 0.2
8.2.6 RNA extraction and PCR
Following exposure to experimental conditions cells were removed from
conduits by washing with sterile PBS and then trypsinising using 1ml of trypsin-EDTA
(0.25 %) which was added for 5 minutes incubation at 37
oC as described in Chapter 4.
RNA was then extracted by using a “Qiagen RNeasy” kit.
The RNA concentration and purity was calculated by measuring the absorbance at 260
nm and 280 nm using. The quality of the RNA was assessed by 2 % agarose gel
electrophoresis and the mRNA obtained was used for PCR of GAPDH, TGF-β1, COL-
1 and PECAM-1 genes (Table 8-2). RT-PCR was performed using a one-step PCR kit.
For sample obtained from the glass conduits and nanocomposite conduits, 0.5 μg and
0.1 μg of template RNA was used respectively. RNase free water was added to give a
total volume of 50 μl. Cycle conditions for GAPDH, 40 cycles (94°C, 50°C, 72°C);
TGF-β1, 35 cycles (95, 55, 60 °C); PECAM-1, 35 cycles (94°C, 50°C, 72°C) and COL-1,
35 cycles (94
o, 59
o and 72
o). Amplification was carried using a MasterCycler Gradient
PCR machine. PCR products were analysed by 2% agarose gel electrophoresis and semi-
quantified using a GeneGenius darkroom with ‘GeneSnap’ version 6.02. GAPDH bandChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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served as the internal standard to normalise TGF-β1, COL-1 and PECAM-1 signals,
since GAPDH is constitutively expressed in HUVEC.
Table 8-2. GAPDH, TGF-β1, PECAM-1 and COL-1 primer sequences.
Locus Sense (5’-‘3) Antisense (5’-‘3)
GAPDH GAAGGTGAAGGTCGGAGT GAAGATGGTGATGGGATTTC
TGF-β1 CACCTGCAAGACTATCGACAT TCGGAGCTCTGATGTGTTGAA
PECAM-1 GCTGTTGGTGGAAGGAGT GAAGTTGGCTGGAGGTGCTC
COL-1 AACGGCAAGGTGTTGTGCGATG AGCTGGGGAGCAAAGTTTCCTC
8.2.7 Scanning electron microscopy
Seeded nanocomposite conduits were examined by ScEM pre- and post-flow to
visualise whether cells were present on the grafts surface. ScEM images were also taken
after trypsinisation of the cells from the conduit in order to determine that complete cell
removal was obtained for RNA extraction. Due to the material nature of the glass tubes,
ScEM was not performed for these samples.
8.2.8 Data analysis and statistical methods
The experiments were repeated four times. RNA quantity is presented in mean ±
SEM. All statistical analysis utilised the Student’s t-test comparing flow to static
conditions.
8.3 Results
8.3.1 Assessment of seeding efficiency and viability
An Alamar blue
TM assay pre-flow following overnight seeding showed no
significant difference in seeding efficiency. Viable cells were present on both the glass
conduit group and the nanocomposite conduit group following exposure to flow orChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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static conditions (Figure 8-4, A (Glass) & B (nanocomposite)). A significant decrease
(Student’s t-test; P<0.05) in cell viability was observed in nanocomposite post four
hours of flow.
ScEM images showed viable cells present on nanocomposite prior to flow
(Figure 8-5, A & B). The efficiency of removal of the cells from nanocomposite is
shown in Figure 8-5 C; no cells were left on the graft following trypsinisation.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Figure 8-4. Cell seeding efficiency and viability post 1 and 4 hour static and flow exposed on A)
glass and B) nanocomposite conduits. *P < 0.05 flow were comparison to static using Student’s
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A
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B
Figure 8-5 B. ScEM of a nanocomposite conduit: seeded with HUVEC at 1.2×104 cells/cm2
overnight.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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C
Figure 8-5 C. ScEM of a nanocomposite conduit after trypsinisation to remove HUVEC.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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8.3.2 Assessment of quantity and quality of RNA extracted
The purity and amount of RNA extracted from HUVEC are shown in Table 8-3.
The purity was high in all samples and in all cases purity was greater than 95%. Levels of
isolated RNA were lower after flow in both glass and nanocomposite conduits.
Nanocomposite conduits showed a significant reduction (Student’s t-test; P<0.05) in
RNA levels after flow and recovery period suggesting that cell loss was greater on the
nanocomposite; the reduction on glass was not significant.
8.3.3 Analysis of GAPDH, TGF-β1, COL-1 and PECAM-1 PCR products
Figures 8-6 A & B show 2% agarose gels of the PCR products resulting from a
one hour and four hour exposure respectively to either static conditions or flow for
HUVEC seeded on the glass conduits.
Figures 8-6 C & D show PCR products resulting from a one hour and four hour static
or flow exposure followed by a four hour static recovery period on the glass conduits.
Similarly, Figures 8-6 E & F show 2% agarose gels of the PCR products amplified from
one hour and four hour exposure respectively to either static conditions or flow for
HUVEC seeded on nanocomposite conduits. Figures 8-6 G & H show the PCR
products resulting from a one hour and four hour static or flow followed by a four hour
static recovery period on the nanocomposite conduits.
The mRNA levels of GAPDH remained relatively constant in static and flow samples,
and slight changes were observed in the other genes (see below). Whilst not fully
quantified this allows an idea of increase and decrease of gene expression.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Table 8-3. RNA purity and yield was measured at absorbance of 260 nm and 280 nm. *P<0.05
compared to static, Student’s t-test.
(a) Post exposure to pulsatile flow
Conduit and treatment
RNA Quantity (ng/µl)
(mean ± SEM)
RNA Purity
(260 nm/280 nm Absorbance)
Glass Conduit
1 hour static 42.7 ± 4.6 1.813
1 hour physiological flow 34.3 ± 1.4 1.800
4 hours static 39.0 ± 3.4 1.903
4 hours physiological flow 44.7 ± 6.4 1.876
Nanocomposite conduit
1 hour static 25.2 ± 4.5 1.960
1 hour physiological flow 6.7 ± 2.2* 1.953
4 hours static 28.4 ± 5.3 1.957
4 hours physiological flow 6.6 ± 0.8* 1.877
(b) Post Recovery Period (Static)
Conduit and treatment
RNA Quantity (ng/µl)
(mean ± SEM)
RNA Purity
(260 nm/280 nm Absorbance)
Glass Conduit
1 hour static 35.6 ± 4.9 1.956
1 hour physiological flow 40.0 ± 1.1 1.970
4 hours static 34.9 ± 2.8 1.913
4 hours physiological flow 44.1 ± 4.5 1.967
Nanocomposite conduit
1 hour static 24.4 ± 2.6 1.946
1 hour physiological flow 10.2 ± 1.8* 1.903
4 hours static 25.0 ± 3.9 1.900
4 hours physiological flow 8.6 ± 2.2* 1.967Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Figure 8-6. Agarose gel (2 %) of PCR analysis from RNA obtained from HUVEC seeded A)
on glass conduits following 1 hour static or physiological flow exposure; B) on glass conduits
following 4 hour static or flow; C) on glass conduits post recovery period prior to 1 hour static
or flow; D) on glass conduits post recovery period prior to 4 hour static or flow; E) on
nanocomposite conduits following 1 hour static or flow, F) on nanocomposite conduits
following 4 hour static or flow; G) on nanocomposite conduits post recovery period prior to 1
hour static or flow; and H) on nanocomposite conduits post recovery period prior to 4 hour
static or flow.
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8.3.4 Intensity of gene expression
Relative levels of TGF-β1, COL-1 and PECAM-1 were determined using
Syngene. After normalisation by the intensity of GAPDH mRNA bands obtained from
static and flow, the levels of gene expression was examined.
Figure 8-7 A & B show the intensity of gene expression resulting from a one
hour and four hour exposure respectively, to either static conditions or flow for
HUVEC seeded on the glass conduits. Significant increase in TGF-β1 (P < 0.05) and
COL-1 (P < 0.05) mRNA levels was observed after one hour of flow compared to static
one hour. There was no significant increase in PECAM-1 mRNA level after one hour of
flow. A further significant increase in expression for all genes (P < 0.01) was observed
after four hours of flow. After four hours recovery, gene expression following one
hours flow (Figure 8-7 C) showed increased differences in expression between static and
flow conditions. Significant (p < 0.01) differences were seen for all genes. This was not
the case when four hour flow was allowed a period of recovery (Figure 8-7 D) where all
significance was lost after recovery.
Figure 8-7 E & F shows the intensity of gene expression from static and flow
one and four hour exposure respectively, for HUVEC seeded on nanocomposite
conduits. Gene expression was increased in the flow groups on nanocomposite.
Significant (P < 0.01) increases under flow were observed in TGF-β1 and COL-1 at
four hours. PECAM-1 also showed a significant (P < 0.05) increase post four hours of
flow. After recovery no significant differences in gene expression were observed for
either one or four hours flow (Figures 8-7 G and H respectively).Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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Figure 8-7. Intensities of gene expression from RNA obtained from various sources. The
Figure shows the intensities of gene expression in arbitrary unit (AU) from RNA obtained from
(A) glass conduits following 1 h static or physiological flow exposure; (B) glass conduits
following 4 h static or flow; (C) glass conduits post recovery period prior to 1 h static or flow;
(D) glass conduits post recovery period prior to 4 h static or flow; (E) nanocomposite conduits
following 1 h static or flow; (F) nanocomposite conduits following 4 h static or flow; (G)
nanocomposite conduits post recovery period prior to 1 h static or flow; and (H)
nanocomposite conduits post recovery period prior to 4 h static or flow. TGF-β1, COL-1 and
PECAM-1 mRNA levels were normalized by GAPDH mRNA level. A significant increase in
gene expression comparing static with flow conditions for each gene at the same time period is
indicated by either ‘*’ (P<0.05 using Student’s t test) or ‘**’ (P<0.01 using Student’s t test).Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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8.4 Discussion
Here described is a study of cell–biomaterial interactions at the level of gene
expression. This work is a step toward the use of mRNA analyses to get information for
the biological performance of a tissue engineering biomaterial. Although valuable
information can be obtained from animal studies, animal studies are often not directly
applicable to human cell/biomaterial interactions.
In order to define how EC respond to shear stress in a tubular model,
nanocomposite conduits were produced as demonstrated earlier in this thesis.
Nanocomposite conduits were successfully seeded with HUVEC then exposed to flow.
The markers of gene expression employed in the present study were chosen to
maximise the amount of information obtained from the amount of RNA isolated in
these initial experiments and investigate two key aspects of EC response to flow: namely
ECM production and adhesion molecule expression. As a validation of the techniques
employed glass conduits of the same length and diameter were seeded with HUVEC
and treated in the same way as the nanocomposite conduits as a positive control as flat
glass surfaces have been used in many studies (504;506).
The initial Alamar blue
TM results demonstrate that both nanocomposite and glass
conduits were successfully seeded with viable HUVEC and those cells remained viable
over the course of the exposure to flow. As might be expected, more cells adhered to
the glass surface than the nanocomposite as glass has been proven to be a successful
surface for cell growth. In the case of the nanocomposite conduits, the successful
seeding was confirmed by ScEM studies that showed cells present on the conduit
material. The fact that a confluent layer of cells was not observed on the conduit prior
to flow may be due to the relatively short seeding time (24 hours), which is a more
clinically realistic seeding time compared with allowing the cells to grow for a period of
days or weeks on the conduit which would result in a confluent cell coverage.
The culture of HUVEC on flat sheets of tissue culture plastic or glass under conditions
of physiological flow results in the cells becoming aligned to flow in a similar manner to
that seen in vivo (252). However, when exposed to static culture a well documented
change in phenotype occurred with a characteristic cobble stone appearance developing.Chapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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It was hypothesised that such an alteration in growth characteristics would also result in
a more in vivo EC like gene expression. In the present study, this was tested by
examining the expression of the EC surface protein PECAM-1. PECAM-1 (also known
as CD31) is a highly abundant cell-surface glycoprotein expressed on EC that is
involved in EC tube formation (refer to review Chapter 2). PECAM-1 may act as a
docking molecule, promoting cell-cell adhesion thereby allowing other proteins, such as
integrins, to further stabilise the assembly of vascular structures (507). TGF-β1 is a
known stimulant of ECM production that is localised in the intima of arteries (392) and
COL-I is a fibrous, ECM protein with high tensile strength (263). After one hour
exposure to flow, no significant difference in gene expression was observed for any of
these genes for the cells present on the nanocomposite. A four hour static recovery
period following exposure to one hour flow similarly resulted in no significant change in
gene expression. Exposure to flow for a longer four hour period demonstrated
significant increases in gene expression for all genes investigated compared with cells
maintained under static conditions. Following a four hour recovery period however,
there was no significant increase in gene expression levels compared with cells
maintained under static conditions. HUVEC seeded on glass conduits showed similar
results although there was a significant increase in TGF-β1 and COL-1 expression after
1 hour of flow which was maintained after a static recovery period.
The increased expression of the COL-1, PECAM-1 and TGF-β1 genes after four
hours exposure to flow may be related to the cells strengthening their attachment to the
nanocomposite substrate under physiological levels of shear stress. The up-regulation of
matrix production under flow has already been defined in flat sheets of cultured cells
and ex vivo EC (508;509). Gene expression one hour post flow was relatively unaltered in
the case of the nanocomposite conduits, suggesting that the change in gene expression
when exposed to flow is not immediate and is dependent on the time of exposure to
flow. This change may also be transitory as after a four hour static recovery period
following exposure to flow, there was no significant difference in gene expression.
Studies on laminar shear stress have been reported to demonstrate that gene expression
is induced in a time-dependant manner (504). The application of shear stress to EC in
static culture has been shown to cause a transient increase in the expression of a large
number of genes with most of the genes investigated down-regulated during sustainedChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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application of shear stress (24 hours) (260). In Chapter 2, the expression of the genes
under study were reviewed
Several groups have looked at gene expression in a comparable way to this
thesis. Comparing such studies is complicated by the differences in conditions used by
different groups. Flow conditions and timings are not consistent so direct comparison is
not possible. To summarise these findings; one study looked at HUVEC without flow
and failed to find any expression of TGF-β1, the isoform studied was not give (314). A
second study looked at TGF-β1 under shear stress of 15dynes and found that
expression was increased over 24 hours.
Looking at the specific isoforms of TGF-β1 reveals that expression TGF-β1 is
seen to rise under conditions of shear stress. Like our study where expressions were
increased under shear stress conditions two other studies demonstrate increased
expression under shear stress. The first looked at expression after 24 hours under an
unspecified stress (510) while the used cyclic stress between 6 and 24 hours (399). Both
demonstrated an increase in TGF-β1 as demonstrated by our studies. TGF-β2 was
studied by one group who studied it in addition to TGF-β1 (510). They demonstrated a
reduced expression under similar flow conditions.
Findings such as this demonstrate the role of TGF-β1 in the production of ECM is
important under flow conditions. This appears to be a response to flow that
corresponds to a need for increased attachment under flow. The evidence that
preconditioning increases TGF-β1 further demonstrates that this may be useful in graft
development.
The expression of PECAM-1 has been investigated in EC seeded on vascular
graft materials, Dacron coated with fibronectin. In one study (378) HUVEC and
adipose microvessels (HAMVEC) were cultured for 1-2 days and the expression of
PECAM-1 were determined by flow cytometry and immunofluorescence microscopy.
The cells were not stimulated. The expression of PECAM-1 was found to be
constitutively expressed with similar mean fluorescent intensities suggesting that its
expression is dependent neither on the EC origin nor on the underlying polymer
surface. In in vivo studies PECAM-1 has been found to be constitutively expressed on
the endothelium of all vessel types (378). In contrast Cenni et al, reported theChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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downregulation of PECAM-1 expression by HUVEC cultured on knitted Dacron (380).
It can be hypothesised that a decrease in the expression of PECAM-1 underlies poor
adhesion capability of these cells on knitted Dacron and that the lack of fibronectin
coating provides no stimulation to the cells to increase attachment molecules.
The data presented in this thesis confirms that PECAM may be affected by the
stimulus of cells. We show that on polymer alone and in initial cells taken from tissue
culture plastic levels of PECAM expression are not as great as is seen under conditions
of shear stress. This evidence further indicates that not only is our nanocomposite better
for cell attachment than knitted Dacron but that it promotes EC growth that more
closely resembles the in vivo situation.
The gene expression changes brought about by exposure to shear stress and stretch are
complex in nature. This suggests that a pathway of events may be necessary to trigger
the expression of the genes studied here and that the results obtained will be dependant
on the time of exposure to flow and the type of flow employed.
Relatively accurate methods to quantify gene expression have been developed,
such as Northern blotting or real-time PCR based on the use of fluorogenic probes.
Northern blot methods usually require additional time consuming selective
chromatography to isolate poly(A)+ (polyadenylated) mRNA and radioactive labelled
probes to generate a measurable signal to quantify. Real-time PCR is a quantitative
method that is based on the concept of monitoring the PCR reaction in the thermal
cycle as it progresses (511;512). Although this technique has a number of advantages,
especially in terms of comparative accuracy, it is not widely available at present. In this
study, a semi-quantitative approach was successively used to determine RNA expression
levels by RT-PCR. This method is based on the use of an internal control, which is a
housekeeping gene (GAPDH) (513). This method was chosen due to feasibility in the
laboratory, the necessity to study different markers in the same sample and the low yield
of RNA.
This study indicates that whilst it is difficult to monitor gene expression when
small amounts of RNA are extracted from cells seeded on to artificial conduits and
exposed to flow, it is, nonetheless, possible to investigate gene expression under these
conditions and obtain useful data. Future studies would benefit from protein analysis toChapter 8: The effect of shear stress on human endothelial cells seeded on cylindrical conduits:
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determine whether changes in gene expression were related to changes in protein levels.
The range of gene expression investigated could also be expanded with genes such as
the MMP, caspase and growth factors being of great potential interest perhaps by using
RNA amplification techniques.
8.5 Conclusion
This study represents an initial investigation that, for the first time, demonstrates
that changes in the gene expression of cultured EC on a tubular vascular prosthesis
when exposed to shear stress in vitro can be determined under more clinically relevant
realistic conditions than previously. This is of great importance to the understanding of
how cells will react when seeded on such conduits and the mechanism by which
exposure to flow affects them and has great potential for future development and
further investigation.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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Shear stress preconditioning of human endothelial cell seeded on
compliant nanocomposite conduits: A study of gene expression
9.1 Introduction
The previous chapter shows the effect of physiological (haemodynamics) shear
stress on EC gene expression. There it was clear that EC seeded on tubular
nanocomposite compliant conduit were viable with appropriate nuclear processes.
However it does not address the question of how to optimise EC behaviour on the
graft. Some of the observed gene expression and in particular increased PECAM-1 is a
reflection of the (often frustrated) attempts of EC to remain adherent in the face of
blood flow. There is now a large body of evidence showing extra-corporeal
preconditioning as a reliable way of potentiating EC adherence and subsequent function
in preparation for the living environment.
Researchers have examined the effect of shear stress preconditioning on vascular
grafts but these are lacking in gene expression studies. Preconditioning has been shown
to positively influence the development of tissue-engineered grafts. Preconditioning
with physiological shear stress using a flow circuit developed in-house can significantly
enhance EC retention, viability and morphology. EC seeded onto polymer grafts have
specific problems with regard to cell attachment and retention (340). SignificantlyChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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studies showed the development of a functional and stable endothelium on the
prosthetic vascular graft in response to low shear stress (1-2 dyne/cm
2) (326). The
mechanism underlying this improvement is suggested to be regulated by the expression
of several factors including growth factors and matrix enhancing factors (514).
However, these assumptions have been made upon numerous flow experiments applied
to cultured monolayer of cells. As reviewed in Chapter 2, cultured cells seeded on flat
surfaces have been exposed to preconditioning flow and the cells molecular response
assessed. Preconditioning of EC seeded on vascular grafts with shear stress in vitro could
be used to improve EC retention and differentiation for subsequent in vivo use.
Unfortunately there has been a lack of studies on understanding the molecular response
of cells to preconditioning when seeded on a tubular graft. In this final chapter, all the
studies were combined to investigate the overall aim in the process of developing a
small diameter coronary bypass graft. This study develops the previous work further by
examining the impact of preconditioning on the gene expression of seeded EC on
cylindrical nanocomposite, and exposed to physiological flow rates and pressures. This
has been shown to enhance cell proliferation, tissue formation and mechanical
properties (326). Conduits were preconditioned by exposure to a low shear stress of 1-2
dynes/cm
2 with or without a 24 hour recovery period and then subjected to
physiological shear stress of 15 dynes/cm
2. As assessed earlier the genes analysed were
GAPDH, TGF-β1, and PECAM-1. Further to this study the expression of VEGFR-1
and VEGFR-2 was studied.
9.2 Materials and Methods
9.2.1 Preparation of nanocomposite polymer conduits
The synthesis of nanocomposite has been described in detail in Chapter 3. An
automated bio-processor employed in Chapter 6 was used to extrude the polymer into
conduits with an internal diameter of 5mm and length of 5cm. Conduits were sterilised
by autoclaving prior to use.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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9.2.2 Human umbilical vein cell culture
HUVEC were isolated from human umbilical cord vein following method
described in Chapter 3. Cell numbers were amplified by tissue culture in complete
medium. At confluence cells were removed using 0.25% Trypsin-EDTA and split in a
1:2 ratio. Confluent cultures at passage three were used in all experiments.
9.2.3 Conduit seeding
Nanocomposite conduits were seeded with HUVEC at 1.2 x 10
4cells/cm
2. Cells
were added as a suspension to each conduit. The ends of the conduit were plugged and
the conduits rotated 90° every 15 minutes for 2 hours to achieve an even covering of
HUVEC on each conduit. Conduits were left overnight at 37° C and 5 % CO2/95 %O2
and used the following day.
9.2.4 Assessment of seeding efficiency and cell viability
Viability of seeded cells on nanocomposite conduits was assessed using an
Alamar blue
TM assay as described previously (see Chapter 3). Following overnight
seeding conduits were washed with PBS and the washings collected for cell counting to
assess seeding efficiency. 1 ml of Alamar blue
TM (10 %) in complete medium was added
to each conduit and incubated for four hours at 37° C and 5 % CO2/95 %O2. Duplicate
100 μl samples were removed and the absorbance’s read spectroscopically at
wavelengths of 570 nm and 630 nm using a Labsystems Multiscan MS UV visible
spectrophotometer. All conduits were washed with PBS prior to exposure to flow. Cell
viability on nanocomposite conduits was also assessed following exposure to flow.
9.2.5 Application of preconditioning shear stress on EC seeded
nanocomposite conduits
To test preconditioning shear stress on the EC, a physiological pulsatile flow
circuit was used to simulate the cardiovascular system (as used in Chapter 8). The
system is described in detail in Chapter 3. The model was primed with cell culture
medium that was adjusted for viscosity and the whole circuit was maintained underChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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sterile conditions. The experimental protocol is summarised in Figure 9-1. Seeded
conduits were randomly split into two groups (A & B) where preconditioning was tested
with or without a static recovery period (see below). Conduits were placed in the flow
system and preconditioned at low shear stress rates of 1-2 dynes/cm
2 (low flow) and
then subjected to pulsatile physiological shear stress of 15 dynes/cm
2 (physiological
flow). The haemodynamic data including peak and mean shear stresses are computed
and recorded in Table 9-1.
9.2.5.1 Preconditioning without a 24 hour recovery period
To test the effect of preconditioning shear stress on EC function without a static
recovery period, group A conduits were preconditioned with 1 hour low flow (P1) or 4
hours of low flow (P4). Control conduits were also included where conduits were placed
with fresh culture medium and incubated under static conditions at 37° C and 5 %
CO2/95 %O2 for 1 hour (S1) or 4 hours (S4). All conduits were then subsequently
exposed to 4 hours of physiological flow.
9.2.5.2 Preconditioning with a 24 hour recovery period
The effect of preconditioning with a 24 hour static recovery period prior to
physiological flow was investigated. After 24 hours of seeding, group B conduits were
either preconditioned with 1 hour low flow (PR1) or 4 hours of low flow (PR4). Control
conduits were incubated under static for 1 hour (SR1) or 4 hours (SR4). After static or
exposure all conduits were then washed with sterile PBS, placed in fresh culture medium
and incubated under static conditions for 24 hours. Post recovery period, all conduits
were exposed to 4 hours of physiological flow.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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Figure 9-1. Schematic representation of the experimental procedure illustrating a summary of
the treatment carried out to each set of conduits. Group A conduits were exposed to either 1 or
4 hours static (S1 or S4) or preconditioning (P1 or P4) prior to exposure to 4 hours physiological
flow while Group B conduits were exposed to either 1 or 4 hours static (SR1 or SR4) or
preconditioning (PR1 or PR4) followed by a 24 hour static recovery period prior to exposure to 4
hours physiological flow.
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Table 9-1. Summary of haemodynamic parameters employed in the study.
Input parameters Computed parameters
Frequency of pulsatile cycle 1 Hz Inlet length (mm) 60
Internal diameter of conduit 5 mm Peak Reynolds number 512
Temperature 37 ± 1.4 Mean shear stress
(dynes/cm2)
14.0 ± 3.2
Seeded graft length (mm) 50 Systolic shear stress
(dynes/cm2)
30.4 ± 5.8
Seeded density (cells/cm2) 1.2 x 104 Diastolic shear stress
(dynes/cm2)
62.7 ± 9.7
Pressure systolic (mmHg) 120 ± 5 Mean velocity (mm/sec) 436 ± 20
Pressure diastolic (mmHg) 70 ± 6 Preconditioning shear
stress (dynes/cm2)
1-2 ± 2.9
pH 7.3 ± 0.1
pO2 (kPa) 21 ± 2
pCO2 of solution (kPa) 4.2 ± 0.2
Viscosity of solution (poise) 0.035 ±
0.2
9.2.6 RNA Extraction and PCR
Following exposure to experimental conditions cells were removed from
conduits by washing with sterile PBS and then trypsinising using 1ml of trypsin-EDTA
(0.25 %) which was added for 5 minutes incubation at 37
oC. RNA was then extracted by
using a “Qiagen RNeasy” kit following the method described in Chapter 3.
The RNA concentration and purity was calculated by measuring the absorbance at
260nm and 280nm and the quality of the RNA was assessed by 2% agarose gel
electrophoresis. RT-PCR was performed using a one-step PCR kit for GAPDH, TGF-
β1, VEGFR-1, PECAM-1 and VEGFR-2 genes (Table 9-2). A master mix containing
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the deoxynucleoside triphosphate, 2 μl Qiagen One-Step RT-PCR enzyme mix and 0.5
μM from each of the primers was added. 0.1 μg of template RNA and RNase free water
was added to give a total volume of 50 μl.
Cycle conditions for GAPDH and TGF-β1 were 40 cycles (94
o, 50
o and 72
o). For
PECAM-1 cycle conditions were 35 cycles (94
o, 50
o and 72
o). Finally for VEGFR-1 and
VEGFR-2 cycle conditions were 35 cycles (94
o, 59
o and 72
o). Amplification was carried
out using a MasterCycler Gradient PCR machine. PCR products were analysed by 2%
agarose gel electrophoresis and semi-quantified using a GeneGenius darkroom with
‘GeneSnap’ version 6.02. The GAPDH band was used as the internal standard to
normalise TGF-β1, VEGFR-1, PECAM-1 and VEGFR-2 signals.
Table 9-2. GAPDH, TGF-β1, PECAM-1, VEGFR-1and VEGFR-2 Primer Sequences.
Locus Sense (5’-‘3) Antisense (5’-‘3)
GAPDH GAAGGTGAAGGTCGGAGT GAAGATGGTGATGGGATTTC
TGF-β1 CACCTGCAAGACTATCGACAT TCGGAGCTCTGATGTGTTGAA
PECAM-1 GCTGTTGGTGGAAGGAGT GAAGTTGGCTGGAGGTGCTC
VEGFR-1
VEGFR-2
ATTTGTGATTTTGGCCTTGC
GTGACCAACATGGAGTCGTG
CAGGCTCATGAACTTGAAAGC
CCAGAGATTCCATGCCACTT
9.2.7 Scanning electron microscopy
Seeded nanocomposite conduits were examined by ScEM post preconditioning
and physiological shear stress to visualise whether cells were present on the graft
surface.
9.2.8 Data Analysis and Statistical Methods
The experiments were repeated four times. RNA quantities are presented in mean
± SEM. All statistical analysis utilised one way ANOVA with post-hoc Tukey’s test.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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9.3 Results
9.3.1 Assessment of Seeding Efficiency and Viability
The Alamar blue
TM assays performed pre-flow (following overnight seeding)
showed no significant difference in seeding efficiency. Viable cells were present on all
seeded nanocomposite conduits.
Figure 9-2 A shows EC viability post 1 and 4 hour static or low flow without a 24 hour
recovery period followed by physiological flow. Conduits preconditioned with 1 or 4
hour low flow (P1 & P4 respectively) showed no significance difference in cell viability
compared to pre-flow. Conduits incubated under static conditions for 4 hours prior to
physiological flow (S4) showed a significant decrease in cell viability (P < 0.01)
compared to pre-flow, whereas no significant decrease was observed after one hour
static incubation (S1). Despite a noticeable decrease in viability between S1 and S4 this
was not significant. Comparing P1 to its static control S1 also showed no significant
difference in cell viability. After four hours of preconditioning P4, had a significantly
higher viability (P < 0.001) compared to time matched control S4.
Pre-conditioning followed by a 24 hour recovery period (Figure 9-2 B) showed
significant changes in cell viability in all groups apart from pre-conditioning for one
hour (PR1) to pre-flow. Control conduits not exposed to preconditioning (SR1 & SR4)
showed significant decreases (P < 0.01) in cell viability compared with pre-flow
conduits. An increase in cell viability was observed for conduits preconditioned for 1
hour (PR1) but this was not significant, whereas preconditioning for 4 hours (PR4)
showed a significant increase (P < 0.01). Very significant differences (P < 0.001) were
observed between conduits SR1 and PR1and SR4and PR4.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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Figure 9-2. Assessment of cell viability by an Alamar blueTM metabolic assay: A) shows Pre-
flow, S1, S4, P1 and P4 groups and B) shows Pre-flow, SR1, SR4, PR1 and PR4 groups. Statistical
analysis was carried out by one-way ANOVA (n = 4) with ** P < 0.01 and *** P < 0.001
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9.3.2 Assessment of Quantity and Quality of RNA Extracted
The amount of RNA extracted from HUVEC is shown in Table 9-3. The purity
was high in all samples and in all cases purity was greater than 95%.
Table 9-3. RNA yield was measured at absorbance of 260 nm and 280 nm and quantity
determined as ng/µl. Group A shows S1, S4, P1 and P4 samples. Group B shows SR1, SR4, PR1
and PR4 samples.
Conduit and treatment
RNA Quantity (ng/µl)
(mean ± SEM)
Group A
S1
4.2 ± 1.2
S4
2.4 ± 0.7
P1
12.4 ± 1.3
P4
18.4 ± 1.5
Group B
SR1
3.7 ± 0.6
SR4
3.0 ± 0.3
PR1
28.7 ± 3.5
PR4
36.0 ± 4.9
9.3.3 Analysis of GAPDH, TGF-β1, VEGFR-1, PECAM-1 and VEGFR-2 PCR
products
Figure 9-3 A shows a 2% agarose gel of the PCR products for group A, resulting
from 1 and 4 hour exposures respectively to either static conditions (S1& S4) or low flow
preconditioning (P1 & P4); following four hours of physiological flow on all conduits.
Figure 9-3 B shows a 2 % agarose gel of the PCR products for group B, resulting from 1
and 4 hour exposure respectively to either static conditions (SR1 & SR4) or low flow
preconditioning (PR1 & PR4); following a 24 hour recovery period on all conduits prior
to four hour exposure to high flow for HUVEC seeded on the nanocomposite conduits.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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The mRNA levels of GAPDH remained relatively constant in static and preconditioned
samples, and changes were observed in the other genes (see below).
A
B
Figure 9-3. Typical 2% agarose gels of PCR products with a 100 bp marker. Each sample was
analysed for GAPDH, TGF-β1, VEGFR-1, PECAM-1 and VEGFR-2 expression: A) shows S1,
S4, P1 and P4 samples and B) shows SR1, SR4, PR1 and PR4 samples.
9.3.4 Intensity of Gene Expression
Relative levels of GAPDH, TGF-β1, VEGFR-1, PECAM-1 and VEGFR-2 were
determined using Syngene. After normalisation by the intensity of GAPDH mRNA
bands obtained from preconditioning, the levels of gene expression were examined.
Figure 9.4 A shows the intensity of gene expression post 4 hours physiological flow
after either 1 or 4 hours of preconditioning (P1 & P4) compared to time matched
controls (S1 & S4). Differences in gene expression were observed only in the expressionChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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of VEGFR-1 and VEGFR-2. Significant decreases (S1-P1, P < 0.01 & S4-P4, p < 0.001)
in VEGFR-1 and significant increases (p < 0.001) in VEGFR-2 were seen after 1 and 4
hour preconditioning compared to time-matched controls. All other genes remained
essentially unaltered under these conditions.
Figure 9-4 B shows the intensity of gene expression post 4 hours physiological flow
after either 1 or 4 hours of preconditioning (PR1 & PR4) compared to time matched
controls (SR1 & SR4) with the addition of a 24 hour recovery period after
preconditioning. PECAM-1 expression remained relatively unaltered. TGF-β1
expression was shown to be significantly higher (P < 0.01) after 4 hours of
preconditioning (PR4) compared to controls (SR4). The expression of VEGFR-1 showed
a significant decrease after 1 hour only (SR1-PR1, P < 0.05). Significant increases in
VEGFR-2 expression were observed at both time points (SR1-PR1, P < 0.001 and SR2-
PR2, P < 0.001).Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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Figure 9-4. Intensity analyses of PCR products to determine gene expression levels following
normalisation for GAPDH: A) shows S1, S4, P1 and P4 samples for TGF-β1, VEGFR-1,
PECAM-1 and VEGFR-2 and B) shows SR1, SR4, PR1 and PR4 samples for TGF-β1, VEGFR-
1, PECAM-1 and VEGFR-2. Statistical analysis was carried out by one-way ANOVA (n = 4)
where * P<0.05, ** P < 0.01 and *** P < 0.001.
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9.3.5 Scanning electron microscopy
ScEM was employed to further elucidate cell retention following exposure to
flow. Figure 9-5 A shows nanocomposite prior to seeding. Figure 9-5 B shows pre-flow
seeded nanocomposite. Figures 9-5 C to F show seeded nanocomposite for treatments
S1, S4, P1 and P4 respectively. Similarly Figures 9-5 G to J show seeded nanocomposite
for treatments SR1, SR4, PR1 and PR4 respectively. All seeded nanocomposites show
cells present on the conduit post-treatment in line with the Alamar blue
TM results earlier.
In the latter chapter ScEM demonstrated no cells were left behind following mRNA
extraction from the conduits.Chapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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Figure 9-5. Typical ScEM of nanocomposite conduits: A (unseeded conduit), B (Pre-flow
conduit), C (S1 conduit), D (S4 conduit), E (P1 conduit), F (P4 conduit), G (SR1 conduit), H (SR4
conduit), I (PR1 conduit) and J (PR4 conduit).
9.4 Discussion
In the previous chapter, the effect of physiological shear stress on EC seeded
nanocomposite conduits was investigated. Significant changes in gene expression were
observed. Pulsatile physiological shear stress (~14 dynes/cm
2) was shown to increase
gene expression in EC seeded nanocomposite conduits in a time dependant manner
(501). Increases in COL-1, PECAM-1 and TGF-β1 genes were seen. It also
demonstrated a significant decrease in cell viability for cells seeded on nanocomposite
after exposure to four hours of physiological flow. This suggested that physiologicalChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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levels of shear stress strips EC seeded on prosthetic materials as has been demonstrated
in several studies previously (340). The study also for the first time, demonstrated that
gene expression shear stress studies can be successfully carried out on tubular conduits.
Previous work has however suggested that cell loss under physiological flow
conditions can be reduced by exposing the cells to a lower preconditioning flow prior to
physiological shear stress and that such prior exposure is beneficial in promoting cell
adherence (339). Chapter 2 has reviewed these studies where investigations have
examined the effects of preconditioning with shear stress on EC function in vitro. EC
that are exposed to shear stress in vitro, applied in a stepwise fashion over days, are
induced to become tightly adherent to the substratum and exhibit more differentiated
features (214;326;515). Therefore this study tested the hypothesis that exposure of EC
seeded on cylindrical nanocomposite conduits to preconditioning shear stress would
induce changes in gene expression and that preconditioning could allow the cells to
adapt to the material in an improved manner and enhance cell growth and adhesion. EC
seeded nanocomposite conduits were exposed to preconditioning shear stress and
compared with conduits that were exposed to physiological shear stress. Conduits were
preconditioned with a low flow of 1-2 dynes/cm
2 followed by physiological flow.
Further conduits were also preconditioned with a 24 hour recovery period prior to
physiological flow.
The Alamar blue
TM results prior to flow (pre-flow conduits) demonstrated that
the nanocomposite conduits employed in the study were successfully seeded with viable
HUVEC in a uniform manner. Pre flow conduits were taken as a baseline, and the
decrease seen after physiological flow was applied without preconditioning suggests that
a significant number of cells are lost under these conditions. This matches to the effect
seen in the previous chapter when physiological shear stress was applied to EC seeded
nanocomposite conduits. Conversely the application of preconditioning prior to
exposure to physiological flow demonstrated that the seeded nanocomposite retained
cells under this regime and suggests an improvement in cell adherence and an increase
in cell numbers or metabolism following preconditioning when compared to the cells
not exposed to preconditioning prior to exposure to physiological flow. The changes are
more marked after 4 hours suggesting that this effect may be time dependent and that a
longer period of preconditioning before the application of physiological flow results inChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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greater protection for the cells. The ScEM studies support these conclusions regarding
the relative numbers of cells remaining following exposure to physiological flow.
The investigation of expression levels for a variety of genes was carried out in an
attempt to elucidate the potential mechanisms behind the changes observed in the study
of cell metabolism and numbers. In the case of TGF-β1 whilst there was a general
increase in expression in the preconditioned groups this increase was only significant in
the case of the 4 hour preconditioning followed by a 24 hour recovery period prior to
exposure to physiological flow indicating that while TGF-β1 may be involved in the
longer term changes observed in this study it’s short term effect is limited (508;509).
PECAM-1 expression remains relatively stable under all treatments suggesting
that the remaining HUVEC following exposure to flow retain their EC phenotype
regardless of the application of preconditioning. A significant decrease in VEGFR-1
expression was observed in both one and four hour preconditioned cells when followed
by immediate exposure to physiological flow and after a 24 hour recovery period. This
situation was reversed in the case of VEGFR-2 where a significant increase of gene
expression was observed in the preconditioned groups. Both VEGFR-1 and VEGFR-2
are known to bind vascular endothelial growth factor (504) with high affinity and
previous studies have shown that VEGFR-2 mediated signalling can result in significant
changes in morphology together with alterations in actin organisation in EC with high
expression levels of this receptor (387). Significantly other studies have shown that the
expression of VEGFR-2 is induced by the application of shear stress associated with a
reduction in VEGFR-1 expression in a similar manner to the results obtained in this
study (387;516). This suggests that the reduction in VEGFR-1 and increase in VEGFR-
2 expression may be associated with mature EC likely to proliferate in response to shear
stress (a situation similar to angiogenesis) and indeed in the case of the PR4 group a
significant increase in cell metabolism or numbers can be seen which may become more
apparent if longer term studies were carried out.
9.5 Conclusion
Although there is a great deal of future work necessary before conclusions can
be drawn with confidence, the following work provides great importance and aChapter 9: Shear stress preconditioning on human endothelial cells seeded on compliant nanocomposite conduits:
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significant improvement in understanding cells genetic behaviour in contact with
biomaterials.
In conclusion this investigation confirms previous findings regarding the
potential benefits of preconditioning and demonstrates that preconditioning under the
right conditions can result in a significant improvement in EC retention when EC are
exposed to physiological flow. The study also builds upon the last chapters work
examining gene expression on cylindrical conduits when exposed to flow and
demonstrates, for the first time, that low flow preconditioning causes alterations in gene
expression in this situation. It suggests that such alterations can be determined
successfully and that further investigations into other potentially significant genes may
well be of benefit in exploring further the potential mechanism by which
preconditioning improves cell retention whilst studies into protein expression via
techniques such as Western blotting would also be of interest. Such studies would also
be valuable in determining the most effective method of preconditioning with regard to
the optimal length of time for preconditioning and the potential advantages of a
recovery period prior to exposure to physiological flow. Finally it also builds on
previous studies and demonstrates further the suitability and potential of the POSS
nanocomposite for future use in tissue engineered coronary artery bypass grafts.Chapter 10: Conlusion of thesis
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Conclusion of thesis
10.1 Summary and conclusion
Synthetic grafts such as Dacron and ePTFE are satisfactory in replacement of
larger vessels, however when dealing with smaller diameter (<6 mm) vessels in low flow
states, the patency is far lower (8;32;53). This is because the biomaterials activate
thrombus formation on its lumen while the differential compliance at the anastomotic
site, contributes to the formation of intimal hyperplasia. As such, autologous grafts
remain the gold standard for coronary artery replacement as they are both compliant
and non-thrombogenic. However, large numbers of patients do not have suitable
arteries or veins for coronary artery bypass surgery therefore there is a great demand of
a synthetic alternative. Chapter 1 described the need for novel small diameter compliant
coronary artery bypass grafts. The Biomaterials and Tissue Engineering Centre of the
Royal Free and University College Medical School have developed a polymer intended
for cardiovascular devices. This polymer material is based on covalently bonding
polyurethane with a silsesquioxane ‘nanomolecule’ (52).
The aim of this thesis was to undergo the development of a small diameter synthetic
coronary artery bypass graft with the aid of tissue engineering. To this end it employed
the novel nanocomposite polymer for the development of a hybrid graft utilising human
umbilical vein endothelial cells as a cell source. It further examined the alterations inChapter 10: Conlusion of thesis
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gene expression of the seeded endothelial cells under varying haemodynamic shear
stress conditions.
The haemodynamic environment has shown to have significant effects on the
function of endothelial cells (89). The endothelial lining of blood vessels is subjected to
a wide range of haemodynamically-generated shear-stress forces throughout the vascular
system. Chapter 2 described the in vivo and in vitro, endothelial cells changes in their
morphology and biochemistry in response to shear stress in a force- and time-
dependent way, or when a critical threshold is exceeded. It also discussed the lack of
studies on the response of shear stress in cell seeded synthetic tubular grafts. Gene
expression associated with cellular proliferation, adhesion and extracellular matrix
formation have been poorly studied on cylindrical prosthetic grafts. A few studies exist
on cell-material interaction but these are limited (314;315). Understanding the cellular
response to a ‘biomaterial’ is fundamental. The investigation of gene expression patterns
allows determining the molecular effects of cells are expressing.
One of the primary challenges in this thesis was encountered in Chapter 4. Prior to any
cell-graft and haemodynamic shear stress studies the initial investigation was based on
defining a suitable method for removing the seeded cells from the graft lumen for
downstream applications. Various methods of RNA isolation was undertaken on seeded
tubular polyurethane based grafts. At this stage, this study was undertaken on
poly(carbonate-urea)urethane grafts as the nanocomposite polymer was under
development in our laboratory. This preliminary study was vital to determine whether
sufficient RNA yields could be obtained for gene expression studies as well as to
produce a reliable and reproducible method in order to progress onto further work in
this thesis. To this date, there have been no other published data (apart from this study)
indicating the isolation of RNA from seeded grafts.
Three methods of cell/RNA isolation from the graft surface were analysed and
demonstrated that there was no significance between cell scraping, direct lysing or
trypsinising the cells from the graft prior to RNA extraction. Despite this trypsinisation
was the best tool to use as no damage occurred on the graft compared to the other two
methods and provided higher levels of RNA. Furthermore, the method of isolation did
not affect RNA stability. The study highlighted a novel approach to the removal of the
cells and the subsequent isolation of the RNA. It demonstrated that the study of gene
expression is possible under such conditions. Efforts were made to ensure that thisChapter 10: Conlusion of thesis
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technique utilised readily available techniques ensuring that this method is reproducible
and could be readily employed by other groups. The key to the study of genes in this
situation is that the isolation of the cells from the conduit should not alter the genes
expressed in a significant way and this was demonstrated by this study.
In Chapter 5 the biocompatibility of the novel nanocomposite polymer for a
tissue-engineering product was assessed for it to perform as a substrate that will support
the appropriate cellular activity, including the facilitation of molecular and mechanical
signalling systems, in order to optimise tissue regeneration, without eliciting any
undesirable effects. It was anticipated that by seeding the grafts a further decrease in the
risk that inclusions would occur would be achieved and that this would help prevent
problems such as intimal hyperplasia developing. The ability of these conduits to be
seeded with endothelial cells was then investigated. As the polymer had not been studied
in this context before no data were available for the effects that it might have on the
cells. The study analysed sheets of polymer showed that not only was it not toxic under
the range of conditions used (including both direct exposure to the polymer itself and
indirect exposure to cell culture medium conditioned with powdered polymer) but that
cells attached readily to the polymer and could be maintained in culture for a period of
time consistent with that needed for the study of gene expression under flow. This was
confirmed by Alamar blue cell viability assays and cell proliferation pico green assays.
In conclusion the nanocomposite can be successfully seeded with endothelial cells and
indicates that, once seeded; the endothelial cells remain viable and proliferate for a
period of days. This combined with its other advantages suggests that nanocomposite is
suitable for further development in the development of a coronary bypass graft.
Having confirmed the anti-cytotoxicity effects of the nanocomposite the next
stage was to fabricate this polymer into compliant small diameter tubular conduits.
Advanced novel fabrication methods were assessed to build three-dimensional conduits
that have a porous internal structure that will enable the growth of cells. Two
techniques, namely electrospraying and extrusion were considered as potential methods
to produce conduits. In electrospraying, the polymer was sprayed from a needle with a
highly charged electrode. This technique has been previously demonstrated to be an
attractive method for the fabrication of small diameter grafts (476). Further to this step
the graft was made porous by placing the electrospun or extruded polymer into aChapter 10: Conlusion of thesis
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coagulant-called phase-inversion. An in vitro flow circuit was used to test the compliance
of these conduits. To measure the burst pressure conduits were placed in a high
pressure syringe pump. Attempts at electrospraying the nanocomposite onto mandrels
as a technique proved futile as polymer deposition was uneven. After phase-inversion
the conduit was relatively weak. The conduits showed to burst when initial pressure was
applied. When tested for compliance all the electrosprayed conduits failed within the
initial application of physiological flow. The extrusion of the polymer solution into
water was found to be the most effective method to create a suitable conduit. The
compliance measured was found to be similar to native arteries. Studies carried out in
parallel in our laboratory have demonstrated that such a conduit possessed the duel
properties of strength and physiological compliance required for the purpose envisaged
in this study. The high levels of structural integrity of the grafts produced by this
method under flow and the physiological compliance it achieved make this an excellent
subject for use in cardiac bypass grafts.
An important aspect of the development of a successful synthetic CABG is to
investigate the possibility of carrying out EC seeding of an artificial conduit. Evidence
for the requirement of a luminal EC lining is provided by the poor patency observed
when unseeded synthetic grafts with diameters less then 6 mm are employed (486). In
order to maximise the efficiency of the experiments and to minimise the requirements
for large numbers of cells to seed the conduits, studies on seeding density and the
optimum duration of seeding were conducted. Following on from Chapter 6, extruded
conduits were seeded with endothelial cells at various concentrations and seeding times.
Cells that were seeded on the graft for 4 hours did not result in many cells adhering over
this period. As hypothesised the longer the seeding time the more adherence of cells.
The nanocomposite demonstrated a time-dependant seeding efficiency requirement.
Cells seeded at 1.2 x 10
4 cells/cm
2 with a 24 hour seeding time were considered the best
condition. Whilst there was a slight increase in seeding efficiency for a higher density of
cells, it was considered more attainable to use this amount. Furthermore, examination of
RNA yield from these cells demonstrated it to be successful. Some reports suggest cells
to be confluent on the polymer surface prior to investigations (314). Many researchers
have allowed culturing of cells on the polymer surface over weeks two achieve
confluency. A longer period of seeding time in this study would have allowed for
possibly more adherence, this has yet to be counterbalanced by the need for mediumChapter 10: Conlusion of thesis
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exchange over such a long period. This in itself could have disrupted the adhesion
process. Furthermore, seeding a large density of cells to achieve a monolayer is relatively
impossible. Firstly this would require extensive cell culturing in the laboratory for two-
three months to achieve the amount of cells required to seed a length of vascular graft
used clinically and thus hoping that most of the cells sufficiently adhere to the grafts.
Further to this study, the large number of cells needed to seed such grafts meant
that alterations in phenotype were a concern. Primary cells in particular have a tendency
to change in phenotype in a number of ways with an increasing number of passages.
Gene expression is one of the factors that may be affected by changes over time in
culture and can be further influenced by the conditions under which the cells are
maintained. As with all gene expression studies another potential problem to be
overcome was that the cells investigated may show different patterns of gene expression
for each individual study. This can invalidate studies and shifts in the ‘baseline’ will
make differences induced by models such as exposure to flow more difficult to monitor
and interpret. In an effort to reduce the potential effect of such problems studies on the
stability of the chosen genes over long periods of culture and successive passages were
carried out and demonstrated that the culture conditions employed did not alter the
gene expression under the conditions investigated. Such stability was also vitally
important if sufficient cells were to be cultured to conduct the types of investigations
carried out in this thesis. These is vital as it demonstrated that the conditions employed
provided a stable and reproducible model and that the use of HUVEC for seeding was
possible despite the need (to obtain adequate cell numbers for seeding) to combine
several different cell isolations.
Addressing these issues, there is much literature to show that cells simply was off
grafts when exposed to pulsatile flow and the high pressures of the arterial circulation
(11;208). It is known that the mechanical stress orientates cells and the extracellular
matrix both in vitro and in vivo. Pulsatile blood flow results in a mechanical stimulation
composed of hydrostatic pressure, tangential shear stress and circumferential stretch-
relaxation. EC because of their contact with flowing blood or medium are exposed to all
three forces (517). Shear stress being the most relevant force has shown to enhance EC
attachment, retention and differentiation as well as being a critical factor in theirChapter 10: Conlusion of thesis
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biological regulatory function. Shear stress increases proliferation of EC and increase in
production of extracellular matrix molecules like collagen.
In Chapter 8, the aim of the study was a first time assessment if the pattern of gene
expression observed was altered under flow conditions in seeded nanocomposite grafts.
Using these principles a flow circuit developed in our laboratory that is capable of
simulating the pressures found in a native artery was used. This circuit was also used in
compliance studies (Chapter 6) of the nanocomposite grafts. Cylindrical nanocomposite
conduits were seeded with endothelial cells and subjected to physiological shear stress of
~14 dynes/cm
2. The genes chosen for study were transforming growth factor (TGF-
β1), collagen-1 (COL-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1).
Changes in gene expression were observed in these studies and although only key genes
could be measured these behaved in ways consistent with the expected results and those
reported by other groups (375;392;502). In particular, changes were observed in a time-
dependant manner as those encountered in studies where EC are exposed to shear
stress (504). A decrese in cell viability from Alamar blue
TM results was observed in
nanocomposite grafts after four hours of physiological shear stress compared to those
maintained under static. Increases in expression of structural and extracellular matrix
genes were seen and are consistent with increased cellular attachment and a suspected
change in phenotype form the resting cultured state to a more in vivo like gene
expression.
At present, attempts to seed EC on vascular prosthesis materials are problematic
with the major concern being the low number of EC that remain on the graft surface
after exposure to in vivo shear stress. The decrease in cell viability and increased
expression of the COL-1, PECAM-1 and TGF-β1 genes observed in the study in
Chapter 8 may be related to the cells strengthening their attachment to the
nanocomposite substrate under physiological levels of shear stress. Preconditioning has
been shown to positively influence the development of tissue-engineered grafts
(326;338;339). Therefore the final aim in this thesis was to address the effects of shear
stress preconditioning on EC seeded on nancomposite conduits. The use of
preconditioning with lower flow rates prior to physiological flow has been highlighted in
many studies to promote continued cellular attachment and reduce cell loss upon
exposure to physiological flow (338). This was confirmed in this study by the increase in
cell viability observed after preconditioning compared to those exposed only toChapter 10: Conlusion of thesis
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physiological flow. The application of 1-2 dynes/cm2 shear stress for four hours prior
to physiological shear stress increases in TGF-β1, whereas PECAM-1 expression
remained relatively constant. A significant decrease in vascular endothelial growth factor
receptor-1 (VEGFR-1) expression was observed in both one and four hour
preconditioned cells when followed by immediate exposure to physiological flow. This
situation was reversed in the case of vascular growth factor receptor-2 (VEGFR-2)
where a significant increase of gene expression was observed in the preconditioned
nanocomposite grafts. Both VEGFR-1 and VEGFR-2 are known to bind vascular
endothelial growth factor (504) with high affinity and previous studies have shown that
VEGFR-2 mediated signalling can result in significant changes in morphology together
with alterations in actin organisation in EC with high expression levels of this receptor
(387). Furthermore studies have shown that the expression of VEGFR-2 is induced by
the application of shear stress associated with a reduction in VEGFR-1 expression in a
similar manner to the results obtained in this study (387;516). This suggests that the
reduction in VEGFR-1 and increase in VEGFR-2 expression may be associated with
mature EC likely to proliferate in response to shear stress (a situation similar to
angiogenesis). The data generated by this investigation showed that this was likely to be
responsible for a rapid change in the gene expression of cells when exposed to low flow
akin to that seen under physiological flow. That this occurs at low flow highlights that
this is a likely mechanism for the promotions of attachment and in future may provide
an insight into the importance of such promotion in the continued attachment of cells
seeded on vascular conduits.
In conclusion this thesis has demonstrated that it is possible to produce and seed
conduits made from a novel nanocomposite and that once seeded the cells remain
adhered under physiological flow. Further it highlights the importance of
preconditioning to promote gene upregulation of potentially significant adhesive
proteins and the further promotion of extracellular matrix proteins. This study
demonstrated the importance of gene studies not only as a potential tool to investigate
promoting cell attachment but also to aid a better understanding of the process. By
understanding the gene expression changes that cells undergo under flow it is hoped
that further understanding of the process of intimal hyperplasia may be promoted. A
limitation to this study has been the number and types of gene studied when seeded on
the grafts. This work would be better afforded with playng particular attention to theChapter 10: Conlusion of thesis
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surface adhesion molecules that determine the migration and adhesiveness of ECs.
Although VEGFR2 was a keen interest in this study, and could have a significant
importance in manipulating growth of a new vessel, investigating the molecules involved
in cell-cell and cell-ECM attachment (such cadherins, selectins and focal adhesion
kinases) as would better our knowledge of increasing cell attachment to artificial
substitutes. Thus the understanding of how ECs attach to the graft would better our
kowledge in the lack of adhessivness of ECs seeded grafts and therefore provide a
manipulative tool in enhancing cell adhesion to artificial grafts.Chapter 10: Conlusion of thesis
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10.2 Future work
This thesis describes initial work that has been undertaken whereby early stages of
developing a small diameter coronary artery bypass graft have been completed. There is
continued research and development required for completion of this work;
1. Animal studies: assess the long term patency of these hybrid grafts and look at
the potential infiltration of host cells both helpful and harmful.
Potential Advantages: Long term studies possible
Closest mimic to clinical environment
Difficulties to be overcome: Different genes may be involved
Initial cell isolation needs to be characterised
2. Long term flow studies in vitro.
Potential Advantages: Development of existing model
No animal use
Genes in humans characterised
Difficulties to be overcome: Long term studies prone to infection
Shorter endpoints compared to animal work
No host interaction
3. Use of adult stem cells as a cell source (endothelial progenitor cells)
Potential Advantages: Better chance of clinically significant cell source
Possible to study cellular interaction with graft
Work already carried out by our group highlights the
potential of these cells for such studiesChapter 10: Conlusion of thesis
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Difficulties to be overcome: May require different genes to be studied and the amount
of RNA extracted may be a problem
Cell attachment of these cells is yet to be characterise
under flow
4. Surface modification of the polymer with peptides and other bioactive molecules
Potential Advantages: Potential for increased cell attachment or adherence and
hence retention
Technology shows promise and indicates usefulness in
Clinical studies but no gene studies yet
Possible to more closely mimic natural cell attachment
Difficulties to be overcome: Genetic alterations after interaction with such molecules
would need to be characterised
Cell type would have to be identified for clinical use as
different interactions would be anticipated with different
cell typesChapter 11: Reference list
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